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1. Summary 
Recombinant in vitro transcribed messenger RNA (ivt mRNA) is a versatile and safe vehicle for 
gene therapy and for vaccination (Pascolo, 2008). It is immunostimulating when composed of 
unmodified nucleotides (stimulation of innate receptors such as Toll Like Receptors (TLR)-3,7 
and -8) or non immunostimulating when containing natural modified nucleotides (e.g. m6A, Ψ) 
(Kariko et al., 2005; Kariko et al., 2008). Even though naked ivt mRNA coding tumor antigens 
have been used in clinical studies to vaccinate cancer patients against tumors (Rittig et al., 2011; 
Sahin et al., 2017a; Weide et al., 2008), improvements of mRNA-based vaccines are being made 
by encapsulation of mRNA in particles (lipoplexes or polyplexes) (Demoulins et al., 2016; Kranz 
et al., 2016b). In parallel, gene-therapy approaches in development also use encapsulation of non-
immunostimulating ivt mRNA in targeted particles (Stadler et al., 2017; Thran et al., 2017). In 
order to further improve ivt mRNA-based therapies we studied the role of natural modifications 
on RNA and optimized functionality of ivt mRNA. 
In the first aspect we studied immunostimulating capacities of natural RNA extracted from several 
organisms to stimulate the human innate immune system and could evidence that a drug, namely 
Pentostatin can be used to “demodify” endogenous RNA enhancing its triggering of innate 
immunity (induction of interferon-alpha). 
In the second aspect, we optimized the primary structure of ivt mRNA namely by modifying the 
5′ untranslated region and also validated formulations that allow targeted expression in vivo. 
Those fundamental and translational studies allow better understanding of RNA biology and give 
new options for therapies, including anti-cancer treatments. Combining standard of care and 
immunomodulation is foreseen as a way towards more efficacious and safer treatments. The 
immunological fitness of treated patients is thereby a key to treatment’s success. Assessing this 
parameter in patients recruited in a clinical study led us to identify interferon gamma receptor 1, 
TLR2 and β2-microglobulin as potential surrogate markers for response to chemotherapy. We 
foresee that a better understanding of RNA biology, an optimized formulation of ivt mRNA and a 
better characterization of patient’s immune system will help in designing personalized efficacious 
treatments to cure cancers. 
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2. Zusammenfassung 
Die rekombinante in-vitro transkribierte Boten-RNA (ivt mRNA) ist ein vielfältiges und sicheres 
Vehikel für Gentherapien Impfungen (Pascolo, 2008). Sie ist immunstimulierend, wenn sie aus 
unmodifizierten Nukleotiden zusammengesetzt ist (Stimulierung von angeborenen 
Immunrezeptoren wie die Toll-Like Rezeptoren (TLR)-3, 7 und -8). Sie ist nicht 
immunstimulierend, wenn sie natürlich-modifizierte Nukleotide enthält (z. B. m6A, Ψ) (Kariko et 
al., 2005; Kariko et al., 2008). Wenngleich auch schon in klinischen Studien nackte, für 
Tumorantigene kodierende ivt mRNAs zur Impfung von Krebspatienten verwendet worden sind 
(Rittig et al., 2011; Sahin et al., 2017a; Weide et al., 2008), werden aktuell, durch eine 
Einkapselung von mRNA in Partikel (Lipoplexe oder Polyplexe), Verbesserungen von mRNA-
Impfstoffen erzielt (Demoulins et al., 2016; Kranz et al., 2016b). Die Einkapselung von nicht-
immunstimulierender ivt mRNA in zielgerichtete Partikel wird parallell auch verwendet in sich in 
der Entwicklung befindenden Gentherapieansätzen (Stadler et al., 2017; Thran et al., 2017). 
Um die ivt mRNA-basierte Therapie weiter zu verbessern, haben wir den Effekt von natürlichen 
Modifikationen auf die RNA untersucht und haben dadurch versucht, die Funktionalitat der ivt 
mRNA zu optimieren. 
Im einem ersten Ansatz haben wir die Fähigkeit von natürlicher, aus verschiedensten Organismen 
extrahierter RNA, das menschliche angeborene Immunsystem zu stimulieren, untersucht. Dabei 
konnten wir zeigen, dass der Arzneistoff Pentostatin zur «Entmodifizierung» von endogener RNA 
verwendet werden kann, welches ihre Stimulierung der angeborenen Immunität noch weiter 
verstärkt (Induktion von Interferon-alpha).  
In einem zweiten Ansatz haben wir die Primärstruktur der ivt mRNA durch Modifikation des 5′ 
untranslatierten Bereichs optimiert. Weiter haben wir unterschiedliche Formulierungen bezüglich 
zielgerichteter Expression in-vivo validiert.  
Unsere Grundlagen- und translationale Studien erlauben ein besseres Verständnis der RNA-
Biologie und ergeben neue Therapiemöglichkeiten wie z.B. in der Tumorbehandlung. Die 
Kombination von aktuellem Behandlungsstandard und der Immunmodulation ist ein Weg in 
Richtung effizientere und besser verträgliche Therapien. Dabei ist die immunologische Fitness der 
behandelten Patienten der Schlüssel zum Therapieerfolg. Patienten in einer klinischen Studie, 
welche zur Evaluierung dieser Parameter durchgeführt wurde, zeigten den Interferon gamma-
Rezeptor 1, TLR2 und β2-Mikroglobulin als potenzielle Surrogatmarker für das Ansprechen auf 
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Chemotherapien. Ein besseres Verständnis der RNA-Biologie, eine optimierte Formulierung der 
ivt mRNA sowie eine bessere Charakterisierung des Immunsystems der Patienten wird bei der 
Planung von personalisierten, wirksamen Therapien zur Heilung von Krebs in Zukunft von 
grossem Nutzen sein. 
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4. Introduction 
4.1. RNA modifications 
• Presence and diversity of RNA modifications 
Similarly to genomic DNA carrying and being regulated by natural nucleotide modifications, RNA 
molecules from Eukarya, Bacteria, or Archaea harbor modifications and some of them have been 
known for decades (Dunn, 1961). To the present day over hundred RNA modifications have been 
identified (Cantara et al., 2011; Machnicka et al., 2013) and listed in dedicated databases 
(http://mods.rna.albany.edu/; http://modomics.genesilico.pl). 
Diverse and abundant modifications are introduced in most cellular RNAs during RNA 
maturations steps. These modifications are made on the canonical A, C, G, and U residues and 
their formation is catalyzed by numerous specific enzymes - RNA modification enzymes or RNA- 
protein complexes (RNPs). Ribonucleotide derivatives can bear single or multiple modifications 
on:  
• the purine/pyrimidine ring where every single position is a potential target for methylation, 
hydroxymethylation, deamination, transglycosylation, acetylation, reduction, thiolation, 
oxidation, ribosylation, formylation, isomerization, selenation, or addition of multiple 
groups; and/or  
• the nucleotide’s ribose can have the 2′-hydroxyl group methylated or ribosylated with an 
adenosine-5′-phosphate group (Figure 1).  
These naturally occurring modified nucleosides play various structural and functional roles in 
different types of RNAs: transfer (tRNA) and ribosomal (rRNA), but also in messenger mRNA 
and small nuclear (snRNAs), micro (miRNA) and long non-coding RNA (lncRNA). The most 
widespread RNA modifications detected in RNA populations are base or ribose methylations, 
Figure 1. Abbreviations used to define position and type (e.g. methylation) of RNA modifications. Adapted from 
(Lorenz et al., 2017). 
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deamination of adenosine to inosine and isomerization of uridine into pseudouridine (Ψ). Special 
emphasis on these modifications will be devoted in the following parts.  
4.1.1. Adenosine related modifications 
4.1.1.1. N6-methyladenosine (m6A) 
4.1.1.1.1. Discovery of m6A 
While characterizing the 5′ cap structure of 
mRNA in mammalian cells researchers 
discovered the presence of adenosine 
variants, bearing a methylation on the exocyclic nitrogen and named N6- methyladenosine (m6A) 
(Figure 2) (Desrosiers et al., 1974).  
Ever since the first studies, m6A has been mapped in the RRACH consensus, A being methylated 
(R=A, G: H=A, C, U), where the first nucleotide next to m6A from the 5′ end is most frequently 
G. From those studies it was evident that m6A is maintained during processing of the precursor
mRNA into mature mRNA (Schibler and Perry, 1977). Follow-up studies confirmed that m6A is 
introduced in the nucleus and completely retained in the cytoplasmic mRNA (Chen-Kiang et al., 
1979). Current estimations classify m6A as the most abundant modification in mRNA occurring 
on average three sites per mRNA (Rana and Tuck, 1990). Nonetheless, m6A was identified also 
in rRNA (Maden, 1990), tRNA (Iwanami and Brown, 1968), snRNA (Bringmann and Luhrmann, 
1987), miRNA (Alarcón et al., 2015b) and lncRNA (Liu et al., 2013b). 
4.1.1.1.2. Detection of m6A 
Localizing of m6A in the transcriptome has been hampered by two facts: (i) m6A, similar to A, 
reverse-transcribes to a thymine (T), and (ii) m6A is not prone to chemical modifications that 
might facilitate its detection. Two groups in 2012 developed an antibody-based deep sequencing 
method for the first transcriptome-wide m6A distribution (m6A/MeRIP-seq). In each method, 
mammalian mRNA is fragmented to 100 nucleotide (nt) sized fragments and immunoprecipitated 
using an m6A-specific antibody. From immunoprecipitated and input control fragments libraries 
are made and later on subjected to high-throughput sequencing. These maps have shown that m6A 
is widely distributed in more than 7,000 mRNA transcripts in human cells, preferably around stop 
Figure 2. Structure of m6A (left) and adenosine (right). Adapted 
from URL: http://modomics.genesilico.pl/reactions/A:m6A/
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codons, in 3′ untranslated regions (3′ UTRs) and within long internal exons (Dominissini et al., 
2012; Meyer et al., 2012). However, antibody-based sequencing cannot reveal which adenosine 
residue is modified in a precipitated fragment. With the intention of quantifying the percentage of 
m6A at a specific site with single-nucleotide resolution new methodologies have been recently 
developed (Linder et al., 2015; Liu et al., 2013b). One of them, site-specific cleavage and 
radioactive labelling followed by ligation-assisted extraction and thin layer chromatography 
(SCARLET), combines: RNase H site-specific cleavage, splinted ligation (RNA bridging to DNA 
oligonucleotide), ribonuclease digestion, and thin layer chromatography (TLC), to directly 
determine m6A modification status at any mRNA/lncRNA site from the total RNA sample without 
the need of purifying a specific RNA (Liu et al., 2013b). The SCARLET method was defined as 
time-consuming, not feasible for high-throughput applications; therefore photo-crosslinking-
assisted m6A-sequencing (PA-m6A-seq) was developed. This method shows improved accuracy 
of the methylation site assignment and provides a high-resolution (~ 23 nt) transcriptome-wide 
mammalian m6A map (Chen, 2015). Recently, m6A individual-nucleotide-resolution cross-
linking and immunoprecipitation (miCLIP) has been developed with exploiting m6A specific 
antibodies and specific mutational signatures at m6A residues after ultraviolet light–induced 
antibody-RNA cross-linking and reverse transcription. This mapped m6A and another 
modification N6, 2′-O-dimethyladenosine (m6Am) at single-nucleotide resolution in human and 
mouse mRNA. In addition, m6A has been detected in small nucleolar RNAs (snoRNAs). When 
validating m6A positive and negative sites with miCLIP, authors found higher specificity and 
sensitivity in comparison to SCARLET methodology (Linder et al., 2015). 
Based on profiled m6A RNA methylomes across many eukaryotes, including human, mouse 
(Dominissini et al., 2012), yeast (Schwartz et al., 2013), and plant (Li et al., 2014; Luo et al., 2014), 
it can be said that mRNA methylation is conserved and dynamic. Consistent with previous studies 
m6A confines to the consensus RRACH sequence and its distribution varies in the transcriptome, 
favoring sites near stop codons, in 3′ UTRs, and within long internal exons. Additionally, m6A-
modified genes are quite well conserved between human and mouse embryonic stem cells (ESCs) 
and somatic cells. However, distinct m6A patterns can also be detected among different species or 
cells at different developmental stages (Batista et al., 2014; Geula et al., 2015; Meyer et al., 2012; 
Schwartz et al., 2013). Some m6A signatures are tissue-specific (Meyer et al., 2012) and altered 
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in response to different stimuli (Bodi et al., 2012) pointing to the potential role of m6A in 
regulating diverse cellular processes. 
4.1.1.1.3. m6A enzymes 
M6A modifications had long been considered static and invariable. Although the enzymatic 
complex responsible for introducing m6A is known since early 90s (Bokar et al., 1994), enzymes 
removing it were only recently identified (Jia et al., 2012; Zheng et al., 2013a) proving m6A a 
reversible post-transcriptional modification (Figure 3).  
4.1.1.1.4. Writers 
‘Writers’ is a term given for enzymes that are part of the methyltransferase complex introducing 
m6A. Components of this complex are methyltransferase-like 3 (METTL3) (Bokar et al., 1997), 
METTL14 (Liu et al., 2014), Wilms tumor 1-associated protein (WTAP) (Ping et al., 2014) and 
KIAA1429 (Schwartz et al., 2014b). 
• METTL3
METTL3 also known as methyltransferase-A70 (MT-A70), is a 70 kDa protein that was the first 
identified component of the methyltransferase complex isolated from Henrietta Lacks (HeLa) cell 
nuclear extracts. In this study it has been shown that the knockdown of METTL3 in HeLa cells 
resulted in a ~30% decrease of the total m6A level (Bokar et al., 1994), while in human hepatoma 
Figure 3. Illustration of enzymatic 
machineries writing, reading and 
erasing dynamic m6A. Adapted 
from (Zhao et al., 2016). 
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G2 (HepG2) cells the same knockdown induced apoptosis, possibly due to upregulation of p53 
pathway (Dominissini et al., 2012). METTL3 contains two subunits: consensus methylation motif 
I (CM I) that binds the methyl-donor for methylation reaction, and CM II that contains catalytic 
residues for methylation activity (Bokar et al., 1997). METTL3 is highly conserved in eukaryotes, 
and homologues in yeast (Clancy et al., 2002), plant (Bodi et al., 2012) and D. melanogaster have 
also been identified (Bujnicki et al., 2002). It has been detected in nucleus and cytoplasm (Chen 
et al., 2015), suggesting that mRNA methylation could be taking place in both compartments, 
which is consistent with early studies showing that cytosolic extracts also possessed RNA 
methyltransferase activity (Harper et al., 1990). 
• METTL14 
Phylogenetic analysis of MT-A70 family indicated 43% of homology of METTL14 with METTL3 
(Bujnicki et al., 2002). METTL14 knockdowns in HeLa and Human embryonic kidney 293 FT 
(HEK293FT) cells decreased m6A levels in mRNA. METTL14 forms a stable heterodimer with 
METTL3 and together this complex shows higher methylation activity of known m6A consensus 
sequence in comparison to separate components. METTL3 and METTL14 co-localize in nuclear 
speckles, and the heterodimer forms the core of the mammalian m6A methyltransferase complex 
(Liu et al., 2014). Until recently, it has been believed that both METTL3 and METTL14 could 
potentially catalyze m6A methylation in the METTL3/METTL14 complex. However, structural 
analysis showed S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) in the 
catalytic cavity of METTL3, proving that METTL3 is the catalytic subunit of METTL3-METTL14 
complex. The role of METTL14 is restricted to stabilization of the complex and recognition of 
RNA substrates (Wang et al., 2016b). 
• WTAP 
Wilms tumour 1-associated protein (WTAP) was initially identified as a protein interacting with a 
WT1 (Wilms’ tumour suppressor gene) protein, localized in the nucleus and co-localizing in the 
nuclear speckles with mRNA splicing factors (Little et al., 2000). However, studies in Arabidopsis 
thaliana (A. thaliana) and yeast revealed that homologs of human WTAP, At FIP37 and Mum2 
respectively, interact with the A. thaliana ortholog of the yeast and human METTL3 (MT-A70), 
suggesting its role in m6A methylation reactions (Agarwala et al., 2012; Zhong et al., 2008). 
Moreover, WTAP has been shown to interact with the METTL3–METTL14 complex (Ping et al., 
2014). Knockdown experiments of WTAP reduced m6A levels in mRNA, although WTAP alone 
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did not show any methyltransferase activity in vitro. These findings assigned WTAP a regulatory 
role in the methyltransferase complex. A recent study identified WTAP-dependent and -
independent m6A modification sites, where WTAP-dependent sites are located at internal 
positions in transcripts, topologically static across diverse human and mouse mRNA, while 
WTAP-independent sites form at the first transcribed base as part of the cap structure. Also in the 
same study, KIAA1429, an additional candidate of m6A methyltransferase complex has been 
validated in knockdown experiments as a requirement for complete methylation in mammals 
(Schwartz et al.). WTAP-null mice exhibit embryonic lethality. 
4.1.1.1.5. Erasers 
Two m6A erasers which are demethylases, have been reported: fat mass and obesity-associated 
protein (FTO) and alkB homologue 5 (ALKBH5). 
• FTO 
Fatso gene coding for fat mass and obesity-associated protein (FTO) was identified from the 
fused toes (FT) mouse mutation, where mice bearing this heterozygous mutation showed a fused-
toe phenotype (Peters et al., 1999). FTO is a member of Alkb protein family (DNA/RNA repair 
enzymes (Gerken et al., 2007), initially identified to demethylate 3-methylthymine and 3-
methyluracil in synthetic single-stranded DNA (ssDNA) and single-stranded RNA (ssRNA) (Jia 
et al., 2008), and later shown to be the first identified RNA demethylase catalyzing oxidation of 
m6A residues in mRNA. In vitro studies of FTO knockdown in human cells induced increased 
amounts of m6A, while overexpression experiments resulted in decreased amounts of m6A in 
mRNA. Moreover, FTO has been shown to localize in the area of nuclear speckles. These findings 
characterized m6A as a reversible and dynamic modification (Jia et al., 2012). 
Oxidation of m6A by FTO is dependent on Fe(II)- and α-ketoglutarate producing N(6)-
hydroxymethyladenosine (hm6A) as an intermediate modification, and N(6)-formyladenosine as 
a further oxidized product (Fu et al., 2013). Impairment of FTO function affects normal growth 
development of the central nervous system in mutant mice, and it has been associated with obesity. 
Single nucleotide polymorphisms within FTO gene are associated with increased body mass and 
obesity in humans (Dina et al., 2007). FTO deficiency in mice caused growth retardation (Fischer 
et al., 2009). Similarly in humans, loss-of-function mutations in FTO causes malformations, severe 
growth retardation resulting in premature death (Boissel et al., 2009). 
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• ALKBH5 
Similarly to FTO, alkylation repair homologue protein 5 (ALKBH5) belongs to the iron- and 2-
oxoglutarate (2OG)-dependent family of AlkB oxygenases. Knockdown of this protein in human 
cell lines yields higher m6A levels in mRNA and accelerates its export from the nucleus to the 
cytoplasm. In the same experiments, ALKBH5 was shown to colocalize with nuclear speckles and 
associate with mRNA processing factors possibly affecting splicing reactions. Unlike FTO, 
ALKBH5 tightly interacts with mRNA and directly removes methyl groups from m6A-methylated 
adenosine without oxidative demethylation (Zheng et al., 2013a), most likely catalyzing the 
decomposition of m6A intermediate hm6A to adenosine (Zheng et al., 2013b).  
Mice deficient in alkbh5 exhibit defective spermatogenesis possibly resulting from altered 
expression of spermatogenesis-related genes and high levels of expression of ALKBH5 in mouse 
testes (Zheng et al., 2013a). 
The specificity of FTO and ALKBH5 for nucleotides in target transcripts remains to be elucidated. 
Current studies suspect that the diversity in structural features in nucleotide binding sites and 
catalytic domains define which m6A residue on a target sequence undergoes demethylation (Aik 
et al., 2014; Xu et al., 2014a; Yang et al., 2016).  
4.1.1.1.6. Readers 
Investigated biological roles of m6A are defined through protein-RNA interactions. Occurrence of 
m6A in RNA destabilizes RNA duplexes thus promoting binding of RNA-binding proteins to 
single-stranded transcripts or preventing double-stranded-binding proteins (Kierzek and Kierzek, 
2003; Spitale et al., 2015). Proteins regulated through this reaction are known as indirect readers 
of m6A. Nonetheless, proteins specifically recognizing and binding m6A rich motifs in the RNA 
have been identified (Dominissini et al., 2012).  
• Direct m6A readers 
Specific binders of m6A were detected in pull down assays from human cell lysate (Dominissini 
et al., 2012). These proteins share an YT521-B homology (YTH) domain and are highly conserved 
in mammals (Stoilov et al., 2002; Zhang et al., 2010). Thus far five members have been qualified 
as members of YTH protein family: YTH domain family protein 1 (YTHDF1), YTHDF2, 
YTHDF3 and YTH domain-containing 2 (YTHDC2) localized in the cytoplasm (Bailey et al., 
2017; Dominissini et al., 2012; Wang et al., 2014), and YTHDC1 found both in cytoplasm and 
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nucleus (Berglund et al., 2008; Xu et al., 2014b). First studies have shown higher binding affinity 
of YTHDF1-3 to methylated probe compared to unmethylated one (Dominissini et al., 2012; Wang 
et al., 2014). YTH domain contains a hydrophobic socket proven to accommodate methyl group 
of m6A (Theler et al., 2014). It has been demonstrated that cytoplasmic readers YTHDF1 and 
YTHDF2 modulate translation and mediate degradation of m6A modified mRNA, respectively 
(Wang et al., 2014; Wang et al., 2015). Recently, YTHDF3 has been shown to promote translation 
through interacting 40S/60S ribosomal subunits (Li et al., 2017a). Nuclear reader YTHDC1 
regulates m6A-dependent mRNA splicing (Xiao et al., 2016) while YTHDC2 probably has an 
Adenosine triphosphate (ATP)-dependent RNA helicase function (Fanale et al., 2014).  
It has been reported that eukaryotic initiation factor 3 (eIF3), a component of 43S translation 
preinitiation complex, directly binds with 5′ UTR m6A of mRNA and mediates cap-independent 
translation particularly in condition of cellular stress (Meyer et al., 2015). Heterogeneous nuclear 
ribonucleoprotein A2/B1 (hnRNPA2B1) has also been shown to selectively recognize methylated 
pri-microRNA in order to promote micro-RNA maturation (Alarcón et al., 2015a; Alarcón et al., 
2015b).  
• Indirect readers 
Presence of m6A weakens base pairing and alters local RNA structure (Roost et al., 2015). Such 
structural changes are referred as m6A switch. M6A switch exposes RNA-binding motifs 
facilitating the binding of hnRNPC and hnRNPG, proteins identified to ultimately affect 
alternative splicing of transcripts (Liu et al., 2015; Liu et al., 2017).  
4.1.1.1.7. Role of m6A in RNA function and fate 
M6A is the most common internal modification in mRNA and long noncoding RNA with 
significant conservation of m6A modified genes between mouse and human in somatic cell types 
(Dominissini et al., 2012; Meyer et al., 2012). Studies about evolutionary conservation of m6A 
methylomes in human embryonic stem cell (hESC) and mouse embryonic stem cell (mESC) 
identified at the gene level, 69.4% (3,609 of 5,204) of hESC genes are also m6A modified in the 
orthologous mouse gene, with 46 % of the m6A peak sites in common. This significant overlap at 
the gene level implied a major role of m6A modification during development in both species 
(Batista et al., 2014).  
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Several reports suggested m6A presence in transcripts mediates transition toward differentiation 
in vivo. M6A marking of transcripts in “naïve” ESC and “primed” epiblast stem cells (EpiSCs) 
facilitates removal of undesired transcripts and allows expression of new gene networks required 
for proper lineage priming and cell differentiation. METTL3 targets majority of the core 
pluripotent factors and developmental regulators in hESC and mESC. Knockout of METTL3 in 
mouse “primed” EpiSCs and “naïve” ESCs led to a reduction of m6A in mRNAs and increased 
stability of pluripotent mRNA transcripts. Subsequently, these stem cells undergo aberrant and 
limited potential differentiation at later implantation stages, resulting in early lethality of embryo. 
Thus, ablation of METTL3 potentiates the already high pluripotency genes in the naive condition 
to create a hypernaive pluripotent state, but produces the dominating developmental factors in the 
primed state and counterbalances towards differentiation (Geula et al., 2015).  
In a separate study, METTL3 silencing delays the nuclear export of mature mRNAs of clock genes 
Aryl hydrocarbon receptor nuclear translocator like (Arntl) and Period circadian regulator 2 (Per2), 
which connect m6A to the pace of the circadian cycle and the clock speed and stability (Fustin et 
al., 2013). 
• Dosage compensation  
M6A is involved in various aspects of sexual development in Saccharomyces cerevisiae (S. 
cerevisiae), Drosophila melanogaster (D.melanogaster) and mammals. Methylation of mRNA in 
yeast is restricted to meiosis induced by starvation or following prolonged rapamycin treatment. 
There m6A marking probably promotes translation of specific transcripts (Agarwala et al., 2012; 
Bodi et al., 2015). In D.melanogaster females presence of m6A promotes splicing of Sex lethal 
(Sxl) thereby enhancing its expression that ultimately inhibits translation of Male-specific lethal-
2 (Msl-2) required for transcription from the single male X chromosome (Haussmann et al., 2016). 
Mammalian long non-coding RNA X-inactive specific transcript (XIST) is highly methylated and 
m6A enhances its function through its recognition by YTHDC1. XIST mediates transcriptional 
silencing of genes on the X chromosome (Patil et al., 2016). 
• M6A site-dependent expression of mRNA  
Several reports suggest that the presence of m6A affects mRNA fate including processing, nuclear 
export, stability and translation. Human and mouse methylomes indicate m6A is enriched at 3′-
UTRs, around stop codons and also marks long exons (Dominissini et al., 2012; Meyer et al., 
2012). First reports defined m6A to promote translation efficiency if it is located in 3′ UTR, open 
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reading frames and near stop codons. Binding of YTHDF1 to m6A near the stop codon and 
possible interaction with the translation initiation factor eIF3 is suggested to stimulate translation 
(Wang et al., 2015). However, a recent report suggests that m6A in both the ORF and the 3′ UTR 
could mediate accelerated poly(A) removal in the cells through recruitment of YTHDF2 that 
interacts with the deadenylation carbon catabolite repressor factor 4 - negative regulator of 
transcription (CCR4–NOT) complex resulting in decay of m6A-containing RNAs (Du et al., 
2016). Additionaly, in glioblastoma stem cells (GSCs) it has been shown that m6A presence in 
3′ UTR of Forkhead box protein M1 (FOXM1) pre-mRNA blocks its expression through 
preventing the interaction with Human antigen R (HuR) protein and thereby the export from 
the nucleus (Zhang et al., 2017). 
M6A marking of both exons and introns was shown to promote alternative splicing. Binding 
ability of Serine and arginine-rich splicing factor-2 (SRSF2) has been found to be dependent on 
m6A, where m6A modified exons are rather included in the mature mRNA (Zhao et al., 2014). 
Other studies indicate that modified exons are recognized by YTHDC1 in pre-mRNA and that 
YTHDC1 promotes exon inclusion through recruiting pre-mRNA splicing factor (SRSF3) while 
blocking SRSF10 binding to pre-mRNA (Xiao et al., 2016). 
On the contrary, m6A found in introns has been identified to prevent exon inclusion in mature 
mRNA. An extensively studied example is the Sxl pre-mRNA. In D. melanogaster females’ 
existence of active Sxl suppresses translation of Msl-2, which transcripts are present in both 
females and males. Msl-2 in males is responsible for upregulation of transcription from X 
chromosome to compensate the unequal numbers of X chromosomes between males and females. 
In Sxl pre-mRNA, m6A is present in introns flanking an alternatively spliced exon that encodes 
for a premature stop codon in males. This exon is excluded in females through Sxl self-regulation 
of alternative splicing in Sxl pre-mRNA. Sxl binds on either side of the intron, close to m6A sites 
and with m6A reader YT521-B fully prevents exon inclusion ultimately resulting in high levels of 
Sxl expression in females. Thus, m6A is required to direct splicing and provide sufficient Sxl for 
sex determination and dosage compensation (Haussmann et al., 2016). 
Recent reports have provided compelling evidence on how m6A localization in 5′ UTR promotes 
cap-independent mRNA translation. Under stress conditions, ultraviolet (UV) or heat shock induce 
preferentially 5′ UTR m6A methylation in stress-inducible mRNA, probably to differentiate 
nascent transcripts from pre-existing mRNA and facilitate selection of mRNA for translation. The 
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nuclear YTHDF2 preserves 5′ UTR m6A methylation of stress-induced transcripts by limiting 
access of FTO and thereby demethylation. In absence of a 5′ end cap structure - a methylated 
purine (N7-methylguanosine, m7G) it is possible that m6A acts as a replacement and thereby 
promotes translation (Meyer et al., 2015; Zhou et al., 2015).  
Additionally, it is probable that there is a preference in polyadenilation sites depending on m6A 
density to its proximity. Namely, in pre-mRNA with two alternative polyA (APA) sites, when a 
proximal polyA site is chosen more frequently than a distal site, m6A density both before and after 
this site was shown to be lower, whereas if the proximal polyA site is used less frequently, the 
m6A density around this site was shown to be greater (Ke et al., 2015). 
4.1.1.2. 1-methyladenosine (m1A) 
4.1.1.2.1. Discovery of m1A 
Methylation on the N1 atom of 
adenosine forms 1-methyladenosine 
(m1A) (Figure 4) identified in RNA 
since early 1960s (Dunn, 1961; Hall, 
1963). This highly conserved RNA modification was found in non-coding RNA, tRNA and rRNA, 
and recently in mRNA of several human and murine cell lines and in yeast (Dominissini et al., 
2016; Li et al., 2016b; Machnicka et al., 2013).  
M1A in cytosolic (cyt)tRNA is found on five different positions typically in the tRNA T-loop, 
with two of them (9 and 58) being in common with mitochondrial (mt)tRNA. Some of these 
methylations are domain specific: m1A modification in nucleotide position 22 (m1A22) identified 
only in tRNAs from Bacteria (Matsugi et al., 1992; Menichi et al., 1980) and m1A57 modification 
found in Archaea, transiently existing as an intermediate leading to 1-methylinosine (m1I) by 
hydrolytic deamination (Grosjean et al., 1995a). Others have been conserved between domains 
like m1A58 modification found on (cyt)tRNAs from all three domains of life and further in 
(mt)tRNAs and m1A9 modification of (cyt)tRNA from Archaea or mammalian (mt)tRNAs (Helm 
and Attardi, 2004). Rarely occuring m1A14, has so far only been identified in (cyt)tRNA(Phe) 
from mammals (Sprinzl and Vassilenko, 2005). m1A is found in 18S and 25S rRNA and the 
responsible machinery for this process has been predominantly investigated in yeast (S. cerevisiae) 
(Meyer et al., 2011; Peifer et al., 2013). 
Figure 4. Structure of m1A (left) and adenosine (right). Adapted 
from URL: http://modomics.genesilico.pl/reactions/A:m1A/ 
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Recently two groups independently performed m1A high-resolution transcriptome-wide mapping 
detecting m1A in 5′ UTR, coding region and 3′ UTR, with preferential localization in highly 
structured, GC-rich regions at the 5ʹ UTR near the start codon (Dominissini et al., 2016; Li et al., 
2016b). m1A was found upstream of the first splice site in human mRNA, close to both canonical 
and non-canonical translation initiation sites (Dominissini et al., 2016). Their work proves m1A, 
besides m6A, as a reversible and dynamic modification in eukaryotic mRNA. Recently, m1A 
mapping at single-nucleotide resolution identified GUUCNANNC (A=m1A) as the sequence 
motif for m1A. According to this mapping m1A is present in a low number of mRNA (Safra et al., 
2017). 
4.1.1.2.2. Detection of m1A 
The N1 of adenosine acts as a hydrogen bond receptor and once bearing a methyl group (m1A) 
modification becomes positively charged and impairs Watson–Crick base pairing. m1A can cause 
both reverse transcription stops and read-throughs accompanied by mismatches. This feature has 
been exploited to sequence m1A at high resolution in mRNA: m1A-seq and m1A-ID-seq 
developed by Dominissini (et al.) and Li (et al.), respectively (Dominissini et al., 2016; Li et al., 
2016b).  
Both approaches consist in selection and enrichment by m1A-specific antibody 
immunoprecipitation. In m1A seq approach a portion of precipitated m1A-containing mRNA 
fragments are treated with alkaline buffer to chemically rearrange m1A to m6A prior to 
complementary DNA (cDNA) synthesis exploiting the Dimroth rearrangement reaction. Further, 
comparison between alkaline buffer treated and untreated samples was performed according to 
mutational rates, where high mutation rates are found in untreated samples (m1A mutation prone 
in reverse transcription) and low in the treated ones (m6A low mutation rate in reverse 
transcription). With this methodology m1A sequencing peaks are at the resolution of 5–15 
nucleotides (conserved m1A sites in rRNA can be mapped at the resolution of one nucleotide). In 
m1A-ID-seq approach, AlkB (an eraser of m1A) from Escherichia coli (E. coli) was used to 
demethylate m1A to regular adenosine. In parallel, since m1A was shown to stop reverse 
transcription under optimized conditions (low dNTPs), Avian Myeloblastosis Virus (AMV) 
reverse transcriptase cDNA directed synthesis is performed to confer cDNA truncations near m1A 
sites. This maps m1A at the resolution of 55 nucleotides by comparing the m1A peak features 
25 
 
between the AlkB untreated and treated samples (Dominissini et al., 2016; Li et al., 2016b).  
Single-nucleotide resolution m1A transcriptome mapping has been recently developed. The 
protocol combines steps employed in previous m1A mapping strategies. However, increased 
reading depth of cDNA libraries obtained from different reverse transcription conditions and 
inclusion of additional filters in the analytical pipeline detected with high confidence m1A sites 
(Safra et al., 2017). 
4.1.1.2.3. Writers  
Two methyltransferase superfamilies: the Rossmann-fold methyltransferase (RFM) and SpoU-
TrmD (SPOUT) are responsible for introducing m1A.  
SPOUT superfamily enzymes exhibit an unusual alpha/beta fold, resembling Rossman fold, with 
a trefoil knot. The SPOUT domain binds SAM as a cofactor thus representing the catalytically 
active subunit of the MTs. Additional nucleic acid binding domains have been identified in SPOUT 
MTs (Aravind and Koonin, 2001; Tkaczuk et al., 2007). The RFM family is named after the 
structural motif (Rossmann-fold) known for binding of adenosine-containing cofactors (Motorin 
and Helm, 2011). It comprises both RNA and DNA MTs containing apart RFM-fold additional 
domains for substrate recognition (Schubert et al., 2003). Members of these two superfamilies are 
responsible for m1A modifications at nucleotide position 9, 22, and 58 in tRNA, while MTs of 
position 14 are unknown. From RFM family tRNA methyltransferase (Trm)K, Trm6/Trm61 and 
Trm61 alone catalyze methylation of nucleotide position 22 in bacterial tRNA, position 58 in 
cytosolic and mitochondrial tRNA of Eukaryotes, respectively (Wang et al., 2016a). Trm10 from 
SPOUT superfamily methylates position 9 in mitochondrial tRNA of Eukaryotes (Motorin and 
Helm, 2011). The TrmK (m1A22 MT) is conserved in Bacteria, having orthologues in Gram-
positive and Gram-negative bacteria, but has no identified homologues in Eukaryotes (Roovers et 
al., 2008). m1A9 in mitochondrial tRNAs is known to stabilize the canonical cloverleaf structure, 
preventing tRNA folding into a nonfunctional structure (Helm et al., 1998). The tRNA 
methyltransferase responsible for m1A58 formation is a heterotetramer complex initially identified 
in S. cerevisiae as a two-subunit enzyme consisting of TRM61 (GCD14) and TRM6 (GCD10) 
(Anderson et al., 2000). Trm61 functions as the catalytic subunit, but both Trm61 and Trm6 are 
required for tRNA binding (Ozanick et al., 2007). TrmI is a homotetrameric enzyme found to 
catalyze m1A58 in bacterial and archaeal tRNA, discovered as a homolog of yeast Trm61 (Roovers 
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et al., 2004). Trmt61B was reported as a mitochondria-specific methyltransferase responsible for 
m1A58 formation in human mitochondrial tRNAs (Chujo and Suzuki, 2012). m1A58 forms in the 
TΨC loop reverse - Hoogsteen base pairing with 5-methyluridine (m5U) at position 54. The 
methylation positively charges the elbow region of the tRNA (Agris, 1996). This positive charge 
is believed to stabilize the tertiary structure of tRNAs, e.g. eukaryotic initiator tRNA(Met) 
(Basavappa and Sigler, 1991). 
Nucleolar essential protein 1 (Nep1) is highly conserved in eukaryotes and is essential for 40S 
ribosomal subunit maturation (Eschrich et al., 2002). Nep1 was identified to catalyze N1-
methylation within loop 35 of the 18S rRNA that contains the unique hypermodification of U1191 
1-methyl-3-(3-amino-3-carboxypropyl)-pseudouridine (m1acp3Ψ) (Meyer et al., 2011). The 
ribosomal RNA processing protein ribosomal RNA processing protein 8 (Rrp8) is known to 
interact with Nep1 and catalysing N-1-methylation of adenine at position 645 in helix 25.1 of S. 
cerevisiae (Peifer et al., 2013). Base methyltransferase of 25S rRNA (BMT2) was reported to be 
responsible for m1A2142 base modification of helix 65 in 25S rRNA in the same model organism 
(Sharma et al., 2013). Specific m1A-MTs acting on mRNA are still under investigation.  
4.1.1.2.4. Erasers 
ALKBH3, an AlkB-family DNA/RNA demethylase and homolog of ALKBH5 and FTO, was 
shown to demethylate m1A in mRNA thus proving m1A as a reversible modification. Specific 
mRNA m1A peaks were identified in ALKBH3−/− HEK293T cells, preferentially located in the 5′ 
UTR suggesting rather a regulatory role of ALKBH3 than its function as a repair enzyme (Li et 
al., 2016b). Human ALKBH1 is another member of the AlkB family proteins, recently found to 
mediate removal of m1A in tRNA (Liu et al., 2016). 
4.1.1.2.5. Readers 
Readers of m1A have not been identified.  
4.1.1.2.6. Role of m1A in RNA function and fate 
Most of m1A roles have been investigated through deletion or transient ablation of MTs in specific 
cells in vitro or in vivo. Deletion of the MTase responsible for N1‐methylation A58 in yeast 
produces non‐viable cells while reduction of this MTase by small interfering (si)RNA‐mediated 
knockdown gave rise to a slow‐growth phenotype in human cells (Anderson et al., 2000; Saikia et 
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al., 2010). This effect seen in yeast might be due to its role in stabilizing and helping maturation 
of initiator tRNA(Met) from yeast. Both TRM61 and TRM6 have been shown to be essential for 
this process. Upon gene inactivation of either of these two genes, the initiator tRNA(Met) is 3′-
polyadenylated by the topoisomerase I related function 4 protein (Trf4p)/Mtr4p complex and 
subjected to exosome complex-mediated degradation (Kadaba et al., 2004). 
Loss of m1A9 modification by knockdown MTs was shown to be embryonically lethal in D. 
melanogaster, while in HeLa cells the knockdown resulted in reduced mitochondrial respiration, 
sustaining the role of m1A MTs in cell viability (Lopez Sanchez et al., 2011; Sen et al., 2016). The 
MTase responsible for tRNA m1A22 in Streptococcus pneumoniae was also shown to be essential 
for bacterium survival (Thanassi et al., 2002).  
It has been shown that retroviruses use tRNA bearing m1A58 as primers to initiate reverse 
transcription. Human immunodeficiency virus-1 (HIV-1) exploits presence of m1A58 in human 
tRNA(Lys) for efficient and accurate reverse transcription (Auxilien et al., 1999).  
Depletion of Nep1 and BMT2 have been shown to affect yeast cell growth (Meyer et al., 2011; 
Sharma et al., 2013). 
M1A presence in mRNA was identified to increase translation thus positively correlating with 
protein production. Being localized at 5′ UTR and translation initiation sites, Li (et al.) suggested 
m1A is affecting mRNA folding to promote translation initiation. Under serum starvation 
conditions and H2O2 treatment inducible m1A marking of mRNA was found in the 5ʹ UTR and 
near start codon regions, similarly to normal conditions, possibly promoting translation of stress 
induced mRNA (Li et al., 2016b). 
4.1.1.3. Inosine 
4.1.1.3.1. Discovery of adenosine deaminases acting on RNA 
Inosine is an RNA modification resulting from a hydrolytic deamination 
of adenosine (Figure 5) catalyzed by enzymes of the Adenosine 
Deaminase Acting on double stranded RNA (ADAR) and Adenosine 
deaminase acting on tRNA (ADAT) families. First report of ADARs 
were in Xenopus laevis oocytes and embryos, where authors named them 
as proteins with unwinding activity of double stranded RNA (Bass and 
Weintraub, 1987, 1988; Wagner et al., 1989). In mammals, first 
Figure 5. Deamination of 
adenosine to inosine (A) 
Base pairing of inosine 
with cytosine (B). 
Adapted from (Valente 
and Nishikura, 2005). 
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discovered gene from ADAR family was ADAR1 in humans (Kim et al., 1994b), where soon after 
also ADAR2 and ADAR3 were identified (Chen et al., 2000; Melcher et al., 1996b). Orthologs of 
these genes are evolutionary conserved in vertebrates and only few genes have been identified in 
invertebrates. D. melanogaster possess one gene of ADAR family dAdar, similar to ADAR2, while 
Caenorhabditis elegans (C. elegans) has two ADAR genes, adr-1 and adr-2. In plant, fungi and 
yeast genomes ADAR genes haven’t been identified (Jin et al., 2009). Members of ADAT family 
are responsible for catalyzing deamination of adenosine to inosine on tRNAs in all domains of life. 
ADATs introduce inosine on three positions on tRNAs: position 34 (Bacteria, Eukaryote), position 
37 (Eukaryotes) and position 57 (Archaea). Inosine on position 34 is found in the final modified 
state while on position 37 and 57 is methylated into m1I37, m1I57 or m1Im57 (Juhling et al., 2009; 
Machnicka et al., 2013). ADAT family comprises in Eukaryotes: ADAT1 (Tad1), ADAT2 (Tad2) 
and ADAT3 (Tad3) (Gerber and Keller, 2001). 
4.1.1.3.2. Detection of Inosine 
A-to-I editing introduces guanosine (inosine) instead of adenosine read in RNA-sequencing by 
next-generation sequencers (NGS). Thus, this A-to-G conversion could be traced by comparing 
with the reference genome. However, true RNA editing sites have to be distinguished from 
genomic variations such as single nucleotide polymorphisms (SNPs). For this purpose, specific 
analytical pipelines using bioinformatics tools with specific filters have been developed. These 
filters including general criteria, to prevent inclusion of single nucleotide variations, and specific 
A-to-I targeted criteria that take into account biological properties of ADARs and localization of 
putative editing sites such as clustering of editing sites (Peng et al., 2012; Solomon et al., 2013), 
Arthrobacter luteus (Alu) and non-Alu elements properties (Ramaswami, 2012), tissue-preferred 
distribution of editing events, RNA folding (Maas et al., 2011). Four bioinformatics tools are 
available for the detection of RNA editing events from FASTQ files and/or mapped datasets: 
ExpEdit, GIREMI, RASER, REDItools and two databases to explore RNA editing events 
DARNED (https://darned.ucc.ie/) (Kiran and Baranov, 2010) and RADAR (http://rnaedit.com/) 
(Ramaswami and Li, 2014). Most recent bioinformatic tool developed for detection of editing 
events is RNAEditor. This tool also uses FASTQ files as input and fully automates all steps needed 
to identify RNA editing events. In RNAEditor a clustering algorithm is implemented to detect 
regions of highly edited sites referred as ‘editing islands’. Compared with a single edited site, an 
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editing island indicates potential ADAR binding sites, gives higher confidence that the contained 
editing sites are ‘true’ editing sites and higher likelihood of biological importance (John et al., 
2016). 
4.1.1.3.3. Writers 
Enzymes of ADAR family possess common functional domains (Figure 6). They have two to three 
double stranded-RNA binding domains, 65 amino acid long, through which they directly bind to 
double stranded RNA (dsRNA) (Stefl et al., 2006). On the C-terminus they contain the catalytic 
deaminase domain forming the catalytic center of an ADAR. According to a proposed catalytical 
model for deaminase activity, the target A base flipped into the active enzyme site (Macbeth et al., 
2005). Some ADARs have a specific structural feature: ADAR1 has two Z-DNA binding domains 
(Zα and Zβ) (Herbert et al., 1997), for which is believed to play a role in increasing the affinity of 
binding double stranded RNA, like siRNA; ADAR3 holds an arginine rich domain (R) at its N-
terminus that binds single stranded RNA, but its role in ADAR3 is still unknown (Figure 6) (Chen 
et al., 2000).  
  
ADAR1 and ADAR2 are functionally active as homodimers, while ADAR3 is a monomer. Almost 
all editing reactions are attributed to ADAR1 and ADAR2, while ADAR3 doesn’t show 
deaminating activity in vitro. Although features of its functional deaminating domain have been 
conserved, it is believed that the incapability to form a dimer is responsible for the absence of its 
activity (Chen et al., 2000; Melcher et al., 1996a; Schneider et al., 2014). ADAR1 and ADAR2 
are expressed in many tissues, ADAR2 is highly expressed in the brain, while ADAR3 is expressed 
only in the brain (Chen et al., 2000; Kim et al., 1994b; Melcher et al., 1996b).  
ADAR1 gives two protein isoforms: long isoform referred as ADAR1L or ADARp150 and 
ADAR1S or ADARp110 an isoform having a shorter N-terminus and lacking a Z-binding domain, 
as a result of generation from different promoters and alternative splicing. ADAR1L is transcribed 
from a promoter induced by interferon and its expression increased in conditions of cellular stress 
Figure 6. Structural features of ADARs. Adapted 
from (Nishikura, 2016). 
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or viral infection while ADAR1S mRNA is transcribed from constitutively expressed promoters 
(George and Samuel, 1999; Patterson and Samuel, 1995). 
ADAR1L is mainly localized in the cytoplasm, while ADAR1S localizes in the nucleoplasm and 
nucleolus, however in conditions of stress (UV irradiation) it translocates in the cytoplasm 
(Sakurai et al., 2017). ADAR2 is found in the nucleolus (Desterro et al., 2003). The nuclear 
localization signal (NLS) located in the third double stranded RNA binding domain (dsRBD) 
drives the nuclear import of both isoforms of ADAR1. In contrast, nuclear export of p150 isoform 
is mediated by binding of exportin 1 to the nuclear export signal (NES) located within the 
Zα domain of ADAR1p150, the mechanism of which is different from the export of p110 isoform, 
requiring exportin 5 (Fritz et al., 2009; Strehblow et al., 2002). ADAR2 N-terminus contains a 
NLS, which allows ADAR2 to localize into the cell nuclei (Maas and Gommans, 2009). The 
significance of this differential distribution is unknown. However, it is probable that ADAR1L 
distribution is owing to the localization of its target molecules in cytoplasm e.g. viral dsRNA or 
dsRNA that are precursors of mi- and small interfering (si)- RNA. 
ADARs are binding to substrates with their dsRBD. Structural features of dsRNA are localized 
deep in the inner part of the molecule therefore ADARs are not recognizing the specific sequence 
of targets but rather the editing activity is dependent on the stability of dsRNA substrate (Lehmann 
and Bass, 1999). 
Intermolecular and intramolecular dsRNA structures longer than 20 base pairs (bp) are possible 
ADAR substrates. Editing destabilizes RNA substrates and probably is ongoing until the enzyme 
can’t recognize its substrate as dsRNA. On the contrary, in short dsRNA (20 to 30 bp) or long and 
partially complementary dsRNA possessing wrong base-pairing, single stranded bulges and loops, 
only few As are specifically edited since deamination of this few As decreases stability of dsRNA 
substrates below the threshold of recognition of ADAR. Thus, the secondary structure of dsRNA 
is the one dictating selection of editing places by ADAR (Lehmann and Bass, 1999; Nishikura et 
al., 1991). 
Some editing places are preferential substrates for ADAR1 or ADAR2, which means that the 
substrate specificity differs between functional forms of ADAR, possibly due to different number 
and relative distance of dsRBD that can facilitate differing between dsRNA of different structure 
and stability. Selection of editing places by ADAR1 and ADAR2 might be driven also through 
functional interactions between ADAR1 and ADAR2 generating heterodimers. Additionally, some 
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sequence preference has been reported where both ADAR1 and ADAR2 have 5′ neighbor 
preference (A=U > C=G), and ADAR2 may have 3′ neighbor preference (U=G > C=A) (Lehmann 
and Bass, 2000). A-to-I editing is found in both coding and non-coding regions but mostly reside 
in noncoding parts of the human transcriptome, such as introns or 3′ UTRs (Li et al., 2009; Peng 
et al., 2012; Ramaswami, 2012).  
In Adar1-/- mice embryonic lethality was evidenced day 12.5 (E12.5) showing ADAR1 is essential 
for life. These mice show substantial overproduction of interferon and widespread apoptosis 
(Wang et al., 2000b).  Furthermore, in response to inflammation ADAR1 editing is detected in 
immune organs and lymphocytes. All these findings suggested ADAR1 may have a role in 
regulating inflammatory and immune responses (Yang et al., 2003). Similarly, human mutations 
of ADAR1 gene cause Aicardi-Goutières syndrome, which is characterized by childhood 
encephalopathy and massive interferon production (Aicardi and Goutieres, 1984). In addition, the 
deadly phenotype of ADAR1 knockdown mouse has been shown to be reversible with concomitant 
knockdown of Mitochondrial antiviral signaling protein (MAVS) or Melanoma Differentiation-
Associated protein 5 (MDA5) (Liddicoat et al., 2015; Mannion et al., 2014). It has been recently 
demonstrated that A-to-I editing of endogenous dsRNA by ADAR1 is essential to prevent the 
activation of the cytosolic dsRNA response by endogenous transcripts (Liddicoat et al., 2015). 
Moreover, in ADAR1 knockout mice death of embryonic liver hematopoietic cells and liver 
disintegration were also observed. This could be explained with the finding that ADAR1 plays a 
role in differentiation of hematopoetic progenitor cells implicating ADAR1 is important in 
hematopoiesis and organ development (XuFeng et al., 2009). 
A large number of ADAR1 mutations (>130) are also associated with dyschromatosis symmetrica 
hereditaria (DSH), an autosomal-dominant disorder mainly found in Asian individuals and is 
characterized by altered skin pigmentation (Suzuki et al., 2007). 
Mice deficient for ADAR2 die within 3 weeks after birth and are prone to seizures. ADAR2 is 
known to edit critical position of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
(AMPA) receptor subunit glutamate R (GluR)-B pre-mRNA in the brain, encoding glutamate 
receptor subunit 2 (Gria2). ADAR2 deficient mice can be rescued when an unedited transcript is 
substituted with an edited one, suggesting Gria2 as the major target of ADAR2 (Higuchi et al., 
2000; Higuchi et al., 1993). RNA editing dysfunction are related also to central nervous system 
diseases. Decrease in editing activity in GluR-B is responsible for motorneuron death in sporadic 
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cases of amyotrophic lateral sclerosis, also it probably plays a role in epilepsy. Imbalanced RNA 
editing, particularly changes in editing patterns is substantially changed in the prefrontal cortex of 
patients with depression and schizophrenia suggesting its role in neuropsychological disorders 
(Eran et al., 2013; Mombereau et al., 2010). C. elegans strains with homozygous deletion of both 
ADAR genes, adr-1, adr-2, have chemotactic malfunction (Tonkin et al., 2002). 
There are two major effects of A-I editing:  
1) A-to-I editing changes the information content of RNA molecules, since inosine (I) is 
preferentially binding to C, so the splicing and translating machinery are interpreting it like 
G; 
2) A-I editing changes tridimensional structure of double stranded RNA with introduction or 
removal of single stranded bulges, that result from imperfect base pairing, and the 
tridimensional structure alone of double stranded RNA determines its interaction with 
RNA binding proteins. 
Editing efficacy of substrates (number of converted A to I) is varying depending on the type of 
substrate, development phase and physiological condition, that allows existence of diverse 
products, and a turnover of products as a response to changed environmental conditions. 
Unlike ADARs, ADATs lacks the dsRBD therefore, their recognition of substrate is mainly 
dependent on the tertiary structure of tRNA. ADATs similarly to ADARs, possess the deaminase 
domain and it is suggested that ADARs evolved from ADATs with fusion of dsRBDs (Keegan et 
al., 2004). 
ADAT1 acts as homodimer introducing inosine on position 37, located after the anticodon in 
eukaryotic tRNA(Ala). After this reaction tRNA methyltransferase 5 (Trm5) introduces 
methylation at N1 position of inosine resulting in final m1I37 (Grosjean et al., 1995a; Grosjean et 
al., 1995b). ADAT1 is localized mainly in the nucleus where studies suggest it may interact with 
a dsRBD containing protein Disconnected Interacting Protein 1 (DIP1) and acts at pre-tRNA level 
(Catanese and Matthews, 2011). ADAT2 and ADAT3 form a heterodimer to catalyze the 
deamination of adenosine on position 34, located at first position of the anticodon (wobble-
position) on 8 cytosolic tRNAs (Torres et al., 2015). ADAT2 is the catalytic subunit while ADAT3 
probably is responsible for substrate recognition (Gerber and Keller, 1999). ADAT2 and ADAT3 
localize mainly in the nucleus but their presence in the cytosol is not excluded, as it was shown 
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that ADAT3 located in the cytoplasm can translocate to the nucleus in presence of ADAT2 (Torres 
et al., 2015). In Prokaryotes I34 is introduced by Tad1 homodimer, only on tRNA(Arg). The 
enzyme catalyzing deamination of adenosine on position 57 in Archaea is not known (Grosjean et 
al., 1995a; Yamaizumi et al., 1982).  
Deficiency in inosine synthesis on tRNAs has not been extensively investigated. Yeast knockouts 
for Tad2 (ADAT2) or Tad3 (ADAT3) are lethal. Tad1 (ADAT1) yeast knockout strains are viable 
and mutants with disrupted Tad1 show no particular growth impairment, suggesting m1I37 and 
I37 modification are not essential in yeast (Gerber et al., 1998).  
The ADAT1 transcript was found to localize mainly to the central nervous system during D. 
melanogaster development, suggesting a possible role for ADAT1 and m1I37 modification during 
brain development (Keegan et al., 2000). In humans, it has been reported that both I34 and m1I37 
of tRNA(Ala), are targets of autoantibodies generated against the anticodon stem loop of 
tRNA(Ala) in serum of patients suffering from myositis, a chronic inflammatory muscle disorder 
(Becker et al., 1999). 
4.1.1.3.4. Erasers 
Inosine specific erasers have not been reported yet. 
4.1.1.3.5. Roles of readers and A-to-I editing by ADAR  
Most frequently editing locations are long, partially complementary RNAs formed from inverted 
non-coding repeats, such as Alu and Long interspersed element (LINE) located in mRNA UTRs 
and introns. Globally editing of non-coding RNA could control gene expression that contains these 
repeated sequences affecting: alternative splicing, nuclear retention, transcript degradation, 
silencing of heterochromatin or suppression of small regulatory RNA (piwi-interacting RNA). 
RNA editing regulates also processing and expression of mature miRNA, while ADAR1L traps 
siRNA, decreasing RNA interference (RNAi) efficacy. 
• Protein sequence recoding – Regulation of protein function 
Before splicing of eukaryotic transcript, the region between intron and exon in precursor 
messenger RNA often forms stem-loop structures. These structures can be edited with ADAR, and 
the formed Is are read as Gs by ribosomes, since they are base-pairing with Cs. Thus, any editing 
in the protein coding region can lead to an amino acid change and this type of editing is known as 
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recoding-type editing (Hood and Emeson, 2012). Around 30 genes for proteins undergo editing. 
Well-investigated examples of mRNA editing are receptor for glutamate (AMPA, GluR-B) and 
receptor for serotonin type 2C (5-HT2CR) in mammals that contain several specific editing 
positions resulting in production of protein isoforms of different functionality (Burns et al., 1997; 
Higuchi et al., 1993).  
L-glutamate is the predominant excitatory neurotransmitter in the nervous system of vertebrates 
and its receptors play roles in neuronal plasticity and complex functions like memory and studying. 
AMPA receptor for glutamate that is also an ion channel for calcium (Ca), takes part in the rapid 
excitatory transmission in central nervous system (CNS) neurons and it contains 4 subunits, 
referred as GluR-A to D. mRNA for GluR-B subunit (Gria2) undergoes ADAR2-A-to-I editing, 
so the codon for glutamine (Q) in exon 11 changes into codon for arginine (R). This editing 
changes significantly AMPA receptor (GluR-B) Ca ions permeability: arginine presence blocks 
Ca conductance through channel, while the existence of genomic encoded Q allows Ca influx in 
cells (Higuchi et al., 1993).  
Serotonin has an important role in physiological process and behavior, like circadian rhythm, 
control of emotions and food related behavior. mRNA of 5-HT2cR is edited in 5 specific places in 
exon 5 coding a long intramolecular loop in the domain for G protein coupling. Different editing 
combinations of these 5 sites lead to a change of three codons into possible six new ultimately 
resulting in expression of 24 different receptor isoforms of different functionality (Burns et al., 
1997).  
Three possible patterns of this functional modulation via editing are known.  
1) Editing of all 5 sites (A, B, C, D and E) changes genome encoded amino acids Ile, Asp and 
Ile on positions 156, 158 and 160, each of them leading to a change in coupling efficacy 
with G protein. Completely edited isoform (5-HT2CR-VGV) has reduced potentiation with 
serotonin, coupling with G protein and agonist binding in comparison to non-edited 
isoform (5-HT2CR-INI).  
2) Editing pattern controls amount of 5-HT2CR mRNA that leads to expression of full-length 
protein through modulation of selection of alternative splicing sites. Between three 
alternative 5′- splicing sites (GU1, GU2 and GU3), use of GU2 site gives full length 
functional 5-HT2CR protein. Non-edited pre-mRNA uses generally GU1 splice site that in 
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case of translation gives rise to a nonfunctional protein. However, most of edited pre-
mRNA are spliced from GU2 site. Therefore, if editing is inefficient, increased splicing in 
GU1 site works as a control mechanism for decreasing synthesis of 5-HT2CR-INI that 
limits serotonin response.  
3) RNA editing controls the ultimate physiological output of constitutively active receptors 
affecting expression of surface 5-HT2CR on cell surface. 5-HT2CR-VGV, that possess the 
lowest level of constitutive activity, is fully expressed on cell surface in basal conditions 
and it internalizes fast upon agonist presence. On the contrary, 5-HT2CR-INI is 
constitutively internalized and is accumulated in endosomes. 
Some sites are specifically edited with ADAR1, some with ADAR2, while others are not showing 
specificity for one or the other enzyme. For instance, A, B sites 5-HT2CR are selectively edited 
with ADAR1 while site D with ADAR2 (Burns et al., 1997; Fitzgerald et al., 1999; Flomen et al., 
2004; Niswender et al., 1998). 
• Changes in splicing sites 
Intron regions can also undergo editing, and that can affect splicing, since splicing machinery can 
interpret I as a G. For this reason, A-I editing has the potential of creating a 5′-splice site, creating 
or eliminating 3′-splice site and removing branching site. For instance, GU in 5′-splice site can be 
created due to editing AU-> IU=GU, likewise AG in 3′-splice site (AA->AI=AG). 
This is clearly evidenced in ADAR2 self-regulation that edits its own double-stranded intronic 
RNA creating an alternative 3′-splice site. Translation of alternatively spliced ADAR2 mRNA 
produces an incomplete protein lacking RNA binding domain and deaminase domain thus 
autoediting leads to ADAR2 repressed expression (Rueter et al., 1999). 
• Effects in noncoding sequences 
There are some evidences that editing of Alu repeats, often localized in 3′ UTRs of mRNA, leads 
to preferential retention in the nucleus through binding of paraspeckle regulatory protein 54-kDa 
nuclear RNA-binding protein (p54nrb), as it was shown for the mRNA of cationic amino acid 
transporter 2 (Cat2). Once edited Alu elements in 3′ UTR form a binding site for p54nrb that keeps 
the mRNA in the nuclear speckles. In stress conditions, Cat2 mRNA is posttrancriptionally cut 
and de novo polyadenilated on an alternative site resulting in transport of Cat2 mRNA in the 
cytosol and translation into protein (Prasanth et al., 2005). 
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Another mechanism for regulating gene expression is the presence of ribonuclease specific for 
RNA containing inosine that cuts both strands of RNA with high numbers of I-U mismatches 
(Scadden and Smith, 2001b). Tudor staphylococcal nuclease (Tudor-SN) was until recently a 
candidate for targeting of pre-mRNA edited in their inverted Alu and LINE repeats. However, 
Endonuclease V (EndoV) was recently identified as this ribonuclease and Tudor-SN acts as a 
cofactor. Thus, this possible Tudor-SN-EndoV degradation would control the level of expression 
of genes containing these sequences (Morita et al., 2013; Scadden, 2005). 
• Crosstalk between editing and RNAi 
RNAi and A-to-I editing are two pathways known to interact. In essence of this interaction is the 
competition of editing A-I and RNAi enzymes for double-stranded RNA substrates. Small 
regulatory RNAs are playing a role in many diverse cellular processes, where most of them are 
double-stranded during their biogenesis, suggesting that ADAR’s editing could have a regulatory 
role in many processes.  
Two recognized models of interaction between RNA editing and RNAi involving endo-siRNA are 
evidenced:  
1) Editing of A-to-I double-stranded endo-siRNA precursor making it more resistant to Dicer 
activity; 
2) Supression of endo-siRNA with ADAR1L, where ADAR1L binds tightly to endo-siRNA 
and decreases the effective endo-siRNA concentration; 
both models result in decreased RNAi efficacy. 
RNAi can be induced with long dsRNA molecules as substrates for Dicer. Post Dicer processing 
produces siRNA that can direct endonucleolytic degradation of the original transcript or any other 
RNA with identical sequence. Long dsRNAs are also a substrate for ADAR, where once I-U 
mismatches are formed they affect the structure of double stranded RNA making it more resistant 
to Dicer activity and producing less endo-siRNA. It is believed that Dicer can differentiate between 
perfectly based paired RNA and edited RNA containing I-U pairs, as in vitro studies suggest 
extensive editing suppresses cutting of double stranded RNA with Dicer thus reducing RNA 
interference (Scadden and Smith, 2001a). 
C. elegans mutants carrying homozygous deletions of adr-1 and adr-2 genes show defects in 
chemotaxis (problems in finding or avoiding certain substances) (Tonkin et al., 2002). Reversion 
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of this phenotype is possible in those worms having a defect in RNAi machinery. Altered 
chemotactic phenotype in C. elegans is resulting from hyperactivity of RNAi pathway, which in 
normal conditions is suppressed by ADAR. Expression of genes controlling chemotaxis depends 
of the balance between A-I editing and RNAi acting on dsRNA formed in the transcripts of these 
genes (Tonkin and Bass, 2003). 
Besides the competition with Dicer for dsRNA substrates, ADAR1L binds tightly to processed ds 
endo-siRNA, decreasing its concentration in the cytoplasm and reducing RNAi efficacy. This is 
confirmed with significantly more efficient gene silencing with siRNA in absence of ADAR1 
(Heale et al., 2009; Warf et al., 2012; Yang et al., 2005). Expression of ADAR1 in mice is induced 
when unspecific siRNA are injected in high amounts, suggesting ADAR1 is a part of a cellular 
mechanism as a response to siRNA (Hong et al., 2005).  
• Effects on miRNA pathway 
A-to-I editing has been found in many endogenous primary RNA (pri-miRNA) and there are in 
vitro evidences of precursor miRNA editing (pre-miRNA), suggesting editing might modulate 
miRNA processing and thereby regulate cell miRNA levels. 
Editing of pri-miRNA can have major impact on biogenesis and expression of miRNA considering 
that short and imperfect double stranded regions of pri- and pre-mi RNA allow ADAR enzymes 
to take part in the miRNA biogenesis (Yang et al., 2006). ADAR editing can affect miRNA 
processing inhibiting endonucleolytic processing by Drosha or Dicer, resulting in decreased 
amounts of mature miRNA (Kawahara et al., 2007). Highly-edited pri-miRNA are further 
degraded with Tudor-SN-EndoV complexes (Morita et al., 2013). In case the miRNA processing 
is not compromised, a mature miRNA is expressed, containing A-to-I substitutions representing 
an edited mature miRNA. These miRNAs can silence a set of genes that is different from the set 
of genes their non-edited copies would target, especially if the editing was in the “seed” region of 
miRNA, crucial for recognition of target mRNA (Ekdahl et al., 2012; Kawahara et al., 2007).  
In most of the cases one guide strand of ds miRNA is selected in the RNA-induced silencing 
complex (RISC) while the passenger strand is degraded. This step in miRNA biogenesis can also 
be modulated with A-to-I editing. Selection of the guide strand is based on thermodynamical 
stability of miRNA 5′-end and editing can change local stability of ds miRNA. Editing induced 
structural changes may affect the guide strand selection majorly affecting the choice of target 
mRNA (Kume et al., 2014). 
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3′ UTRs in mRNA are also subjected to editing. Changing A into I in 3′ UTR makes a new target 
site for miRNA, thus 3′ UTR editing can increase or repress silencing of specific mRNA. Similarly, 
editing can destabilize secondary structures in 3′ UTR allowing RISC complex to interact with 
previously unavailable sites (Zhang et al., 2016b). 
4.1.1.3.6. Role of ADAT in RNA function and fate 
Codon-anticodon recognition is essential for amino acid incorporation into proteins. Wobble 
nucleoside A34 can pair with U while I34 is capable of pairing with A, U and C. This ability of 
inosine to pair with more nucleosides suggest I34 increases number of codons recognized by a 
tRNA. Since I is recognized as G, codons having C at their end are possibly affected by the 
presence or absence of the I34 modification. Presence of A34 tRNAs and G34 tRNAs were shown 
to be exclusive in the same genome suggesting I34 in tRNA is important in reading C-ended 
codons (Grosjean et al., 2010). Most expressed genes show to have a preference for specific codons 
resulting in increased translation efficiency (Gustafsson et al., 2004). Since anticodon 
modifications may affect codon recognition by tRNA, changes in ADATs activity and 
modification status of tRNAs could have an impact on translation of specific genes. 
4.1.1.4. 2′-O-methylation of ribose 
4.1.1.4.1. Discovery of 2′-O-methylation 
Methylation of the 2′-hydroxyl group of the 
ribose (Figure 7) is a predominant internal 
modification of rRNA and spliceosomal RNA. 
Mammalian rRNA carries 105-107 2′-O-
methylated residues while it has been reported 
that the spliceosomal snRNAs (U1-U6 snRNAs) 
bear a total of 30 2′-O-methylated residues 
(Maden, 1990; Reddy and Busch, 1988). SnoRNA U3 has also abundant 2'-O-methylations (Reddy 
and Busch, 1988). 2'-O-methylation is identified in all tRNAs (Grosjean et al., 1995b). 
Additionally, small noncoding RNA, including piwi-interacting RNAs (piRNAs), endogenous 
small interfering RNAs (endo-siRNAs) and plant miRNAs, are 2′-O-methylated at their 3′-ends 
by methyltransferases (Horwich et al., 2007; Pelisson et al., 2007; Yu et al., 2005). This 3′-
Figure 7. Structure of Am (left) and adenosine 
(right). Adapted from URL: 
http://modomics.genesilico.pl/modifications/Am/ 
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methylation in the small RNAs prevents terminal uridylation (Li et al., 2005) and degradation by 
exonucleases (Ramachandran and Chen, 2008) possibly playing a role in specific RNA 
interference (RNAi) pathways. All eukaryotic mRNAs contain a 5′ cap structure that carries a 
methyl code. This methyl code contains m7G - cap 0, and it can additionally possess one or both 
of the first nucleotides methylated on the 2ʹ-hydroxyl group to form ‘cap-1’ or to form ‘cap-2’, 
respectively (Langberg and Moss, 1981). 
4.1.1.4.2. Detection of 2′-O-methylation 
2′-O-methylation as a sugar ring modification changes the biochemical properties of the modified 
nucleotide compared to the unmodified nucleotide. This methylation favors 3′- endo axial 
conformation of the sugar and changes the hydration sphere around the 2′-O thus affecting RNA 
structure (Auffinger and Westhof, 1997; Auffinger and Westhof, 1998). Phosphodiester bonds 
adjacent to 2′-O-methyl groups are resistant to alkaline hydrolysis (Maden, 2001). Similarly, 
RNaseH non-specific cleavage of RNA-DNA hybrids is prevented in presence of 2′-O-methylation 
on a RNA residue (Yu et al., 1997). These specific features have been exploited for mapping 2′-O 
-methylation extensively in rRNA and tRNA.  
Diverse biochemical approaches have been developed to detect and quantify 2′-O-methylation. 
Initial studies relied on liquid chromatography coupled with mass spectrometry (LC/MS) 
(Douthwaite and Kirpekar, 2007) and two-dimensional thin-layer chromatography (2D-TLC) 
approaches (Grosjean et al., 2004). However, these procedures were found quite demanding in 
terms of preparation and purification of starting material. To avoid tedious RNA purification, 
primer extension by reverse transcriptase was favored as a faster approach. In this methodology 
the RNA of interest is specifically selected through the annealing reaction with specific 
oligonucleotide DNA primers. Three main variations of the standardized reverse transcription 
(RT) reaction have been developed: (1) conditions of low dNTP concentration where reverse 
transcriptase stalls on 2′-O-methyl groups (Maden et al., 1995), (2) the use of partial alkaline 
hydrolysis followed by RT (Kiss-Laszlo et al., 1996) and (3) Reverse Transcription at Low dNTP 
concentrations followed by PCR (RTL-P) (Dong et al., 2012). RTL-P represents the most 
advanced modification of RT to detect 2′-O-methylation, able to detect both previously identified 
and novel 2′-O-methylated sites in human and yeast rRNAs, as well as mouse piwi-interacting 
RNAs (piRNAs), without requiring substantial amount of initial material (Dong et al., 2012). Site-
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specific methodologies based on the resistance of 2′-O-methylated sites to cleavage by RNase H 
have also been developed (Lapham et al., 1997; Yu et al., 1997). In this methodology a specific 
DNA-RNA chimera oligonucleotide is constructed to base-pair with the target RNA, where the 
“chimera” consists of a DNA oligonucleotide, hybridizing to the target RNA, and flanking 2′-O-
methyl ribonucleotides. RNase H will cleave target RNA at the phoshodiester bond 3′ to the 
ribonucleotide that is base-paired with the 5′- most deoxynucleotide of the chimera. RNase H will 
not cleave a bond adjacent to a 2′-O-methyl in target RNA. Therefore, target RNA containing 2′-
O-methylation will result in a single large product whereas in absence of 2′-O-methylation two 
products will be detected on gel electrophoresis. RNAse H based approach is quantitative approach 
and it requires a radiolabeling step (Lapham et al., 1997; Yu et al., 1997). More recent approaches 
are high-throughput methods based on sequencing of different depth. Ribometh-seq detection is 
based on random RNA fragmentation under alkaline conditions and library preparation followed 
by next-generation sequencing (NGS). By randomly hydrolyzing RNA and performing NGS at 
very high depth, uniform coverage of 3′-end positions is expected across regions of interest except 
at positions of 2′-O-methylation. This “negative” selection of RNA 2′-O-methylation can then be 
converted into a peak diagram and a methylation score expressing the fraction of molecules 
methylated at a specific site (Krogh et al., 2017). 
Ribose oxidation sequencing (RibOxi-seq) employs Benzonase nuclease for RNA degradation 
instead of alkaline conditions. Fragmented RNAs containing 3′-ends that are either unmethylated 
or 2′-O-methylated undergo an oxidation step where 2′ and 3′-hydroxyls of non-2′-O-methylated 
riboses are converted into dialdehydes using sodium periodate (NaIO4), thus preventing them from 
being ligated to linkers in subsequent sequencing library construction. Only samples being 
“positive” for 2′-O-methylation will be included in the sequencing library. After sequencing, the 
reads are aligned to a reference genome and only positions of the 3′-ends of aligned fragments are 
evaluated. After normalizing the data is analyzed using DESeq2 for single-base resolution 
methylation site determination (Zhu et al., 2017). 
4.1.1.4.3. Writers 
Introducing 2′-O-methylation on ribose in rRNA, mRNA and tRNA is mediated by complexes of 
guide RNA and proteins named Small nucleolar ribonucleoproteins (snoRNP) complexes (Figure 
8) or solely methyltransferases. 
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• SnoRNP  
SnoRNP complexes consists of proteins: Nop1p (the 
catalytic component, also known as fibrillarin in human), 
Nop56p, Nop58p and Snu13p subunits (Lafontaine and 
Tollervey, 1999; Schimmang et al., 1989; Wu et al., 1998), 
guided by Box C/D small snoRNAs to the appropriate base 
(Balakin et al., 1996; Kiss-Laszlo et al., 1996). Fibrillarin 
(Nop1p) shares a conserved domain with known SAM‐
dependent methyltransferases, suggesting that fibrillarin is 
the methyltransferase in box C/D snoRNPs (Wang et al., 
2000a).  
Box C/D snoRNA were identified in studies where substantial complementarity has been detected 
with rRNA, suggesting their role in ribosome biogenesis (Bachellerie et al., 1995). Additionally, 
Bachellerie (et al.) found that methylation sites were closely located to complementary regions 
between rRNA and snoRNA suggesting that box C/D snoRNAs function as guides for 2'-O-
methylation of rRNA. Tollervey (et al.) reported that certain mutations in the yeast Nop1 homolog 
resulted in reduced methylation of pre-rRNA (Tollervey et al., 1993). Soon after rRNA 2'-O-
methylation was localized 5 nucleotides upstream from box D (or D') in the residue base-paired to 
the nucleotide in snoRNA (Cavaille et al., 1996). Deletion of a particular box C/D snoRNA 
resulted in loss of 2'-O-methylation at the target site in rRNA in yeast. However, site-specific 
methylation could be restored upon reintroduction of the box C/D snoRNA into the deletion strain 
(Kiss-Laszlo et al., 1996), and modification of novel target sites could be directed by introduction 
of snoRNAs with appropriate guide sequences (Cavaille et al., 1996).  
The 2′-O-methylation guide snoRNAs possess the conserved C (consensus RUGAUGA) and D 
(CUGA) boxes, that can be folded together with an adjacent 5′, 3′-terminal stem, and incomplete 
copies of the C and D boxes called C′ and D′ boxes in the internal regions of box C/D snoRNAs. 
Positioning of D or D’ box exactly 5 nt from the future 2′-O-methylated ribosomal nucleotide is 
supported through formation of double helices between rRNA sequences and the recognition 
sequence (10–21 nt long) that precedes D and/or D′ boxes (Cavaille et al., 1996; Kiss-Laszlo et 
al., 1996). The C/D boxes are required for snoRNA stability and localizing snoRNAs to the 
nucleolus, which was confirmed with findings indicating snoRNA synthesis and localization are 
Figure 8. SnoRNP complex introducing 
2′-O-methylation in pre-rRNA. Adapted 
from (Kakihara and Saeki, 2014). 
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coupled (Samarsky et al., 1998). In addition to snoRNAs, cells contain small Cajal body-specific 
RNAs (scaRNPs) that can possess a C/D box but they contain additional elements that retain them 
in Cajal bodies (CBs). Many of them target modifications of spliceosomal snRNA (Jády et al., 
2003). 
• Methyltransferases  
Human cap1 2′-O-ribose methyltransferase, hMTr1, catalyzes the methylation of the 2′-O-ribose 
of the first transcribed nucleoside of a capped RNA. Its methyltransferase activity was shown not 
to be dependent on guanosine N7-methylation of the cap structures (Belanger et al., 2010). The 
product encoded by the hMTr1 gene has been previously described (called ISG95), however its 
role in cap1 formation was underinvestigated. In that study authors noted ISG95 associates with 
the C-terminal domain of RNA polymerase II, suggesting that cap1 methylation occurs co-
transcriptionally (Haline-Vaz et al., 2008).  
Cap2 MTase in human is hMTr2 encoded by HMTR2 gene, similarly to hMRT1 and its 
methylation activity shows no preference between m7GpppN and GpppN structures. However, 
hMTr2 is less efficient for RNA without cap1. Cellular localization of hMTr1 is nuclear, and 
hMTr2 is present in the cytoplasm and the nucleus (Werner et al., 2011).  
2′-O-methylation of adenosine at residue 4, identified only in tRNA(His), is catalyzed by protein 
Trm13 protein in S. cerevisiae (Wilkinson et al., 2007).  
4.1.1.4.4. Erasers 
Enzymes capable of “erasing” 2′-O-methylation have not been identified. 
4.1.1.4.5. Readers 
Proteins associating with cap1 and cap2 including the translation machinery are known to 
recognize 2′-O-methylation in mRNA. However, proteins recognizing 2′-O-methylation in other 
positions than 5′ cap have not been identified. 
4.1.1.4.6. Role of 2′-O-methylation in RNA function and fate 
Distribution of 2′-O-methylation within the ribosome is restricted to functionally relevant regions 
of 40S and 60S. Most of the structural and functional studies to investigate the role of ribosomal 
2′-O-methylation were conducted in E. coli and S. cerevisiae. In S. cerevisiae the positions of 2′-
O-methylation confine to the decoding and tRNA binding sites (the A-, P- and E-sites), the 
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peptidyltransferase center (PTC site) and the intersubunit bridge. This defined spatial distribution 
has been conserved throughout evolution although the abundance and locations of these 
nucleotides within functional regions vary phylogenetically (Decatur and Fournier, 2002; 
Rozenski et al., 1999). Their high concentration in functionally important regions of the ribosome 
reflects either direct or indirect contribution to ribosome activity. Direct contribution of 2′-O- 
methylation is probably due to maintenance of secondary and tertiary structures owing to 
stabilization of helices by increasing base-stacking (Auffinger and Westhof, 1997; Auffinger and 
Westhof, 1998; Decatur and Fournier, 2002). Through structural stabilization of ribosomes most 
likely it indirectly mediates translation (Decatur and Fournier, 2002). Early studies using 
catalytically inactive Nop1 mutants demonstrated the importance of 2′-O-methylation for cell 
growth and ribosome production in yeast (Tollervey et al., 1993). Additionally, it has been proven 
in yeast that Nop1 can be functionally complemented with expression of human or X. laevus 
fibrillarin indicating that its function has been conserved from yeast to vertebrates (Jansen et al., 
1991). Deletion of each box C/D snoRNA individually in cells revealed phenotypes with subtle 
defects in translation and growth (Esguerra et al., 2008). 
In addition, discoveries of new snoRNAs, also known as ‘orphan’, are predicted to target other 
RNA species than ribosomal RNAs or small non-coding RNA (Jorjani et al., 2016). In particular, 
a brain-specific snoRNA C/D box (SNORD) 115, named MBII-52 may guide 2′-O-methylation of 
the serotonin receptor 5-HT2C pre-mRNA, thereby regulating gene expression. Importantly, the 
nucleotide that is predicted to be modified by MBII-52 C/D RNA is precisely the ADAR2 edited 
C-site within 5-HT2C pre-mRNA. A 2′-O-methylation of adenosine was shown to specifically 
decrease the deamination rate of the modified adenosine in vitro (Yi-Brunozzi et al., 1999). 
Therefore, MBII-52 negatively regulates ADAR2-mediated nucleolar editing of an RNA substrate 
in a sequence-specific manner (Vitali et al., 2005). 
Presence of cap1 2′-O-methylated mRNA represents a signature of “self” preventing recognition 
through retinoic acid inducible gene I (RIG-I) receptor (Devarkar et al., 2016; Schuberth-Wagner 
et al., 2015). Cap2 methylation may lead to increased translation of mRNA by promoting its 
stability (Werner et al., 2011). Many viruses possess mRNA 5′-structures or encode functions 
associated with the formation of a 5′ cap that are homologous to those found in eukaryotic cells 
e.g.: RNA 5′-triphosphatase, RNA guanylyltransferase, RNA guanine-N7-methyltransferase (N7-
methyltransferase), and 2′-O-methyltransferase (Furuichi and Shatkin, 2000). It has been reported 
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that human and mouse coronavirus mutants lacking 2′-O-methyltransferase activity induced higher 
expression of type I interferon compared to wild-type strains and that this induction was dependent 
on the cytoplasmic RNA sensor MDA5. This defines 2′-O-ribose methylation in mRNA as a 
molecular marking that helps our immune system to distinguish between self and non-self mRNA 
(Zust et al., 2011). 
U2 snRNA cap1 and cap2 methylations are required for spliceosome E complex formation and 
ultimately for efficient pre-mRNA splicing (Donmez et al., 2004). 
4.1.2. Cytosine related modifications 
4.1.2.1. 5-methylcytosine (m5C)  
4.1.2.2. Discovery and detection of m5C 
Cytosine base methylation 5-methylcytosine 
(m5C) (Figure 9) has been identified in rRNA, 
tRNA and recently in mRNAs, particularly 
enriched in the untranslated regions and near 
miRNA binding regions (Squires et al., 2012). This has been facilitated in large part by the ease 
of its detection in DNA using bisulfite sequencing, which involves chemical conversion of 
cytosine (but not m5C) to uracil (Lister et al., 2009). Bisulfite sequencing adapted for RNA 
bisulfite conversion in combination with next generation sequencing further identified m5C in both 
coding and non-coding RNAs in addition to tRNAs and rRNAs (Squires et al., 2012).  
4.1.2.3. Writers 
Enzyme responsible for introduction of m5C are the DNA methyltransferase homolog (Dnmt2) 
and members of the NOP2/Sun (NSun) RNA methyltransferase family.  
While Dnmt2-mediated methylation of cytosine 38 in the anticodon loop of tRNA(Asp) is highly 
conserved, plants, insects and mice lacking Dnmt2 protein show no morphological defects (Goll 
et al., 2006). However, in zebrafish morpholino-mediated loss of Dnmt2 was shown to impact on 
late differentiation resulting in half-sized morphants with liver, brain and retina defects (Rai et al., 
2007). In D. melanogaster, overexpression of Dnmt2  was evidenced to increase lifespan and 
resistance to stress  (Lin et al., 2005) while loss-of-function mutants had reduced viability in 
Figure 9. Structure of m5C (left) and cytosine (right). 
Adapted from (Van Haute et al., 2017) 
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thermal and oxidative stress conditions. Moreover, in these mutants stress-induced cleavage of 
tRNA was reduced upon ectopic expression of Dnmt2 (Schaefer et al., 2010). 
NSun2 and NSun4 are members of the SAM-dependent methyltransferase superfamily and both 
are able to introduce 5-methylcytidine in RNA in mammals (Frye and Watt, 2006; Metodiev et al., 
2014). Deletion of Nsun2 in mice, similarly to Dnmt2 loss in zebrafish causes defects in late 
differentiation affecting growth and specific tissues including skin and testis (Blanco et al., 2011; 
Hussain et al., 2013). Lack of tRNA methylation in absence of Dnmt2 and Nsun2 impairs 
differentiation, particularly of brain, liver and adipose tissue (Tuorto et al., 2012). Human Nsun2 
gene mutations have been identified to cause autosomal-recessive intellectual disability and 
symptoms similar to the phenotype observed in D. melanogaster lacking Nsun2 in Dubowitz-like 
syndrome. These symptoms include growth and mental retardation and cutaneous abnormalities 
(Abbasi-Moheb et al., 2012; Martinez et al., 2012). The role of RNA methylation in these complex 
diseases is currently unknown.  
Nsun4 is responsible for cytosine (C911) methylation of 12S rRNA in mitochondria. Unlike, 
Nsun2 deletion, Nsun4 germline knockout was shown to be lethal and with embryos at E8.5 
showing growth retardation and lacking anatomical structures. Nsun4 heart-specific deletion 
affects not only methylation of 12S rRNA but also interaction with mitochondrial transcription 
termination factor-4 (MTERF4) important for mitoribosome assembly and impaired respiratory 
chain biogenesis resulting in mitochondrial dysfunction and cardiomyopathy (Metodiev et al., 
2014).  
Protoncogene c-Myc was shown to transcriptionally target Nsun2 in mammalian epidermis. 
Upregulated expression of Nsun2 is possibly implicated in wide variety of cancers. Knockdown 
of Nsun2 in human squamous-cell-carcinoma xenografts were shown to decrease their growth 
(Frye and Watt, 2006). Nsun2 is a substrate of Aurora kinase B and independently of its 
methyltransferase activity, has a potential in stabilizing mitotic spindle and promotion of cell 
division in cancer cell lines (Hussain et al., 2009; Sakita-Suto et al., 2007). 
4.1.2.4. Erasers and readers 
m5C-demethylases and m5C specific readers have not been reported yet. 
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4.1.2.5.  Role of m5C in RNA function and fate 
Functions of RNA m5C methyltransferases are still poorly understood. The link to human diseases 
may be explained by a direct role of m5C in rRNA and tRNA to regulate global protein translation 
through structural stabilization. However, the potential roles of m5C in mRNA remain still to be 
investigated. 
4.1.3. Uridine related modification  
4.1.3.1. Pseudouridine  
4.1.3.1.1. Discovery of Pseudouridine 
Six decades ago the fifth nucleoside was 
identified in yeast (Davis and Allen, 
1957). Soon after this fifth base was 
named Pseudouridine (Ψ) (Cohn, 1959), 
and currently is one of the abundant nucleoside modification present in all three life domains 
(Machnicka et al., 2013). After its initial detection in rRNA and tRNA, Ψ was found in mRNA, 
lncRNA, snRNA, like U2 snRNA, and snoRNA (Kim et al., 2010; Schwartz et al., 2014a). In 
yeast, Ψ is present in many positions in cytoplasmic and mitochondrial tRNAs, around 50 across 
the four rRNAs (25S, 18S, 5.8S, and 5S), and in six positions in U1, U2, and U5 snRNA (Charette 
and Gray, 2000; Ofengand, 2002; Yu et al., 2011). Studies in HEK293 and human fibroblast 
confirmed these conserved Ψ profiles in human, but the number of Ψ increases with around 100 Ψ 
found per one human ribosomes (Schwartz et al., 2014a). 
4.1.3.1.2. Detection of Ψ 
Pseudouridylation results from enzymatic isomerization (an internal transglycosylation) of a 
uridine in an RNA molecule (Figure 10). This isomerization results in the change of C-N glycosidic 
bond to a more inert C-C bond (Cohn, 1959) and presence of two NH imino protons available to 
serve as hydrogen bond (Davis, 1995). Such structural changes enhance base stacking and rigidity 
of the phosphodiester backbone resulting in more stable pairing with any of the 4 major bases than 
their U equivalents (Arnez and Steitz, 1994; Davis, 1995; Kierzek et al., 2014). Nuclear magnetic 
Figure 10. Structure of uridine (left) isomerization into Ψ 
(right). Adapted from (Penzo et al., 2017). 
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resonance (NMR) studies of tRNA indicated an involvement of Ψ’s N1-H proton in a stable 
hydrogen bond, even within putative single-stranded regions (Roy et al., 1984). 
Uridine and Ψ share a similar UV spectrum and identical molecular mass (Yu and Allen, 1959), 
and during RT its pairing with adenosine is possible due to Watson–Crick pairing with an 
unmodified template leaving no traces in cDNA. Thus, being mass- and RT-silent, detection of Ψ 
has been hampered for decades. Main methodologies in mapping Ψ were a combination of RNAse 
digestion, radiolabeling, and chromatography-based methods (Gupta et al., 1979; Holley et al., 
1965; Tanaka et al., 1980). Owing to the possibility of chemically modify Ψ with N-cyclohexyl-
N′-β-(4-methyl-morpholinium) ethylcarbodiimidep-tosylate (CMC), a novel approach has been 
developed and it is still the basis of current most sensitive detection methods (Bakin and Ofengand, 
1993). CMC under physiological conditions acylates guanosine and uracile at N1 and N3 positions, 
respectively. The acylation reaction upon CMC treatment in Ψ occurs on both N1 and N3 positions. 
With alkaline conditions (pH=10.4), CMC adducts undergo hydrolysis except on N3 position of Ψ 
leaving CMC irreversibly bound. This blocks RT one base downstream of Ψ and helps its 
detection. However, not all Pseurdouridines are equally ‘marked’ due to incomplete acylation with 
CMC. Similarly, the hydrolysis from U and G residues can be partial and result in false positives. 
After CMC treatment of RNA, RT-stalls on CMC-acylated G, U and Ψ residues. Since alkaline 
hydrolysis removes CMC from G and U residues, Ψ’s CMC residues resists hydrolysis under these 
conditions and therefore can be detected as RT-stopping signals. Recently, in four sequencing 
approaches: Pseudo-seq, Ψ-seq, Pseudouridine site identification sequencing (PSI-seq), and N3-
CMC-enriched pseudouridine sequencing (CeU-seq), for Ψ mapping in yeast and human 
transcriptomes a combination of this chemical treatment and RT has been exploited.  Sequencing 
approaches applying RT-CMC differ in enrichment of initial Ψ-containing transcripts, library 
preparation and bioinformatical analysis (Carlile et al., 2015; Li et al., 2015; Lovejoy et al., 2014; 
Schwartz et al., 2014a).  
In principle polyA-RNA fractions undergo CMC treatment followed by alkaline hydrolysis. Then, 
an adaptor is ligated to the 3′ end of RNAs and transcripts are reverse transcribed. Ψ-CMC-induced 
RT arrest results in truncated cDNA products. Depending on the method, 3′ adaptors are ligated to 
the resulting cDNAs or RT products that were circularized for PCR amplification and deep 
sequencing. Control libraries are constructed in parallel from samples without CMC treatment. In 
Ψ-seq and PSI-seq polyA-RNAs is fragmented to a uniform size range selected prior to CMC 
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treatment and RT. Upon alkaline hydrolysis CMC will be removed from uridines and guanosine 
and remaining on Ψ in treated samples. Truncated cDNA from treated samples will contain a 
reproducibly enriched set of fragments due to CMC marking and following RT stopping. CeU-seq 
(N3-CMC-enriched Ψ sequencing) enriches the fraction of CMC-labeled transcripts by applying 
CMC-azide derivative which allows biotin conjugation with click chemistry following 
derivatization and subsequent hydrolysis. Ψ-CMC-biotin containing transcripts are then pulled 
down with streptavidin beads, increasing the method’s sensitivity with a benefit of approximately 
15–20-fold enrichment of pseudouridylated RNAs. PSI-seq unlike other sequencing approaches 
relies solely on bioinformatical analysis without any enrichment steps (Carlile et al., 2015; Li et 
al., 2015; Lovejoy et al., 2014; Schwartz et al., 2014a).  
4.1.3.1.3. Writers 
Introducing Ψ in eukaryotic RNA can be mediated through RNA 
dependent pseudouridine synthases (PUSs) or RNA-independent 
PUSs.  
RNA dependent PUSs are SnoRNP complexes consisting of 
H/ACA snoRNA that guide catalytically active proteins to 
target site via base-pairing to target RNA (Figure 11).  
SnoRNA H/ACA possess hairpin-hinge-hairpin-tail structure 
with the hinge region containing the conserved sequence block 
ANANNA (box H) and the ACA motif found 3 nucleotides away from the 3′-end (Ni et al., 1997). 
Specific base-pairing with target RNA is mediated through two short guide sequences in a loop 
part of the duplex structures with 14-15 nt distance from H or ACA motifs. Upon transient base-
pairing of target RNA, uridine is placed in a pocket between the flanking paired regions where it 
undergoes isomerization. The canonical target of a majority of snoRNAs is rRNA, but snRNAs 
are also modified through a distinct population of snoRNAs known as small Cajal body-specific 
RNAs (scaRNAs) (Wu et al., 2011b). 
SnoRNP proteins that assemble during transcription of H/ACA RNA are in human (yeast): 
dyskerin (Cbf5p), hGar1p (Gar1p), hNhp2p (Nhp2p), and hNop10p (Nop10p) where dyskerin is 
the PUS catalyzing the reaction and is the only human RNA-dependent PUS (Li et al., 2016a). 
This assembly in human cells includes binding of dyskerin to hNop10, which binds to hNhp2 to 
Figure 11. SnoRNP complex 
involved pseudouridylation in pre-
rRNA. Adapted from (Kakihara 
and Saeki, 2014). 
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constitute the heterotrimer core of the complex. Dyskerin binds also Naf1, a chaperone present in 
early H/ACA RNP assembly, eventually exchanged with hGar1 for mature RNP formation 
(Darzacq et al., 2006; Hamma and Ferre-D'Amare, 2010).  
The group of PUSs proteins acting independent of guide RNA, alone modifies tRNAs, rRNAs and 
snRNAs through recognition of structural and sequence motifs in their RNA substrate, e.g. Pus7p 
in S. cerevisiae recognizes a 7 nt long sequence and a stem-loop structure close to the target U 
nucleotide (Urban et al., 2009). Twelve RNA independent PUSs identified in human belong to five 
of six known PUSs families, named after prominent representative: tRNA uridine (Tru)A, TruB, 
TruD, RIuA and Pus10p, where RsuA-related family is missing compared to Eubacteria (Li et al., 
2016a). They share some structural feature and require an aspartate in active site for catalysis, 
implying a common mechanism of action (Hamma and Ferre-D'Amare, 2006). 
Genetic experiments revealed that several Pus proteins and/or snoRNAs are responsible for Ψ 
formation within mRNAs (Carlile et al., 2015; Lovejoy et al., 2014; Schwartz et al., 2014a). 
4.1.3.1.4. Erasers and readers 
Specific readers and erasers of Ψ have not been described yet. 
4.1.3.1.5. Role in RNA function and fate 
Studies have shown that the number of Ψ modifications increases with complexity of the organism 
(Ofengand and Bakin, 1997). Ψ formation is dynamically induced in response to environmental 
stimuli. However, the introduction of Ψ might not be reversible as it forms an inert C-C bond. Ψ 
thanks to an additional H-bond donor in the N1H binds a water molecule to bridge the interactions 
of this N1H and the preceding phosphate groups, thus promoting base stacking and hydrogen-
bonding interactions that stabilizes RNA secondary and tertiary structures. It has previously been 
noted that Ψ sites in rRNA and snRNAs tend to occur in “important” regions that directly interact 
with other molecules. In U1, U2, U4, and U6 snRNAs, for example, Ψ sites occur at or close to a 
site that base-pairs with intronic RNA to facilitate RNA splicing (Charette and Gray, 2000). 
Mutations of yeast U2 snRNA at position 35 result in decreased splicing efficiency (McPheeters 
and Abelson, 1992). Ψ at this position was found to structurally stabilize an altered structure 
making the 2′-hydroxyl (OH) of the branch site accessible at the 5′ splice site thus facilitating RNA 
splicing (Newby and Greenbaum, 2001). In rRNA, there is a high density of conserved Ψ sites at 
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the PTC and at the decoding center of the 23S rRNA subunit, which interacts with mRNA and 
with the tRNA stem loop (Bakin et al., 1994; Lane et al., 1992).  
Presence of a snoRNA in yeast that introduces highly conserved 2258 and 2260 Ψ residues located 
near the PTC of the ribosome of helix 69 in domain IV of the large subunit (LSU) rRNA provides 
a growth advantage (Badis et al., 2003). Furthermore, loss of Ψs in helix 69 impairs growth and 
affects ribosome synthesis indicating the relevance of these modifications for ribosome stability 
or assembly (Liang et al., 2009). In yeast, depletion of 1-5 snoRNA that guide formation of 6 Ψ in 
the PTC of rRNA suggested that inhibition of the formation of individual residues in yeast 
ribosomal RNAs depending on its location had no or mild effects on translation, while the lack of 
more residues has a cumulative effect on survival. Most probably a combination of modifications 
is required for proper structural formation and optimal functioning of ribosomes that ultimately 
can support cell survival (King et al., 2003).  
In tRNA, Ψ at position 39 stabilizes its tertiary structure and through structural effects influences 
anticodon recognition (Yarian et al., 1999). 
Besides the constitutive Ψ sites, stress-induced introduction of Ψ in U2 snRNA, U6 snRNA and 
mRNA has been reported. In S. cerevisiae, U2 snRNA has three constitutive Ψ sites at positions 
35, 42 and 44. Under nutrient deprivation Ψ is incorporated at positions 56 and 93 by Pus7p and 
snR81. Presence of Ψ93 reduces pre-mRNA splicing showing function of inducible 
pseudouridylation (Wu et al., 2011a). Under starvation conditions that results in filamentous 
growth of S. cerevisiae, Pus1p was found upregulated and catalyzing Ψ28 in U6 snRNA. Mutations 
in specific sites of U6 snRNA can result in robust pseudouridylation at U28 and change in 
pseudohyphal growth phenotype suggesting that inducible Ψ plays a role also in cell physiology 
(Basak and Query, 2014). 
The role of Ψ in mRNA has been speculated to be stabilizing or altering mRNA metabolism 
(Carlile et al., 2014; Schwartz et al., 2014a). While reading of Ψ by translating machinery is not 
qualitatively affected, translation and resulting protein expression are increased (Kariko et al., 
2008). Kariko (et al.) showed that High-performance liquid chromatography (HPLC)-purified 
pseudouridylated mRNAs do not trigger an immune response and are more stable compared with 
mRNAs containing only uridine. Similarly, they show in mice that synthethic Ψ-modified 
erythropoietin mRNAs generates 10–100 times more erythropoietin compared to synthetic U-
containing mRNAs (Kariko et al., 2012). Although Ψ – containing mRNA in rabbit reticulocyte 
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lysate showed enhanced translation, in wheat germ and E. coli it inhibited translation (Kariko et 
al., 2008). Altogether these data suggest Ψ translation effects might be machinery dependent. 
One vertebrate H/ACA snoRNA E1/U17 (yeast homolog snR30) as part of H/ACA snoRNP was 
identified to take part in cleavage of precursor 18S rRNA (Atzorn et al., 2004). This SnR30 in 
yeast was shown to be essential for cell viability (Bally et al., 1988).  
Mutations in the catalytic domain of dyskerin required for rRNA pseudouridylation have been 
implicated in Hoyeraal-Hreidarsson syndrome, which is characterized by severe spectrum of 
pathologies including immunodeficiency, growth retardation, and microcephaly (Knight et al., 
1999; Yaghmai et al., 2000). 
4.1.3.2. 2-Thiouridine (S2U)  
4.1.3.2.1. Discovery and detection of S2U 
Replacement of oxygen at C2 position of 
the uracil ring with a sulfur atom results in 
2-thiouridine (S2U) (Figure 12). S2U is a 
naturally occurring modification mainly 
identified in the first (wobble) position of 
the anticodon in yeast and in human at the 
wobble position (U34) of mitochondrial tRNA(Lys), tRNA(Glu) and tRNA(Gln) (Umeda et al., 
2005). In yeast S2U is mainly found as part of 5- methylcarboxymethyl-2-thiouridine (mcm5S2U) 
while in human is 5-taurinomethyl-2-thiouridine (tm5s2U) of mitochondrial tRNA(Lys), 
tRNA(Glu), and tRNA(Gln) at the wobble position. S2U units were found to facilitate Watson–
Crick base pairing with adenosine and the wobble pairing with G in the third position of the codon 
thus contributing to translational regulation through codon–anticodon interactions (Johansson et 
al., 2008).  
4.1.3.2.2. Writers, erasers and readers  
tRNA-modifying enzyme mitochondrial tRNA-specific 2-thiouridylase 1 (MTU1) is responsible 
for the 2-thiolation of the wobble position in human and yeast (mt)tRNAs. No specific erasers or 
readers have been identified. 
 
Figure 12. Structure of S2U (left) and uridine (right). Adapted 
from http://modomics.genesilico.pl/modifications/Y/. 
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4.1.3.2.3. Role of S2U in RNA function and fate 
Disruption of the yeast MTU1 gene eliminates the 2-thio modification of (mt)tRNAs and impaires 
mitochondrial protein synthesis resulting in reduced respiratory activity (Umeda et al., 2005). 
S2Us are used together with other modifications by the innate immune system to distinguish 
between self and pathogen RNAs (Kariko et al., 2005).  
4.2. RNA as a danger signal 
Exogenous or endogenous RNA is a danger signal for the immune system (Rettig et al., 2010; 
Scheel et al., 2004; Tusup and Pascolo, 2017). Recognition of RNA is mediated through 
intracellular receptors located on the endosomal membrane or in the cytosol. Receptors associated 
with the endosomal membrane are members of the TLR family including: mouse and human TLR3 
binding dsRNA (Alexopoulou et al., 2001), TLR7 (Diebold et al., 2004; Heil et al., 2004), human 
TLR8 recognizing single stranded RNA (Heil et al., 2004) and only present in mice TLR13 
recognizing single stranded bacterial 23S rRNA (Oldenburg et al., 2012).  
Expression of these receptors varies among cells. While TLR7 is predominately expressed in 
plasmacytoid dendritic cells (DCs) and, to some extent, in B cells and monocytes/macrophages 
(Gantier et al., 2008; Hornung et al., 2002), TLR8 is known to be primarily expressed in 
monocytes/macrophages and myeloid DCs (mDCs) (Hornung et al., 2002), TLR13 is mainly 
expressed in conventional mouse DCs and macrophages (Shi et al., 2011) and TLR3 is widely 
expressed in macrophages and mDCs but was also identified in fibroblasts, neurons, and epithelial 
cells (Cario and Podolsky, 2000; Hewson et al., 2005; Lafon et al., 2006; Matsumoto et al., 2002; 
Shi et al., 2000). Binding of RNA drives dimerization (TLR3 and TLR13) or conformational 
changes (TLR7 and TLR8) of these receptors resulting in their activation (Song et al., 2015). Upon 
activation these receptors recruit and interact with TIR-domain-containing adaptor proteins such 
as Myeloid differentiation primary response 88 (MyD88) (TLR7, TLR8 and TLR13) and TIR-
domain-containing adapter-inducing interferon-β (TRIF) (TLR3).  
In MyD88-dependent signaling, recruitment of a complex consisting in ubiquitin-ligases and 
kinases: TNF-associated factor 3 (TRAF3), TNF-associated factor 6 (TRAF6), IL-1R-associated 
kinase 1 (IRAK1), IL-1R-associated kinase 4 (IRAK4), inhibitor of NF-κB kinase (IKK)α, leads 
to activation and nuclear localization of interferon-regulatory factor 7 (IRF7), nuclear factor-κB 
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(NF- κB), activator protein 1 (AP-1) and cyclic AMP-responsive element-binding protein (CREB) 
where they trigger the production of type I interferon and pro-inflammatory cytokines.  
TRIF interacts with receptor-interacting protein 1 (RIP-1), TRAF6 and TRAF3 which in turn 
interact with kinase complexes leading to activation of NF-κB, mitogen-activated protein kinase 
(MAPK) and interferon-regulatory factor 3 (IRF3) induction of inflammatory cytokines and 
interferon-beta (IFNβ) (Akira et al., 2006; Kawai and Akira, 2010).  
Cytosolic receptors are part of retinoic acid–inducible gene (RIG)-I–like receptors (RLR) family 
where RIG-I and MDA5 bind dsRNA. Preferential binding to short dsRNA or 5′ppp uncapped 
ssRNA is attributed to RIG-I while MDA5 binds long, capped, di- or mono-5′ phosphate dsRNA 
(Hornung et al., 2006; Kato et al., 2008; Kato et al., 2006). Ligand binding induces RIG-I and 
MDA5 to assemble with mitochondrial antiviral-signaling protein (MAVS) on the mitochondrial 
and peroxisome membranes. Through caspase activation and recruitment domains (CARD)-
CARD interaction MAVS undergoes activation thereby orchestrating recruitment of kinases 
IKKα, IKKβ and IKKγ that activate transcription factor NF-κB, and IKKε and TANK-
binding kinase 1 (TBK1) activating IRF3 and IRF7. These transcription factors translocate to the 
nucleus and bind regulatory elements where they stimulate expression of type I interferon genes 
(Chan and Gack, 2016). 
4.2.1. Immune recognition impaired by RNA modifications 
Immunogenicity of RNA confines to their RNA modifications. Presence and abundance of RNA 
modifications correlates with the complexity of the organism. Studies have shown that total 
bacterial RNA is highly immunogenic for cytokine production in comparison with not 
immunostimulating total mammalian RNA in lipofectin-RNA transfected dendritic cells (Kariko 
et al., 2005).  
The activation of immune receptors depends on the type and proportion of specific modifications 
in total RNA. Ivt RNAs activate human TLR3, TLR7 and TLR8, while chemically synthesized 
oligoribonucleotides (ORNs) stimulate murine TLR7 and human TLR8. Some sequences are 
known to enhance the potential of RNA to stimulate TLR7 and TLR8, such as GU- rich sequences 
and oligo-G tails (Heil et al., 2004; Hornung et al., 2005; Peng et al., 2005). In different cell types, 
such as HEK cells transfected with TLR3, TLR7 or TLR8 and monocyte-derived dendritic cells 
(MDDCs), transfection with lipofectin-ivt RNA containing m6A, m5C, Ψ, S2U or a combination 
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of modifications (m6A and Ψ) gave less or no immunostimulation in comparison to unmodified 
ivt RNA as recorded by production of interleukin (IL)-8, IL-12p70, tumor necrosis factor-alpha 
(TNF-α) and interferon-alpha (IFN-α). Presence of S2U and m6A in ivt RNA was shown to 
suppress recognition by TLR3 while m6A, m5C, Ψ and S2U limit the capacity of RNA to activate 
TLR7 and TLR8 in HEK cells transfected with respective TLRs. However, Ψ-containing ivt RNA 
was shown to activate TLR3 and induce IL-8, although to a lesser extent compared to unmodified 
RNA. This has been associated with base stacking properties of Ψ and possible stabilization of 
existing RNA duplexes. Conversely, presence of m6A destabilizes RNA duplexes thus preventing 
TLR3 activation (Kariko et al., 2005).  
Polyinosinic:polycytidilic acid (poly(I:C)) is known to be a more potent inducer of IFN-α 
production compared to polyadenylic:polyuridylic acid (poly(A:U)) through TLR3 activation 
(Field et al., 1967). Introducing 2′-O-methylation in double-stranded RNA to generate poly(I:Cm) 
and poly(A:Um) reduced or abrogated triggering of IFN-α (De Clercq et al., 1972). 2′-O-
methylation of uridines in single stranded ORNs blocks TNF-α induction in peripheral blood 
mononuclear cells (PBMCs) (Sioud, 2006). Recently it has been reported that 2′-O-methylation in 
ORNs turns a TLR7 agonist into a TLR8 specific ligand (Jung et al., 2015). Moreover, the 5′ cap 
structures of higher eukaryote mRNAs are known to possess ribose 2′-O-methylation in cap1 and 
cap2. Studies suggest that viruses incorporate similar or identical modifications in their mRNA to 
mimic host mRNA and evade immune system recognition. Sensing of 2′-O-methylation in viral 
RNA was attributed to MDA5 and TLR7 since infection of murine herpes virus (MHV) with 
mutated 2′-O-methyltransferase did not affect replication and spreading of viral mutants in MDA5 
ko and TLR7 ko while wild-type mice were virus-free (Zust et al., 2011). Additionally, N1 2′-O-
methylation in mRNA was shown to prevent binding to RIG-I thereby blocking its activation 
(Devarkar et al., 2016). Similarly, m6A and Ψ in polyU/UC RNA (derived from Hepatitis C virus 
genomic RNA) were identified to impede activation of RIG-I. However, these RNAs bound with 
poor (m6A RNA) and high affinity (Ψ) to RIG-I, but failed to trigger conformational changes in 
RIG-I required for its activation (Durbin et al., 2016). 
SsRNA containing inosine and formulated in DOTAP (liposome) was shown to induce higher 
TNF-α production in PBMCs than a control RNA containing canonical nucleotides. Increase in 
TNF-production is mostly TLR8 dependent in human PBMCs. Moreover, this inosine ssRNA 
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induced lower IFN-α induction than unmodified RNA in human immune cells (Sarvestani et al., 
2014).  
Importantly, RNA immunostimulation studies have shown that 1.7-3.2% (14-29 nucleotides in 
1571 long RNA) modified nucleotides are sufficient to decrease TNF-α to half of the amount 
induced by lipofectin- unmodified RNA transfection in MDDCs (Kariko et al., 2005).  
Taken altogether, our immune system has evolved to distinguish heavily modified self RNA from 
less modified non-self RNA as a danger signal.  
4.2.2. DNA-demethylating chemotherapies inducing endogenous RNA 
DNA methylation inhibitors (DNMTis) were shown to be clinically efficient in solid and 
hematopoietic tumors. Their efficacy is attributed to demethylation of hypermethylated CpG island 
(CGI) present in the promoters of tumor-suppressor genes (TSGs) in cancer. However, recently a 
novel concept has emerged of possible DNMTis off-targets contributing to their potency. 5-aza-2-
deoxycytidine (5-AZA-CdR) is a DNMTis used in hematological malignancies known to act as a 
cytidine analog that traps DNA methyltransferases after incorporation into DNA, resulting in 
global DNA demethylation as cells divide (Juttermann et al., 1994; Kelly et al., 2010). Transient 
low dose exposure to 5-AZA-CdR was shown to target colorectal cancer initiating cells by 
inducing dsRNA expression, activation of the cytosolic pattern recognition receptor MDA5 and 
downstream activation of MAVS and IRF7. Induced dsRNAs were identified as human 
endogenous retrovirus (ERV), reported to trigger signaling by cytosolic pattern-recognition 
receptors and activate MAVS in mammals (Roulois et al., 2015). Moreover, transient treatment of 
ovarian cancer cell lines with 5-azacytidine (Aza) and 5-aza-2′-deoxycytidine (Dac) shown 
upregulation in immune genes. These DNMTis trigger cytosolic sensing of ERV, with MAVS and 
TLR3 involved in Aza induced Type I Interferon response (Chiappinelli et al., 2015). Re-
evaluation of known chemotherapies at low-doses and possibly in combination with other 
therapies could give insight into their immunomodulatory mechanisms and potentiate their anti-
cancer efficacy. 
4.3. Enhancing in vitro transcribed mRNA translation using RNA modifications 
Therapeutic ivt mRNA production demands accurate structural mimicking of mature eukaryotic 
mRNA (emRNA). Similarly, to emRNA, ivt mRNA contains a 5′ cap, an open reading frame 
with start and stop codons and flanking 5′ and 3′ UTR sequences, and a 3′ poly(A) tail. For each 
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of these mRNA units, strategies are being developed to improve ivt mRNA stability and prevent 
immune recognition that would ultimately enhance its translatability in eukaryotic cells.  
Current strategies include employment of: 
• 5′ cap - Phosphorothioate modified- cap analogues capable of attracting eukaryotic 
translation machinery and preventing decapping enzymes responsible for mRNA decay 
(Kuhn et al., 2011). N1-2′-O-methylation to mimic Cap1 and Cap2 structures and 
prevent TLR7, MDA5 and RIG-I signaling (Grudzien-Nogalska et al., 2007; Kowalska 
et al., 2008). Introduction of base and ribose modifications – N1-methyl Ψ, Ψ, m5C, 
S2U, 5-methyluridine or m6A decreasing TLR3, TLR7, TLR8, RIG-I and protein kinase 
RNA-activated (PKR) signaling (Kariko et al., 2005; Kariko et al., 2008).  
• Codon optimization – employment of frequent synonymous codons and CUG start 
codon instead of AUG (Gustafsson et al., 2004; Malarkannan et al., 1999). 
• 3′ end of the poly(A) tail should not be masked by additional bases and that the optimal 
length of the poly(A) tail is between 120 and 150 nucleotides (Holtkamp et al., 2006). 
• Incorporate 5′- and 3′-UTRs containing regulatory sequence elements that have been 
identified to modulate the translation and stability of endogenous mRNA such as 3′-
UTRs of α- and β-globin mRNAs (Carralot et al., 2004; Holtkamp et al., 2006; Kariko 
et al., 1999). 
 
Considering the technological advances improving quantification and localization of mRNA 
modifications, novel options could be exploited for enhancing ivt mRNA therapeutic properties 
(Tusup et al. 2017, submitted). 
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5. Aims of the thesis 
Studies conducted in this thesis used formulations of RNA, with the following specific aims: 
A1. Characterization of immunostimulatory profiles triggered by modified (natural) RNA 
molecules in vitro. 
A2. Changing immunostimulation profiles of natural RNA by drug treatment steering RNA 
modifications. 
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Abstract 
The functional impact of modifications of cellular RNAs, including mRNAs, miRNAs 
and lncRNAs, is a field of intense study. The role of such modifications in cancer has 
started to be elucidated. Diverse and sometimes opposite effects of RNA modifications 
have been reported. Some RNA modifications promote, while others decrease the growth 
and invasiveness of cancer. The present manuscript reviews the current knowledge on 
the potential impacts of N6-Methyladenosine, Pseudouridine, Inosine, 2’O-Methylation 
or Methylcytidine in cancer’s RNA. It also highlights the remaining questions and 
provides hints on research avenues and potential therapeutic applications, whereby 
modulating dynamic RNA modifications may be a new method to treat cancer. 
 
Key words: RNA modifications; m6A; m5C; 2’O-mN; Pseudouridine; Inosine 
 
 
Core tip: The present manuscript reviews the current knowledge on RNA modifications 
in cancer. The potential impacts of N6-Methyladenosine, Pseudouridine, Inosine, 2’O-
Methylation or Methylcytidine in cancer’s RNA is presented and discussed. The review 
also highlights the remaining questions and provides hints on research avenues and 
potential therapeutic applications, whereby modulating dynamic RNA modifications 
may be a new method to treat cancer. 
 
Tusup M, Kundig T, Pascolo S. Epitranscriptomic of cancer.  
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INTRODUCTION 
Diverse and abundant modifications are introduced posttrancriptionally in cellular 
RNAs during their maturation. These modifications are made on canonical A, C, G, and 
U residues, and their formation is catalyzed by numerous specific enzymes or RNA-
protein complexes (RNPs). Ribonucleotide residues can bear single or multiple 
modifications on the purine/pyrimidine ring and/or ribose. To date, over one hundred 
RNA modifications have been identified and listed in dedicated databases 
(http://mods.rna.albany.edu/; http://modomics.genesilico.pl)[1,2]. These naturally 
occurring modified nucleosides play various structural and functional roles in different 
types of RNAs: Transfer RNAs (tRNAs), ribosomal RNAs (rRNAs), messenger RNAs 
(mRNAs), small nuclear RNAs (snRNAs), microRNAs (miRNAs) and long non-coding 
RNAs (lncRNAs). The most widespread RNA modifications are base or ribose 
methylations, deamination of adenosine to inosine and isomerization of uridine into 
pseudouridine. Over the past decades these modifications have been studied in the 
context of   malignancies. Frequently, a modification is found to have pro-cancer or anti-
cancer effects depending on the type of RNA, the location of the modification and, most 
importantly, the cell type and context (e.g., hypoxia). This review presents the current 
knowledge on the potential link between RNA modifications and cancer by 
systematically addressing the “pro-cancer”, “anti-cancer” and mixed effects of RNA 
modifications. Since such a relationship has been reported for only some abundant 
modifications and for modifications for which a detection method is available [N6-
Methyladenosine (m6A), 5-Methylcytidine (m5C), 2’O-mN, Ψ and I], the present review 
will focus on these modifications (Figure 1). 
 
M6A IN CANCER RNA 
Serendipitously discovered during the characterization of the mRNA 5’ cap, methylation 
of the exocyclic nitrogen of adenosine, named m6A, is by far the most abundant mRNA 
modification, occurring on an average of three sites per mRNA[3-5]. Recent technological 
advances have facilitated m6A profiling across eukaryotes, including humans, mice[6], 
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yeasts[7], and plants[8,9], indicating that m6A is a conserved but dynamic modification. 
m6A has also been identified in rRNA[10], tRNA[11], snRNA[12], miRNA[13] and lncRNA[14]. 
M6A patterns are attributed to the consensus RRACH sequence (A is methylated; R = 
A or G; H = A, C, or U; and the first nucleotide next to m6A from the 5’ end most 
frequently is G), with preferential distribution near mRNA stop codons and 3’ 
untranslated regions (UTRs) and within long internal exons. Additionally, the m6A sites 
are conserved between human and mouse embryonic stem cells (ESCs) and somatic cells. 
However, distinct m6A patterns can also be detected among different species or cells at 
different developmental stages[4,7,15,16]. Some m6A signatures are tissue specific[4], and are 
altered in response to different stimuli[17], pointing to the potential role of m6A in 
regulating diverse cellular processes. m6A dynamics are assigned to the complex m6A 
enzymatic machineries, comprising m6A “writers”, “readers” and “erasers”. Although a 
plethora of studies suggest crucial and versatile roles of m6A and its machineries, its roles 
in cancer that have recently emerged are contradictory and require further investigation.  
 
High m6A levels in cancers 
“Writers” is a term given to enzymes that are part of the methyltransferase complex that 
introduces m6A. Components of this complex are methyltransferase-like 3 (METTL3)[18], 
METTL14[19], Wilms tumor 1-associated protein (WTAP)[20] and KIAA1429[21].  
METTL3 protein levels were found to be elevated in lung adenocarcinoma cell lines 
compared to healthy tissue[22]. Depletion of METTL3 was shown to result in the inhibition 
of cancer cell growth, decreased invasive ability of cancer cells and increased cell 
apoptosis in the same study. Additionally, METTL3 was shown to function as an m6A-
binding protein (‘reader’) in a specific subset of m6A-modified mRNAs, where it recruits 
eIF3 during translation initiation and therefore promotes translation. Expression of 
several oncogenes, including the mRNA of epidermal growth factor receptor (EGFR) and 
the Hippo pathway effector transcriptional co-activator with the PDZ-binding 
motif (TAZ) protein, was found to be promoted upon METTL3 recognition[22]. 
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Similarly, in acute myeloid leukemia (AML), mRNA levels of METTL3 and METTL14 
are significantly higher than in most cancers[23]. METTL3 depletion in MOLM13 caused 
differentiation and increased apoptosis, suggesting that high m6A levels may play a role 
in sustaining undifferentiated leukemic cells in AML[23] (Table 1). 
 
Low m6A levels in cancers 
Two m6A ‘erasers’ have been described: demethylases fat mass and obesity-associated 
protein (FTO) and alkB homolog 5 (ALKBH5)[24,25].  
Single nucleotide polymorphisms within FTO known to be involved in the 
development of obesity in genome-wide association studies have been associated with 
the risk of developing diverse cancer types: Lung cancer, kidney cancer, high-grade 
prostate cancer, endometrial cancer, pancreatic cancer, pancreatic cancer in patients with 
type 2 diabetes, and breast cancer[26-33]. All these cancer types share a single SNP 
(rsrs9939609): The obesity-associated SNP in intron 1 of the FTO gene. This SNP was 
shown to increase primary transcript levels of the FTO gene, suggesting a gain-of-
function mutation in cancers associated with this SNP[34].  
In human epidermal growth factor receptor type 2 (HER2)-overexpressing subtypes of 
breast cancer, FTO is highly expressed in comparison to other breast cancer subtypes[35]. 
Contrary to the studies of high m6A levels in AML discussed in the previous chapter, 
low m6A levels have also been reported in AML subtypes. FTO expression can be 
upregulated by certain oncogenic proteins (e.g., mixed lineage leukemia (MLL)-fusion 
proteins, promyelocytic leukemia/retinoic acid receptor alpha (PML-RARA), fms-related 
tyrosine kinase 3–internal tandem duplication (FLT3-ITD), and nucleophosmin 1 (NPM1) 
mutant), and dataset analysis of human AML confirmed that FTO was expressed at 
significantly high levels in t(11q23)/MLL-rearranged, t(15;17)/PML-RARA, FLT3-ITD, 
and/or NPM1-mutated AMLs[36]. Overexpression of FTO reduces m6A levels in ankyrin 
repeat and SOCS box containing 2 (ASB2) and retinoic acid receptor alpha (RARA) 
mRNA transcripts. It has been shown that the loss of m6A markings reduces mRNA 
stability, resulting in the partial repression of ASB2 and RARA expression in AML cells. 
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In four different AML cohorts, ASB2 and RARA exhibit a significant inverse correlation 
with FTO expression. ASB2 and RARA are upregulated during normal hematopoiesis 
and are important regulators of all-trans-retinoic acid (ATRA)-induced differentiation of 
leukemia cells. Through regulating the expression of such targets, FTO inhibits ATRA-
induced AML cell differentiation. Both gain- and loss-of-function studies of FTO in 
leukemic cell models showed an oncogenic role of FTO in these AML subtypes[36]. 
However, recent studies have suggested that FTO acts as a demethylase of N6-2’O-
dimethyladenosine in mRNA 5’ caps, having only minor effects on m6A[37]. Thus, the role 
of FTO in AML might be independent of m6A. 
Recently, both FTO and ALKBH5 have been found to play similar roles in glioblastoma 
stem cells (GSCs) and their tumorigenesis[38]. These studies shed light on their crucial 
roles in the regulation of mRNA m6A levels for maintaining GSC growth, self-renewal, 
and tumor development. Enhanced growth and self-renewal of GSCs in vitro were 
detected upon the depletion of METTL3 or METTL14, resulting in reduced mRNA m6A 
levels, and promoted the ability of GSCs to form brain tumors in vivo. Accordingly, 
treatment with the FTO inhibitor MA2, the ethyl ester form of meclofenamic acid, 
increased mRNA m6A levels and suppressed GSC growth in vitro and GSC-initiated 
tumorigenesis, ultimately prolonging the survival of GSC-engrafted mice.  
In a similar study, the authors checked the expression levels of m6A regulators in 
available datasets for glioblastoma multiforme (GBM) and discovered elevated 
expression of m6A demethylase ALKBH5 that correlated with poor clinical outcomes for 
GBM patients[39]. Stable knockdowns in cultured human GSCs showed that the loss of 
ALKBH5 decreases GSC proliferation and reduces the expression of the stemness 
markers Nestin, Sox2, Nanog, and Oct4, which are normally expressed in GSCs. In rescue 
experiments, wild-type, but not catalytically inactive, ALKBH5 recovers the phenotype, 
suggesting that it plays a role in stemness maintenance and that the proliferation of GSCs 
is solely based on demethylation activity. Moreover, these authors examined the 
expression of transcription factor FOXM1 (forkhead box m1), which is known to play a 
pivotal role in regulating GSC proliferation, self-renewal, and tumorigenicity, and found 
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that it depends on ALKBH5 demethylating activity. All these findings were based on 
m6A hyper erasing, which opens new possibilities for promising targeted treatments in 
glioblastoma (Table 1). 
It has been reported that the hypoxia-inducible factors (HIFs) HIF-1α and HIF-2α 
activate ALKBH5 gene transcription under hypoxic conditions in breast cancer cells, thus 
inducing m6A demethylation. This demethylation was shown to stabilize NANOG 
mRNA and promote the breast cancer stem cell (BCSC) phenotype. Depletion of ALKBH5 
in hypoxic breast cancer cells was identified as an effective strategy to decrease NANOG 
expression and limit the presence of BCSCs in vivo[40] (Table 1).  
 
Mixed role of m6A in cancer 
The primary microRNA (pri-miRNA) junction region between the hairpin stem and the 
flanking single-stranded RNA was found to be abundant in m6A consensus motifs. The 
recognition of the junction regions is mediated by Dicer, followed by the recruitment of 
the ribonuclease Drosha (the microprocessor complex), which cleaves the RNA duplex to 
yield the premiRNA product. Depletion of HNRNPA2B1 (a nuclear “reader”) or METTL3 
knockdown in HEK293 and MDA-MB-231 cells resulted in a significant reduction in the 
expression levels of the mature forms of a number of m6A-marked miRNAs. The tumor-
suppressor miRNA let-7 was significantly reduced upon the depletion of METTL3 
possibly due to diminished Dicer binding to pri-miRNAs, thus preventing the formation 
of mature miRNAs. However, these METTL3-depletion experiments also showed a 
decrease in the expression of onco-miRNAs, such as miR-221 and miR-222[13,41]. Taken 
together, the presence of m6A affects diverse pri-miRNA and mature miRNA 
subpopulations, but its relevance in the context of cancer still needs to be investigated. 
 
2’O-METHYLATION IN CANCER RNA 
Methylation of the 2′-hydroxyl group of ribose is one of the predominant internal 
modifications of rRNA and snRNA[10,42]. This modification is also found in tRNA and 
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mRNA, mostly at the first and second nucleotides in Cap1 and Cap2 structures, 
respectively. 
Introducing 2’O-methylation on ribose is mediated by complexes of guide RNA and 
proteins named small nucleolar ribonucleoprotein (snoRNP) complexes or by 
methyltransferases: human cap1 and 2, 2′-O-ribose methyltransferase, hMTr1 and 
hMTr2[43-45]. snoRNP complexes consist of Fibrillarin (the catalytic component in humans, 
also known as Nop1p in yeast), Nol5a (Nop56p), Nop58 and Snu13 subunits[46-48], which 
are guided by C/D Box snoRNAs to the appropriate base[49-50]. 
 
High 2’O-methylation levels in cancer 
Tumor suppressor p53 and Fibrillarin seem to be linked[51]. Knockdown of p53 in cellular 
models of breast and colon cancer resulted in the overexpression of Fibrillarin at both the 
mRNA and protein levels. It is suggested that tumorigenesis associated to mutated p53 
promotes an increase in the methylation status of rRNAs, which alters their ribozyme 
activity, thus affecting their translation fidelity and rate. Through the methylation of 
rRNA, Fibrillarin stimulates the translation of cancer-promoting proteins:  
(1) Insulin-like growth factor 1 receptor (IGF1R), which plays a role in tumor progression, 
cell survival, and the response to chemotherapy (reviewed by Pollak et al[52]); (2) c-Myc, 
a pleiotropic pro-oncogene (reviewed by Dang et al [53]); (3) Fibroblast growth factor 1/2 
(FGF1/2), which is involved in epithelial-mesenchymal transition[54], and (4) Vascular 
endothelial growth factor A (VEGFA), which acts in tumoral angiogenesis[51,55].  
Translation of these proteins relies on internal ribosome entry site (IRES) in the mRNA, 
which is a 5’ cap-independent translation mechanism that may be used in specific 
conditions. The inhibition of rRNA methylation was shown to impair IRES translation 
initiation by perturbing the association of the 40S and 60S subunits[56]. Therefore, it is 
conceivable that enhanced ribosomal methylation increases the translation of IRES-
containing mRNAs. Nevertheless, clinical analysis shows that a high level of Fibrillarin in 
primary breast tumors is associated with poor survival, independent of other biological 
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markers[51]. Elevated expression levels of Fibrillarin were previously reported in primary 
and metastatic prostate cancers and in squamous cell cervical carcinoma (Table 1)[57,58].  
NOL5A gene was found to be overexpressed in Burkitt’s lymphoma-associated c-Myc 
mutants[59], and human NOP58 mRNA levels were found to be elevated in metastatic 
melanoma lesions[60]. 
 
Low 2’O-methylation levels in cancer   
Contrary to Fibrillarin’s indirect promotion of IRES-driven translation, in MCF-7, a breast 
cancer cell line, Fibrillarin knockdown resulted in the accumulation of p53, possibly 
affecting the UTR of the p53 mRNA and increasing IRES-driven de novo synthesis[61]. 
These studies suggest a complex interplay between p53 and Fibrillarin, while IRES-
dependent translation is not exclusively stimulated by increased rRNA methylation.  
 
Mixed 2’O-methylation in cancer 
SnoRNA expression profiles were investigated in endometrial, lung and prostate cancers, 
as well as in glioma and chronic lymphocytic leukemia. High-throughput screening of 
snoRNAs in cancerous versus normal tissues underlined their overexpression or 
underexpression as common molecular events in tumorigenesis, with the former being 
more pronounced than the latter[62-66]. Analysis of blood serum has shown the possibility 
of detecting snoRNAs in breast cancer patient samples and the associated upregulation 
of a specific snoRNA, U6, in active disease [67]. Therefore, profiling snoRNAs with their 
respective RNA 2’O methylation modification signatures might be used as a noninvasive 
biomarker in the diagnosis and prognosis of cancer. 
 
PSEUDOURIDINE IN CANCER RNA 
The fifth base, known as pseudouridine (Ψ)[68], is one of the most abundant nucleotide 
modifications present in all three life domains[2]. After its initial detection in rRNA and 
tRNA, pseudouridine was detected in mRNA, lncRNA, and snRNAs, such as U2 snRNA 
and snoRNA[69,70]. Introducing Ψ in eukaryotic RNA can be mediated through guide 
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RNA-dependent H/ACA BOX snoRNA pseudouridine synthases (PUSs) or guide RNA-
independent PUSs. A recent review by Penzo et al[71] reports on the functional roles of 
pseudouridines and related human pathologies. 
Only low Ψ levels have been reported in cancer tissues/cells; thus, this chapter will 
contain only a section titled “Low Ψ levels in cancer”. Surprisingly, elevated levels of 
circulating Ψ have been measured in the body fluids of cancer patients, but its role and 
origin are not well defined, so this finding will not be further discussed here. 
The highly conserved protein dyskerin is the human PUS that catalyzes the 
pseudouridylation of snoRNPs that assemble during the transcription of guide H/ACA 
RNA. Mutations in the Dkc1 gene coding for dyskerin can be found in the X-linked form 
of dyskeratosis congenita (DC). DC is a rare, inherited disorder that is characterized by 
mucocutaneous abnormalities and bone marrow failure. DC can be inherited as an X-
linked recessive, autosomal dominant or autosomal recessive disease[72]. Although the 
absence of dyskerin, which results in the loss of pseudouridine in rRNA, was suggested 
as a primary cause of DC, a recent study assigned telomerase dysfunction as the primary 
cause of DC[73]. Namely, mutations in H/ACA-resembling domains in the RNA 
component of telomerase RNP, which are required for telomerase accumulation, stability, 
3’ end processing and function, are associated with an autosomal form of DC[74-76] .  
In patients with DC, a higher predisposition to cancer has been reported, although low 
mutational frequency in the DKC1 gene was shown in primary tumors[77]. This 
predisposition might be a synergistic outcome of impaired pseudouridylation. Most 
likely, the dysregulation of rRNA pseudouridylation precedes disease onset, as studies 
in hypomorphic Dkc1-mutant mice suggest. A specific defect of the internal ribosome 
entry site also occurs upon DKC1 loss, causing a specific defect in the translation of some 
IRES-containing mRNAs. Ribosomes that lack pseudouridine modifications show a 
direct impairment in binding to IRES elements[78]. Consequently, in hypomorphic DKC-
1 mice, cap-dependent translation of mRNA is not compromised, but translation of IRES-
containing mRNAs, including the tumor suppressors p27 and p53, is perturbed[79-82], 
resulting in a higher incidence of cancer development in these mice. Thus, this impaired 
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translation of tumor suppressor mRNA might also be a driver of cancer in DC patients. 
Moreover, recent identification of Ψ in mRNA[83] brings an additional level of complexity 
and regulation of the expression of target RNAs. 
In hematological cancers, such as leukemias, lymphoma and multiple myeloma, 
downregulation of specific subsets of dyskerin-associated H/ACA snoRNAs has been 
demonstrated[84-86] (Table 1). Thus, lower pseudouridylation levels are a widespread 
feature of cancer. 
 
INOSINE IN CANCER RNA 
Inosine is an RNA modification resulting from the hydrolytic deamination of adenosine 
catalyzed by adenosine deaminase enzymes acting on double-stranded RNA (ADAR) or 
adenosine deaminase acting on transfer RNA (ADAT), which are families known to 
function in A-to-I RNA editing. Enzymes of the ADAR family are catalytically active 
ADAR1, ADAR2 and ADAR3, which still has an unknown function.  
ADARs introduce inosine in coding and non-coding RNAs and have drastic impacts 
on the cellular transcriptome and translatome. The hypo- or hyper-editome has been 
associated with diverse types of cancer. The role of ADAT in cancer has not been 
reported. 
High editing levels in cancer 
Most frequently editing locations are long, partially complementary RNAs formed from 
inverted non-coding repeats, such as Arthrobacter luteus (Alu) and long interspersed 
element (LINE) located in mRNA UTRs and introns. Two major studies have investigated 
RNA-editing patterns in tumors versus normal tissues. Each of the studies employed 
RNA-Seq datasets from The Cancer Genome Atlas (TCGA) project 
(https://cancergenome.nih.gov/) and compared them to reference datasets of editing 
sites. High-confidence RNA editing sites are annotated in the Rigorously Annotated 
Database of A-to-I RNA Editing (RADAR, http://rnaedit.com/), where one study 
focused on detecting Alu and non-Alu RNA editing events in 17 cancers, whereas the 
other study focused on Alu RNA editing events in 9 different cancers[87,88]. 
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In general, elevated Alu editing activity in tumors compared to matched normal tissues 
was found in bladder urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA), 
colon adenocarcinoma (COAD), head and neck squamous cell carcinoma (HNSC), lung 
adenocarcinoma (LUAD) and thyroid carcinoma (THCA). This hyperediting of Alu was 
attributed to ADAR1, whose expression levels matched in all these types of cancer, except 
COAD. Similarly, a study by Han et al. where more patient samples and non-Alu edited 
sequences were included, confirmed hyperediting in BLCA, BRCA, HNSC, LUAD, 
THCA compared to normal tissues. Again, increased editing levels correlated with the 
mRNA levels of ADAR1.  
Increased ADAR-1 levels were reported in non-small cell lung cancer (NSCLC), 
hepatocellular carcinoma (HCC), esophageal cell carcinoma (ESCC), gastric (GC) and 
cervical cancer, suggesting that tight regulation of editing levels might have implications 
in cancer development and that ADAR1 might act as an oncogene[89-92] (Table 1 and 
Figure 2).  
 
Recoding editing: In non-small cell lung cancer samples, ADAR1 gene amplification was 
shown to increase the editing of the DNA base excision repair glycosylase enzyme NEI-
like protein 1 (NEIL1). Pre-mRNA editing of NEIL-1 causes a lysine to arginine (K242R) 
change in the lesion recognition loop of the protein. The edited NEIL1 protein removes 
thymine glycol from duplex DNA at a lower rate compared to the unedited form, while 
repair of the guanidinohydantoin lesion is enhanced by edited NEIL1[93]. In 
overexpression experiments, transfection of edited NEIL1 enhanced the growth of A459 
cells in comparison with the transfection of unedited transcripts. Thus, increased 
recoding editing of NEIL1 as a proposed target of ADAR1 could contribute to the 
phenotype of lung cancer cells[94].  
AZIN1 (encoding antizyme inhibitor 1) is edited by ADAR1, which has increased 
expression levels in HCC and was found to positively correlate with AZIN1 editing 
frequency. AZIN1 is an antizyme inhibitor whose activity is crucial in limiting cellular 
proliferation. Antizyme binds and induces the degradation of the growth-promoting 
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proteins ornithine decarboxylase (ODC) and cyclin D1 (CCND1)[95,96]. AZIN1 is 
homologous to ODC and has a greater binding affinity to antizyme compared to ODC. 
Binding of AZIN1 to antizyme prevents the degradation of ODC[97]. Thereby, AZIN1 acts 
as an oncogene by inhibiting the tumor-suppressor activities of antizyme[96]. AZIN1 
expression was found to be substantially elevated in cancers of the prostate, brain, breast 
and liver, and gene expression data have identified alterations in the AZIN1-to-antizyme 
ratio in many human cancers, confirming its role in promoting growth[98-100]. In HCC, 
increased A-I editing of the AZIN1 transcript introduces serine-to-glycine substitution at 
residue 367 in the protein. This recoding editing is associated with conformational 
changes and translocation from the nucleus to the cytoplasm and results in a higher-
binding affinity to antizyme and greater protein stability, thus promoting cell 
proliferation. AZIN editing increases during the progression from primary liver cancer 
and cirrhosis to advanced HCC with recurrence and metastasis, suggesting its use as a 
prognostic marker[101] . It is plausible that similar editing events occur in other types of 
cancer, as has been confirmed in esophageal squamous cell carcinoma (ESCC) and breast 
cancer[87,92,102]. Recently, tumorigenesis of NSCLC was also attributed to high levels of 
AZIN1 editing[103]. It has been reported that AZIN1 editing levels correlate with 
sensitivity to drug treatment in cancer cell lines. Cancer cells lines with increased levels 
of AZIN1 editing showed more sensitivity to some of the chemotherapies used in small 
cell lung cancer (SCLC): paclitaxel, irinotecan, and topotecan[87]. 
Filamin B (FLNB) is an actin cross-linking protein and, together with filamin A, it forms 
homo- and heterodimers mediating orthogonal branching of actin filaments [104]. Filamin 
B is known to be a target for editing [105], and interestingly, one recoding editing event 
was shown to be increased in two types of cancer. In HCC, ADAR1 and ADAR2 were 
both reported to mediate FLNB transcript editing in codon 2269, resulting in the amino 
acid change Met→Val. Increased editing of FLNB compared to matched non-tumor liver 
tissues has been closely associated with HCC pathogenesis from normal to clinically 
verified HCC. In this study, ADAR1 levels were shown to be increased, while ADAR2 
levels were decreased in HCC samples compared to non-tumor liver tissues[90]. The same 
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recoding editing was found in ESCC, where unlike HCC, only ADAR1 was responsible 
for this hyperediting. FLNB hyperediting correlated with ADAR1 levels in ESCC 
samples[92]. The functional role of FLNB editing is not known. 
Ras homolog family member Q (RHOQ) belongs to a family of Rho GTPases that are 
known to be intracellular signaling molecules regulating the actin cytoskeleton and 
thereby cellular functions, such as cell polarity, migration, and vesicular trafficking. Rho 
GTPases are present as either an active GTP-bound form or an inactive GDP-bound 
form[106]. Activation of Rho GTPases is implicated in the development and progression of 
many types of human malignancies, including CRC[107]. RhoQ has been most extensively 
studied for its central role in insulin-stimulated GLUT4 transport in adipocytes[108]. 
Amino acid substitution of asparagine with serine (N136S) in the edited RhoQ was 
identified in colorectal cancer (CRC). The ADAR responsible has not been identified. This 
editing was suggested to change RhoQ protein–protein interactions and induce increased 
levels of RhoQ binding of GTP, causing actin cytoskeletal reorganization and increased 
invasion potential without affecting proliferation in CRC cell lines. Moreover, edited 
RHOQ was associated with recurrence of CRC when present in the tumor[109].  
Protein tyrosine phosphatase non-receptor type 6 (PTPN6) is a cytoplasmic protein 
expressed in hematopoietic cell development, proliferation and the receptor-mediated 
mitogenic signaling pathway[110,111]. In bone marrow mononuclear cells (BMMCs) of 
patients with acute myeloid leukemia, a novel PTPN6 transcript retaining intron 3 has 
been identified. This transcript arises from an alternative splicing reaction where editing-
mediated deamination of A7866 in intron 3 erases this branch formation site, making it 
invisible to the splicing machinery. The ADAR responsible has not been identified. It is 
suggested that this retention results in the translation of a nonfunctional protein where 
the intron 3-encoded sequence is located in the N-terminal Src homology 2 (SH2) domain. 
PTPN6 binding with partner proteins, such as proto-oncogene receptor tyrosine kinase - 
c-Kit[112], and its self-inhibition of phosphatase activity occurs via its N terminal 
domain[113]. All this information suggests that its deregulation ultimately leads to 
uncontrolled hematopoietic growth and function. The tumor-specific editing seen in 
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AML might correlate with the clinical course of the disease since low levels of intron-
retaining transcripts in patient BMMCs at remission compared to those at diagnosis 
suggest that editing promotes tumorigenesis[114].  
 
High miRNA editing levels in cancer: ADAR1 gene amplification in NSCLC 
demonstrated ADAR1 overexpression in patients with early-stage lung cancer, 
underlining its potential oncogenic role in this cancer. Increased levels of ADAR1 
corresponded with edited miR-381 levels in NSCLC. Overexpression of edited miR-381 
in NSCLC possibly contributes to stemness and chemoresistance[94].  
 
Low editing levels in cancer 
Low levels of mRNA open reading frame editing in cancer: The same correlation but in 
the opposite direction was shown in hypoedited cancers, such as kidney chromophobe 
(KICH) and kidney renal papillary cell carcinoma (KIRP), with ADAR1 mRNA paired 
editing levels. The ADAR2 levels checked in both studies showed a complex expression 
pattern but no matching editing levels (Table 1 and Figure 2)[87,88].  
The role of ADAR1 in breast cancer is not fully understood. A recent study reported high 
ADAR1 expression in half of the examined triple-negative-cancer patients[115]. 
Conversely, it has been proposed that ADAR1 prevents tumor progression by editing the 
transcript coding for the alpha-3 subunit of gamma-aminobutyric acid type A (Gabra3). 
The chloride-permeable gamma-aminobutyric acid type A (GABAA) receptors are 
crucial mediators of fast inhibitory neurotransmission in the central nervous system[116]. 
The Gabra3 transcript undergoes recoding editing of isoleucine to methionine (I/M) in 
the third transmembrane region. This substitution was found to affect GABAA surface 
presentation and its cellular trafficking[117]. In addition to being normally expressed in 
normal neuronal tissues, Gabra3 has been identified in breast cancer, where its high 
expression inversely correlates with breast cancer survival. ADAR1-edited Gabra3 was 
found in non-invasive breast cancer cell lines and was linked with the protein kinase B 
(Akt) pathway. A proposed mechanism for the non-invasive phenotype is that Gabra3 
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editing reduces its surface expression and indirectly prevents Akt activation, thereby 
preventing cell proliferation and invasiveness. Thus, the unedited form of Gabra3 in 
breast cancer is suggested to promote tumor progression, invasion and metastatic 
potential[118].  
Lower ADAR2 levels are recognized in gastric cancer, glioblastoma, HCC and ESCC 
[91,119-120] (Figure 2). ADAR2 levels were found to correlate with changes in podocalyxin-
like (PODXL) and GluR-B functions. The PODXL RNA editing event is an amino acid 
substitution from histidine (His) to arginine (Arg) at codon 241. This editing in the gastric 
cancer cell line MKN28 was shown to prevent increased growth rates and invasive 
capability compared to cells with the unedited form. Moreover, recoding editing of a 
single position located in the channel-pore-loop domain in GluR subunit B (GluR-B) (the 
Q/R-site) from Gln to Arg results in a channel that is impermeable to Ca2+[121]. Tight 
regulation of editing is essential for the adequate function of this channel. Hypoedited 
PODXL and GluR-B with altered functions are associated with gastric cancer and 
malignant glioblastoma, respectively. Consequently, a tumor-suppressor role has been 
attributed to ADAR2[91,119].  
In ESCC, it has been reported that ADAR2 promotes apoptosis by editing and 
stabilizing insulin-like growth factor-binding protein 7 (IGFBP7) RNA. IGFBP7 is a 
secreted factor binding to and interfering with the activation of IGF1R. Through receptor 
occupation, IGFBP7 blocks downstream phosphatidylinositol 3-kinase (PI3K)-AKT 
signaling, resulting in the inhibition of protein synthesis and cell apoptosis[122]. IGFBP7 
was previously reported to be an apoptotic promoter in prostate cancer[123], colorectal 
cancer[124] and breast cancer[125]. The editing site in IGFBP7 is at position 284 of the coding 
sequence, and codon 95 is changed from AAG (lysine) to AIG, which is read as AGG 
(arginine) (K95R). This editing was shown to protect IGFBP7 against matriptase 
proteolysis in ESCC culture and xenografts, thus enabling the proapoptotic function of 
IGFBP7. ADAR2 is known to be downregulated in ESCC, and its upregulation induces 
apoptosis in ESCC cell lines in vitro, suggesting that IGFBP7 underediting may promote 
tumorigenesis in esophageal squamous cell carcinoma[120].  
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Low miRNA editing levels in cancer: ADAR2 rescue in glioblastoma cells was shown to 
inhibit cell proliferation and migration, confirming its possible tumor-suppressor role 
[126]. This anti-tumor effect might be explained though the regulation of onco-miRNAs in 
glioblastoma. Three particularly investigated onco-miRNAs, miR-221, miR-222 and miR-
21, are overexpressed in glioblastoma[127]. ADAR2 can edit miR-222/221 and miR-21 
precursors and decrease the expression of the corresponding mature onco-miRNAs in the 
normal mouse brain and in different lines. Decreased levels of ADAR2 identified in 
glioblastoma probably push the balance of onco-miRNA/tumor-suppressor miRNA 
towards increased expression of onco-miRNAs, such as miR-221, miR-222 and miR-21, 
thereby supporting tumor progression[128]. 
In the human brain, the miR-376 cluster encodes 4 pri-miRs that give rise to 5 distinct 
mature miRNAs, which are subjected to specific A-to-I RNA editing on 9 adenosines. In 
noninvasive U87 glioma cells, the expression of the unedited miR-376a* was shown to 
promote aggressive tumor migration and invasion of these cells both in vitro and in vivo. 
The editing reaction missing in the GBM cell lines generally occurs in the seed region of 
pri-miR-376a1 at the +9 site, ultimately giving rise to mature edited miR-376a*. The 
absence of this editing changes the specific targets of the miRNA. It has been identified 
that nonedited miR-376a*, through its binding to 3’ UTR, has a novel target, RAP2A, 
which is a member of the RAS oncogene family with an unknown function. However, the 
nonedited miR-376a* targeting of RAP2A is unable to target the autocrine motility factor 
receptor (AMFR), resulting in its upregulation and possibly contributing to increased 
migration and invasiveness of glioma cells[129]. 
Melanoma is the most aggressive type of skin cancer. It has been reported that there is 
a significant decrease in ADAR1 expression in ~65% of metastatic melanoma specimens 
compared to melanocytes[130] (Table 1 and Figure 2). ADAR-1 transcripts were found to 
be targeted by miR-17 and miR-432, thus decreasing ADAR1 expression. Both miR-17 
and miR-432 were identified to be overexpressed in melanoma possibly due to the 
amplification of encoding genes[130]. However, studies suggest that ADAR1 
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insufficiencies contribute to the enhancement of proliferation of melanoma cells through 
editing the independent regulation of miRNA biogenesis. miRNA-455-5p was identified 
as a target of ADAR1 in low-metastatic melanoma cells but not in highly metastatic cell 
lines. ADAR1 was shown to edit pri-miR-455-5p at +2 and +17 positions. This editing 
probably results in the reduction of the processing of pri-miRNA by Dicer or Drosha by 
lowering the binding affinity. However, it is also possible that ADAR1 binds to Dicer 
since the amount of miR-455-5p bound to Dicer and Drosha was inversely correlated with 
ADAR1 expression. ADAR1 was shown to form a complex with Dicer through protein-
protein interactions[131]. In this study, the authors gave a model of RNA editing in the 
context of melanoma progression and metastasis, where cAMP response element binding 
(CREB) downregulates ADAR1 and gives rise to non-edited miR-455-5p. Expression of 
miR-455-5p suppresses the tumor suppressor gene cytoplasmic polyadenylation 
element-binding protein 1 (CPEB1), resulting in growth promotion and metastasis in 
melanoma cells[132].  
 
 M5C IN CANCER RNA 
Cytosine base methylation - m5C has been identified in rRNA, tRNA and recently in 
mRNAs and is particularly enriched in untranslated regions and near Argonaute-binding 
regions[133]. The enzymes responsible for the introduction of m5C are members of the 
DNA methyltransferase homolog (Dnmt2) and the NOP2/Sun (NSun 2 and 4) RNA 
methyltransferase family[134-136]. The role of these enzymes in the methylating activities of 
tumorigenesis is currently unknown. However, in circulating tumor cells from lung 
cancer patients, increased RNA m5C levels were shown compared to those in whole 
blood cells[137]. Further investigation of the role of m5C in cancer is required. 
 
Concluding remarks 
Tight regulation of the writing, reading and eventual erasing of RNA modifications is 
essential for RNA metabolism. Misbalanced expression of the enzymes responsible for 
introducing, and in some cases removing, these modifications is considered a possible 
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signature for specific types of cancer (Table 1). Considering the broad effect of RNA 
modifications on tumor cell biology, future methylome, pseudome and editome studies 
will shed light on those relatively unexplored epitranscriptomic mechanisms in tumors. 
Those studies will pave the way for the development of anti-cancer drugs that could act 
by steering RNA modifications. 
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Figure 1. Ribonucleotide RNA modifications known to be of relevance in cancer and 
their enzymatic machineries. m6A: N6-methyladenosine; METTL3: Methyltransferase 
like 3, METTL14: Methyltransferase like 14, WTAP: Wilms' tumor 1-associating protein; 
m6A erasers: ALKBH5: Alkylation repair homologue protein 5, FTO: Fat mass and 
obesity-associated protein. Inosine (I) writers: ADAR1 (p110 and p150) and ADAR2: 
Adenosine deaminase acting on RNA 1 and 2. 5-methylcytosine (5mC): NSUN2: 
NOP2/Sun domain protein 2, TRDMT1: tRNA aspartic acid MTase 1. 2’O-methylation 
writers: Nol5a: Nucleolar Protein 5A, Nop58: Nucleolar protein 58, Snu13: Small Nuclear 
Ribonucleoprotein 13, SnoRNA: Small nucleolar RNA. 
METTL3
METTL14
WTAP
ADAR1 p110
ADAR1 p150
ADAR2 
IAm6A
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Figure 2 Editing of double-stranded RNA on mRNA and miRNA. Below, high ADAR1 
levels are associated with breast cancer, NSCLC, colon cancer and cervical cancer, while 
low ADAR1 levels are shown in melanoma. Low levels of ADAR2 are present in 
glioblastoma. HCC, ESCC and gastric cancer are indicated as ADAR2-low and ADAR1-
high cancers. The potential roles of ADAR1 and ADAR2 in cancer are depicted by mind 
map. Red means high expression/inosine content and blue means low 
expression/inosine content. In circles are the name of molecules/cancers and in 
diamonds are the mechanisms. Abbreviations: NSCLC: non-small cell lung cancer, HCC: 
hepatocellular carcinoma, ESCC: esophageal cell carcinoma, GC: gastric cancer, ESCC: 
esophageal squamous cell carcinoma, AML: acute myeloid leukemia, SCLC: small cell 
lung cancer, BLCA: bladder urothelial carcinoma,  BRCA: breast invasive carcinoma,  
COAD: colon adenocarcinoma, HNSC: head and neck squamous cell carcinoma,  LUAD: 
lung adenocarcinoma, THCA: carcinoma, KICH: kidney chromophobe, KIRP: kidney 
renal papillary cell carcinoma,  NEIL1: NEI-like protein 1, Gabra3: alpha-3 subunit of 
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gamma-aminobutyric acid type A, FlnB: Filamin B, PTPN6: Protein tyrosine phosphatase 
non-receptor type 6 , PODXL: podocalyxin-like, GluR-B: glutamate R -B, IGFBP7: insulin-
like growth factor-binding protein 7 . 
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Table 1. Relative amount of modification (directly quantified or extrapolated from the 
expression level of writers/erasers). In brackets are the names of genes that have been 
analyzed 
RNA 
modifications 
High in cancer Low in cancer 
m6A Lung 
adenocarcinoma[22], 
AML[23]. 
HER2 overexpressing subtypes breast cancer[35], 
t(11q23)/MLL-rearranged, t(15;17)/PML-RARA, 
FLT3-ITD, and/or NPM1-mutated AMLs (ASB2 and 
RARA)[36], GBM (FOXM1)[39], breast cancer 
(NANOG)[40]. 
2’O-
Methylation 
Breast cancer [51][67]; 
primary and 
metastatic prostate 
cancers[58], 
squamous cell 
cervical 
carcinoma[57]. 
Ψ Leukemia, lymphoma, multiple myeloma[84-86] 
Inosine BLCA, BRCA, 
COAD, HNSC, 
LUAD, THCA[87-88], 
NSCLC (NEIL1[94], 
AZIN1[103]), miR-
381[94]), SCLC 
KIRP, KICH[87-88], Breast cancer (Gabra3)[118], Gastric 
cancer (PODXL)[91], Glioblastoma (GluR-B)[119], onco 
miR-21, miR-221, miR-222[128], ESCC (IGFBP7)[120], 
Glioma (miR-376a*)[129], Melanoma[130] (miR-455-
5p)[132].  
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AZIN1: Antizyme inhibitor 1, RHOQ: Ras homolog family member Q , PODXL: 
Podocalyxin-like , IGFBP7: Insulin-like growth factor-binding protein 7 , PTPN6: Protein 
tyrosine phosphatase non-receptor type 6 , NEIL1: NEI-like protein 1 , GluR-B: Glutamate 
R-B, Gabra3: Alpha-3 subunit of gamma-aminobutyric acid type A , FlnB: Filamin B,
ASB2: Ankyrin repeat and SOCS box containing 2 , RARA: Retinoic acid receptor alpha, 
FOXM1: Forkhead box protein M1, GBM: Glioblastoma multiforme , HER2: Human 
epidermal growth factor receptor type 2, MLL : Mixed lineage leukemia , PML/RARA: 
Promyelocytic leukemia/retinoic acid receptor alpha, FLT3-ITD: Fms-related tyrosine 
kinase 3–internal tandem duplication, NPM1: Nucleophosmin 1, NSCLC: Non-small cell 
lung cancer, HCC: Hepatocellular carcinoma, ESCC: Esophageal cell carcinoma,  GC: 
Gastric cancer, CRC: Colorectal cancer , AML: Acute myeloid leukemia , SCLC: Small cell 
lung cancer, BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, 
COAD: Colon adenocarcinoma, HNSC: Head and neck squamous cell carcinoma, LUAD: 
Lung adenocarcinoma , THCA: Thyroid carcinoma, KICH: Kidney chromophobe , KIRP: 
Kidney renal papillary cell carcinoma. 
(AZIN1)[87], HCC  
(AZIN1 
[101],FLNB[90]), 
GC[91], ESCC 
(FLNB)[92], cervical 
cancer[89], CRC 
(RHOQ)[109], AML 
(PTPN6)[114] 
5mC circulating tumor 
cells in lung 
cancer[137] 
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Abstract
As a versatile and safe vector, in vitro transcribed messenger RNA (ivt mRNA) is currently 
being intensively evaluated as an active pharmaceutical ingredient. Its therapeutic uses 
encompass vaccination, cell reprogramming, genome engineering, gene 
complementation and the expression of protein drugs (e.g., growth factors or antibodies). 
The therapeutic efficacy of ivt mRNA correlates with the efficacy of its translation. 
Untranslated regions (UTRs) from stable mRNA, such as globin mRNA, and optimized 5’ 
cap structures have been used to improve the functionality of ivt mRNA. However, the 
recruitment of the eukaryotic initiation factor 4E (eIF4E) protein to the 5’ end of transfected 
ivt mRNA remains a rate-limiting parameter for translation. We added aptamer sequences 
that bind the eiF4G protein to the 5’ UTR of ivt mRNA. One of these aptamer sequences 
produced a several fold increase in ivt mRNA expression (specifically, an increase of 
threefold to over tenfold depending on mRNA sequence and cell type). This simple 
modification of the 5’ UTR of ivt mRNA may represent an efficacious and general method 
for improving the therapeutic index of all new mRNA-based therapeutic products. 
1 Introduction
The expression of recombinant genes in vivo can be used for vaccination and gene 
therapy. Although plasmid DNA and recombinant viruses were initially used for this 
purpose, in vitro transcribed messenger RNA (ivt mRNA) emerged as a safe alternative 
in the 1990s and has become a broadly accepted method that has attracted increasing 
interest during the last ten years (Sahin et al., 2014). With the implementation of the first 
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good manufacturing practice (GMP) and large scale mRNA production facility (Pascolo, 
2004; Probst et al., 2007), several human clinical studies demonstrating the safety, 
versatility and efficacy of directly injected ivt mRNA have been published (Bahl et al., 
2017; Kranz et al., 2016a; Rittig et al., 2011, 2016; Sahin et al., 2017b; Weide et al., 2008; 
Weide et al., 2009). Key features of mRNA-based therapies are (i) the intrinsic 
translatability of the ivt mRNA (the level of protein expression),(ii) the ivt mRNA’s 
immunogenicity (whether innate immune receptors are triggered) and (iii) formulation (site 
of delivery and expression). With respect to the former consideration, the optimization of 
the cap structure, untranslated regions (UTRs), open reading frames and poly A-tail has 
been reported (Holtkamp et al., 2006; Sahin et al., 2014). Due to such optimization, ivt 
mRNA has become a vector with high expression of the encoded protein. One limiting 
factor in cellular mRNA translation is eukaryotic initiation factor 4E (eIF4E), which 
recognizes the 5’ cap structure of mRNA (Lee and Pelletier, 2012). eIF4E then recruits 
the scaffolding protein eIF4G, which, in turn, recruits all other components of the initiation 
complex to form the eIF4F complex that moves along the mRNA to the ATG start codon. 
We rationalized that direct recruitment of eIF4G to the 5’ UTR could improve the efficacy 
of translation of ivt mRNA. Aptamers that bind eIF4G have been identified in attempts to 
block translation in tumor cells (Miyakawa et al., 2006). Miyakawa et al. demonstrated 
that three out of eight such aptamers indeed inhibited translation. We took advantage of 
the aptamers that did not block translation; in particular, we utilized these aptamers as 
bait to bring eIF4G to the 5’ end of ivt mRNA. One of the non-blocking aptamers was most 
efficient at enhancing the translation of a downstream open reading frame. The addition 
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of this aptamer to ivt mRNA could be proposed as a universal method for improving ivt 
mRNA-based therapies. 
2. Materials and Methods
2.1 Production of ivt mRNA 
Plasmids containing a wild-type luciferase-coding gene or an optimized luciferase-coding 
gene (a synthetic gene purchased from Blue Heron Bio with a 5’ UTR of human alpha 
globin, a codon-optimized open reading frame and a double 3’ UTR from human beta 
globin) were used as matrices for PCR amplification with upstream primers that contained 
a T7 promoter followed by a sequence complementary to the 5’ end of the targeted gene, 
with or without an aptamer sequence between the promoter and the complementary 
sequence. Similarly, a synthetic codon-optimized gene encoding ZsGreen (a synthetic 
gene purchased from Blue Heron Bio with a 5’ UTR of human alpha globin, a codon-
optimized open reading frame and a double 3’ UTR from human beta globin) was 
amplified using PCR. The primer sequences and corresponding mRNA products are 
presented in supplementary Figure 1. The PCR products were analyzed on an agarose 
gel and purified using a PCR cleanup kit from Qiagen in accordance with the 
manufacturer’s instructions. mRNA was produced by utilizing a HiScribe™ T7 ARCA 
mRNA Kit (with tailing) (New England Biolabs) to obtain ARCA-capped poly-adenylated 
mRNA or using GenScript capping and poly-adenylation kits on mRNA produced using a 
T7 RNA polymerase (New England Biolabs) reaction containing all 4 canonical 
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nucleotides or a mixture of A, C, G, and pseudouridine (as triphosphate nucleotides from 
TriLink). Capped poly-adenylated mRNA was precipitated using LiCl, washed with 75% 
ethanol, and resuspended in pure water. This mRNA was then quantified using a 
NanoDrop instrument and analyzed via agarose gel electrophoresis. 
2.2 Cells and transfection 
Human embryonic kidney (HEK) cells and CT26 mouse colon carcinoma cells were 
maintained in RPMI medium (Thermo Fisher Scientific) containing 10% fetal calf serum 
(FCS) and 0.2% antimicrobial reagent Normocin (Invivogen). Human dendritic cells were 
produced from adherent monocytes harvested from peripheral mononuclear blood cells 
(PBMCs) after 45 minutes of adhesion to plastic and cultured for 6 days in the presence 
of GM-CSF (800 U/ml) and IL4 (500 U/ml) from PeproTech (with medium replacement at 
day 3). They were eventually matured by 24 hours culture in the presence of Protamine-
RNA nanoparticles at 5 g/ml (Tusup and Pascolo, 2017). Transfections were performed 
with 200 000 cells per well in 100 microliters of RPMI medium supplemented with 10% 
FCS and 0.2% antimicrobial reagent Normocin (Invivogen) by adding either 200 ng of 
mRNA in 12 microliters of Opti-MEM (Thermo Fisher Scientific) and 200 ng of 
Lipofectamine 2000 (Thermo Fisher Scientific) in 12 microliters of Opti-MEM to each well 
or 200 ng of mRNA in 5 microliters of Opti-MEM and 400 ng of MessengerMax (Thermo 
Fisher Scientific) in 5 microliters of Opti-MEM to each well. Luciferase activity was 
recorded one day after transfection by adding 25 microliters of Bright-Glo (Promega) and 
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measuring activity using GloMax equipment (Promega). ZsGreen signal was recorded by 
acquiring cells using Flow activated cell cytometry (FACS) (Canto, BD Biosciences) and 
analyzing the results using FlowJo. 
3. Results and Discussion
3.1 Aptamer 17 enhances cis mRNA expression 
Miyakawa et al. reported the sequences of eight aptamers that could bind to eIF4G 
(Miyakawa et al., 2006). Five of these molecules (aptamers 2, 14, 17, 18, and 19) did not 
inhibit translation. We tested the shortest four of these five molecules (aptamers 2, 14, 
17, and 19), which were 41 bases or less in length; aptamer 18, which is 70 residues 
long, was not tested. Oligonucleotides with a T7 promoter sequence followed by the 
aptamer sequence and a 20-base sequence that recognizes the wild-type luciferase 
sequence at its start codon (see supplementary Figure 1 for the primer sequences) were 
used to generate DNA templates for in vitro transcription. Uncapped, enzymatically 
capped and ARCA-capped mRNAs were produced using the aforementioned PCR 
matrices. mRNAs were transfected into human tumor cells (HEK cells) using 
Lipofectamine 2000, and luciferase activity was recorded. As presented in Figure 1A, 
uncapped mRNAs, even those with aptamer sequences at their 5’ end, were not 
translated. However, detectable luciferase activity was observed for mRNAs that were 
enzymatically (Figure 1B) or co-transcriptionally (Figure 1C) capped. Remarkably, 
mRNAs with the aptamer 17 sequence consistently exhibited several fold increases in 
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luciferase activity compared with mRNAs without a 5’ aptamer sequence and mRNAs 
with the aptamer 2 sequence (aptamers 14 and 19 moderately enhanced translation in 
certain experiments). The same results were obtained when mRNAs were transfected 
into mouse tumor cells (CT26 cells, Figure 1D) or when transfection reagents other than 
Lipofectamine 2000 (such as MessengerMax, which is a liposome optimized for mRNA 
transfection, Figure 1E) were used. The addition of the aptamer 17 sequence to different 
mRNAs, such as codon-optimized luciferase (Figure 1F) or ZsGreen (Figure 1G) with 
globin stabilization untranslated 5’ and 3’ sequences, enhanced the expression of reporter 
proteins. Thus, the aptamer 17 sequence is an optimization element that can function 
alone or in combination with other mRNA-optimizing sequences, such as stabilizing 
UTRs.  
For gene therapy approaches, the mRNA must be deficient in triggering RNA sensors 
such as Toll-like receptors. This objective can be achieved by substituting modified 
nucleotides for canonical nucleotides, most notably by replacing canonical uridine with 1-
methyl-pseudouridine. As shown in Figure 2, the aptamer 17 sequence could increase 
luciferase expression produced by mRNA molecules containing 1-methyl-pseudouridine 
instead of uridine, regardless of whether mRNAs are transfected into tumor cells (HEK, 
cells, Figure 2A) or untransformed human cells (immature dendritic cells, Figure 2B, or 
mature dendritic cells, Figure 2C). 
In conclusion, the addition of an eIF4G-binding aptamer to the 5’ UTR of ivt mRNA can 
be used as a universal method to increase the quantity of protein produced from 
recombinant mRNA. The numerous ongoing pre-clinical and clinical studies that involve 
evaluating the efficacy of mRNA-based therapies should take advantage of the method 
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reported here to increase the functionality of ivt mRNA and thereby achieve a higher 
therapeutic index with the same dose of mRNA or the same therapeutic index with a lower 
dose of ivt mRNA. 
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Figure legends 
Figure 1: Effects of eIF4G-binding aptamers on the efficacies of ACGU ivt mRNAs. 
Uncapped (A), enzymatically capped (B) or ARCA-capped (C) mRNAs with (Apt 2, Apt 
14, Apt 17 and Apt 19) or without (No Apt) a 5’ eIF4G-binding aptamer sequence were 
transfected into HEK cells (A, B, C, E, F, G) or CT26 cells (D) using Lipofectamine 2000 
(A, B, C, D, F) or MessengerMax (E, G). Twenty-four hours after transfection, luciferase 
activity was recorded (A to F, means and deviations for experiments performed in 
triplicate are shown). At that time, fluorescence was measured using FACS (G), with 
representative results presented: the filled histogram represents untransfected cells, the 
gray line represents cells transfected with an mRNA without an aptamer in its 5’ UTR, 
and the black line represents cells transfected with an mRNA with the aptamer 17 
sequence in its 5’ UTR.  
Figure 2: Effects of eIF4G-binding aptamers on the efficacies of ACG ivt mRNAs. 
Enzymatically capped mRNAs in which uridine residues were replaced by 1-methyl 
pseudouridine residues and the 5’ UTR contained (Apt 17) or lacked (No Apt) the eIF4G-
binding aptamer 17 sequence were transfected into HEK cells (A), immature human 
dendritic cells (B) or mature human dendritic cells (C) using MessengerMax. Twenty-four 
hours after transfection, luciferase activity was recorded. The means and deviations for 
experiments performed in triplicate are shown. 
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 Abstract 
Mammalian RNA, which is heavily modified, does not trigger innate immune receptors 
when delivered in liposomal particles in vitro (Kariko et al., 2005). In contrast, using 
delivery by protamine nanoparticles (Tusup and Pascolo, 2017), we found that 
mammalian RNA induces TNF-alpha in human peripheral blood mononuclear cells 
(PBMCs). However, these mammalian RNA particles did not induce type I interferon in 
PBMCs. RNA from lower organisms induced TNF-alpha as well as type I interferon in 
PBMCs when formulated with protamine. Thus, RNA modifications in higher organisms, 
which are primarily inosines and methylations prevent the recognition of this nucleic acid 
by receptors associated with triggering type I interferon. We hypothesize that these 
modifications are potentially druggable. Direct or indirect inhibition of adenosine 
deaminase activity reduces inosine production and has also been reported to lower the 
methylation index. Hence, we screened inhibitors of adenosine deaminases and identified 
pentostatin (2-deoxycoformycin) as a drug that enhances the capacity of endogenous 
RNAs to trigger type I interferon. Used for over thirty years as an anti-cancer drug 
(particularly against hairy cell leukaemia), pentostatin, which is not directly toxic to tumour 
cells, has an unknown mode of action. Here, we show that pentostatin is an 
immunomodulating drug that promotes endogenous RNA sensing as a danger signal for 
TLR3 and induces type I interferon, which triggers effective anti-cancer responses.  
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Foreign or mislocalized endogenous RNAs are recognized as danger signals by several 
cellular immune receptors from the Toll-like receptor (TLR) and RIG-I-like receptor (RLR) 
families. The TLR family members TLR7, TLR8 and TLR3 located on endosomal 
membranes (reviewed in (Kawai and Akira, 2010)) as well as cytosolic retinoic acid-
inducible gene I (RIG-I) and melanoma differentiation-associated protein 5 (MDA5) 
receptors in the RLR family (Hornung et al., 2006; Kato et al., 2006) promptly react to 
such RNA stimuli. Several modifications of RNA bases or backbones inhibit nucleic acid 
recognition by these dedicated immune receptors, thereby labelling metazoan cellular 
RNA as self and preventing immune stimulation by endogenous RNAs. Indeed, 
mammalian RNA delivered in liposomes does not trigger cytokine production in TLR-
transfected cells or antigen-presenting cells in vitro (Kariko et al., 2005). In contrast, we 
found that total RNA extracted from mammalian cells or tissues and formulated in 120 nm 
protamine nanoparticles (Figure 1A and Extended Figure 1A) induced TNF-alpha 
production in human peripheral mononuclear cells (hPBMCs) (Figure 1B). Other 
inflammatory cytokines, such as IL-6, IL-17, and interferon-λ, were also induced by all 
tested RNAs in the protamine formulation (Supplementary Table 1). By comparing the 
immunostimulation profiles of natural RNAs packaged in protamine or liposome particles, 
we confirmed that only the protamine-RNA formulation unmasked the potential of human 
RNAs to induce TNF-alpha (Figures 1B and C). Meanwhile, independent of packaging 
type, alpha interferon is only produced by hPBMCs when the RNA originates from more 
basal organisms (Escherichia coli (E. coli), Saccharomyces cerevisiae (S. cerevisiae), 
and Drosophila melanogaster (D. melanogaster)) but not humans (Figure 1D and E). 
Cytokines such as IL-12 and IL-1alpha are also preferentially induced by RNAs from more 
basal organisms (Supplementary Table 1). The protamine-RNA nanoparticle triggers 
endosomal TLR7, TLR8 and TLR3 when both unmodified ssRNAs and dsRNAs are 
condensed (Extended Figure 1B). Because TLR7 or TLR3 stimulation triggers type I 
interferon production and TLR8 stimulation promotes inflammatory cytokine production, 
we concluded that mammalian RNA modifications block recognition by TLR3 and/or 
TLR7. We postulated that the pathways leading to these immunosuppressive RNA 
modifications might be druggable.  
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Inosine and base/sugar methylation are abundant, naturally occurring modifications to 
mammalian RNA (Wang and He, 2014) that block RNA recognition by immune sensors 
(Jung et al., 2015; Sarvestani et al., 2014). To unmask the type I interferon-inducing 
potential of endogenous RNA, we screened drugs that altered the pathways responsible 
for introducing these modifications. Inhibition of adenosine deaminases impedes inosine 
production and simultaneously induces adenosine accumulation. This hinders S-
adenosyl-L-homocysteine (SAH) hydrolase activity, which leads to an imbalance in 
production of the methylation donor S-adenosylmethionine (SAM) and results in 
decreased SAM/SAH methylation index (Glazer and Hartman, 1980; Johnston and 
Kredich, 1979; Kredich, 1980). By testing direct (erythro-9-(2-hydroxy-3-nonyl) adenine 
(EHNA) (North et al., 1983) and deoxycoformycin (Agarwal et al., 1977)) and indirect 
(metformin (Ouyang et al., 2011) and methotrexate (Riksen et al., 2006)) adenosine 
deaminase inhibitors, we found that deoxycoformycin (pentostatin, Nipent), the most 
specific and effective adenosine deaminase inhibitor, increased the capacity of total RNA 
extracted from in vitro-treated tumour cells to trigger type I interferon in hPBMCs (Figure 
2A and Supplementary Figure 2A). The TNF-alpha induction capacity of packaged RNA 
was not significantly affected (Figure 2B). Similarly, RNA extracted from organs of mice 
injected intravenous with pentostatin induced more alpha interferon production in 
hPBMCs than RNA extracted from organs from untreated mice (Figure 2C and D and 
Extended Figure 2B and 2C). Pentostatin (2'-deoxycoformycin), a natural adenosine 
analogue produced by the bacterium Streptomyces antibioticus and the fungus 
Emericella nidulans, has been reported to be the most potent adenosine deaminase 
inhibitor (Agarwal et al., 1977). T cells are particularly dependent on adenosine 
deaminase activity. Deoxycoformycin has been tested to treat diverse types of leukaemia 
and lymphoma and is reported to be efficacious against hairy cell leukaemia (Spiers et 
al., 1984), chronic lymphocytic leukaemia (Dillman et al., 1988), prolymphocytic 
leukaemia (Dohner et al., 1993), Hodgkin lymphoma (Braiteh et al., 2006), and adult T-
cell lymphoma, especially cutaneous T cell lymphoma (Grever et al., 1983; Kurzrock et 
al., 1999). However, pentostatin is not directly toxic to tumour cells ((Wilson et al., 1998) 
and Extended Figure 2D), and its mode of action is indirect and still unknown 35 years 
after its introduction into clinical practice.  
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Our in vitro and ex vivo data prompted us to investigate whether the anti-cancer effects 
of pentostatin are mediated by the immune system. Indeed, we found that the drug only 
exhibited anti-cancer activity in tumour models in which immune checkpoint inhibitors 
(reviewed in (Grosso and Jure-Kunkel, 2013) were also efficacious (Extended Figure 3A). 
In the two models, we found that immune mediators were required to promote anti-tumour 
responses after Pentostatin intravenous injection: type I interferon receptor (Figure 3A) 
and T cells (Figure 3B and Extended Figure 3B). Pentostatin did not significantly enhance 
the frequency of circulating anti-cancer T-cells (extended Figure 3C). Mice cured by 
pentostatin were protected from tumour challenge (Figure 3B). Histological studies 
indicated that after pentostatin injection, tumours were infiltrated with T cells (Figure 3C). 
Heterozygous reporter mice carrying luciferase reporter genes under the control of an 
interferon-beta promoter (Lienenklaus et al., 2009) were used to monitor IFN-beta 
induction in tumour-bearing mice. After pentostatin injection, a luciferase signal was 
detected in the tumour, further demonstrating the indirect (only in tumor, Figure 3D and 
not seen in vitro on mouse splenocytes incubated with Pentostatin, Extended Figure 3D) 
immunostimulating role of pentostatin. The local induction of type I interferon in tumours 
and the requirement of type I interferon receptor for pentostatin activity are particularly 
striking: before 1984, when pentostatin was introduced, hairy cell leukaemia was treated 
with recombinant alpha interferon. To further investigate the link between RNA-sensing 
and pentostatin, we tested the efficacy of the drug in TLR3, TLR7 and mitochondrial 
antiviral-signalling protein (MAVS, deficient signal transduction from RIGI and MDA-5) 
knock-out (KO) mice. The efficacy of pentostatin was decreased only in the TLR3 KO 
(Figure 4A and Extended Figure 4A). Accordingly, TRIF KO mice also did not respond to 
the drug treatment (Extended Figure 4B). MAVS deletion had no effect on pentostatin 
efficacy. In addition, pentostatin induced only mild differential gene expression in the 
kidneys (only a slight increase in cellular respiration as can be anticipated from the 
reported increase in mitochondrial biomass in pentostatin-treated cells (Garcia-Gil et al., 
2016), Figure 4C), and no induction of endogenous retroviruses (Extended Figure 4C). 
This is excluding the possibility of chromatin reorganization and immunostimulation by 
endogenous retroviruses as previously reported for DNA methylation inhibitors 
(Chiappinelli et al., 2015). Our experiments demonstrated that pentostatin acts in vivo by 
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sensing endogenous RNA through the immune system and triggering an immune 
response. The following two types of RNA modifications block recognition by TLR3: (1) 
the creation of inosine in double stranded RNA by adenosine deaminase acting on RNA 
and (2) the methylation of the base or sugar. RNA-seq analysis of the total RNA extracted 
from organs from pentostatin-treated mice showed similar occurrence of inosine in mRNA 
from untreated and treated mice (Figure 4B). This finding agrees with previous reports 
indicating that pentostatin does not inhibit adenosine deaminases acting on RNA (Kim et 
al., 1994). Meanwhile, previous reports show that cells from pentostatin-treated patients 
showed an impaired ability to methylate nucleic acids (DNA and RNA) ex vivo. This day-
lasting inability to methylate RNA post-pentostatin treatment was demonstrated for ribose 
2′-O-methylation, which blocks RNA recognition by TLR3 and TLR7 in human cells (De 
Clercq et al., 1972; Jung et al., 2015). Based on these findings, we concluded that 
pentostatin promotes TLR3 by decreasing 2′-O-methylation of endogenous RNA. 
Because intravenous pentostatin injection induced a systemic decrease in the 
methylation index but type I interferon induction only in tumours in vivo, we postulated 
that demodified dsRNA arises from dying cells in the tumour microenvironment. 
Our experiments demonstrate that silencing endogenous RNA immune sensing by 
inhibiting methylation is a druggable process. The anti-cancer drug pentostatin, which is 
not directly toxic to tumour cells and has an unknown mode of action when used to treat 
cancer patients, unmasks endogenous RNA and thereby promotes TLR3-TRIF signalling 
to induce the production of type I interferon in tumours. Thus, pentostatin, which is 
classified as a chemotherapy drug, should be reclassified as an immunotherapy drug. Its 
rational utilization with chemotherapies and immune checkpoint inhibitors should be 
evaluated in view of the actual mode of action revealed here. We anticipate that the 
original mode of pentostatin action will allow repurposing of this drug for combination 
treatments incorporating the induction of type I interferon at tumour sites into standard-
of-care treatments.  
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Legends 
Figure 1: Total mammalian RNA in protamine-RNA nanoparticles induces hTNF-
alpha but not hIFN-alpha in hPBMCs. 
A) In vitro study workflow. Total RNA (1 µg) extracted from Escherichia coli (E. coli),
Saccharomyces cerevisiae (S. cerevisiae), Drosophila melanogaster (D. melanogaster),
humans and mice were combined with protamine (2 µg) to generate 120 nm nanoparticles
and incubated with hPBMCs. After overnight incubation, IFN alpha and TNF alpha were
measured by ELISA in the corresponding supernatants.
B) Human TNF-alpha (hTNF-alpha) was induced by all natural RNAs when packaged in
protamine-RNA. hTNF-alpha quantified in supernatants from hPBMCs incubated with
protamine-RNA formulations (E. coli, S. cerevisiae, D. melanogaster, human, mouse) with
protamine and PBMC only controls (n=3).
C) Protamine-RNA nanoparticles containing total RNA from human cells revealed the
potential of these RNAs to induce hTNF compared to RNA in liposomes. hTNF-alpha in
supernatants from PBMCs incubated with protamine-RNA (human cancer cell line,
human healthy tissue and E. coli RNA) and the same RNA in liposomes (n=3).
D) Human IFN-alpha (hIFN-alpha) is induced only by RNA from lower organisms (E. coli,
S. cerevisiae and D. melanogaster). hIFN-alpha quantified in the supernatants of
hPBMCs incubated with protamine-RNA (E. coli, S. cerevisiae, D. melanogaster and
human) and showing protamine and PBMC only controls (n=3).
E) Protamine-RNA nanoparticles exhibit the same hIFN-alpha induction profile as RNA in
liposomes. hIFN-alpha from PBMC cell supernatants incubated with protamine-RNA
formulations (human cancer cell line, human healthy tissue and E. coli RNA) and the
same RNA in liposomes (n=3). Error bars are the mean±s.d.
Extended Figure 1: 
A) Agilent 2100 Bioanalyzer measurement of total RNA (eukaryote total RNA Nano chip)
lanes: Ladder, E. coli, S. cerevisiae, D. melanogaster, human RNA, mouse RNA (from
left to right; 500 ng).
B) Mouse IFN-alpha quantification in supernatants from splenocytes incubated with
protamine and double-stranded RNA (dsRNA), protamine and single-stranded (ssRNA),
protamine and ssRNA+dsRNA, protamine alone, dsRNA alone, ssRNA alone and
medium only.
Supplementary Table 1 
Human Cytokine Multiplex ELISA quantification in supernatants from hPBMCs incubated 
overnight with protamine-RNA nanoparticles (2 µg:1 µg) or protamine alone, peripheral 
blood mononuclear cells (PBMCs) alone and each total RNA alone as controls. Total RNA 
from a bacterium (E. coli), yeast (S. cerevisiae), insect (D. melanogaster), and mammal 
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(human and murine) for human IFN Alpha 2 (IFN-α 2), IFN Beta (IFN-β), IFN Lambda 
(IFN-λ 1, 2 and 3), and IFN Gamma (IFN-γ); human Interleukin-1 Alpha (IL-1α), 
Interleukin-4 (IL-4), Interleukin-5 (IL-5), Interleukin-6 (IL-6), Interleukin-8 (IL-8), 
Interleukin-10 (IL-10), Interleukin-12 (IL-12p70), Interleukin-13 (IL-13), Interleukin-15 (IL-
15), Interleukin-17 (IL-17) and Interleukin-23 (IL-23); and Human Tumour Necrosis 
Factor-Alpha (TNF-α). Abbreviations: ND represents not detected, and OR represents 
outside of the value range. Values represent the mean±s.d of respective duplicates in 
pg/ml. 
Figure 2: Pentostatin enhanced the potential of total RNA from cells or organs to 
induce hIFN-alpha in hPBMCs incubated with protamine-RNA nanoparticles.  
A) and B) Total RNA extracted from CT26 cells treated with the half maximal inhibitory 
concentration (IC50) of EHNA (erythro-9-(2-hydroxy-3-nonyl) adenine), MTX 
(methotrexate), MTF (metformin), and 0.3 µg/ml (near clinical dose) Pento (Pentostatin) 
for 72 h formulated packaged with protamine and incubated overnight in hPBMCs. Ratios 
are calculated according to the following formula: (protamine-RNA from 
treatment/protamine-RNA untreated)/(RNA alone from treatment/RNA alone untreated). 
A significant fold change was observed for hIFN alpha induction after pentostatin 
treatment. All the values represent three independent experiments with ELISA 
measurements for (A) hIFN-alpha pan and (B) hTNF-alpha. Error bars are the mean±s.d. 
** based on the T-test, p=0.0054 Pento vs. MTF, p=0.0024 Pento vs. MTX, and p=0.003 
Pento vs. EHNA. C) and D) Total RNA extracted from mouse kidneys 18 h after mice 
were i.v. injected with 10 µg pentostatin or were not injected combined with protamine to 
generate protamine-RNA nanoparticles, which were incubated with hPBMCs overnight. 
(C) hIFN- alpha pan and (D) hTNF-alpha were quantified in supernatants. Biological 
duplicates with experimental duplicates and technical duplicates of each value were 
performed Error bars are the mean±s.d. **** based on T-test, p<0.0001 is extremely 
significant. 
Extended Figure 2:  
A) Total RNA was extracted from HEK293 cells treated with the IC50 of EHNA (erythro-
9-(2-hydroxy-3-nonyl) adenine), MTX (methotrexate), MTF (metformin), and 0.3 µg/ml of 
pentostatin for 72 h and then packaged with protamine to generate nanoparticles, which 
were incubated overnight with hPBMCs. The ratios were calculated according to the 
following formula: (protamine-RNA from treatment/protamine-RNA untreated)/(RNA 
alone from treatment/RNA alone untreated). A significant fold change was observed for 
hIFN alpha induction after pentostatin treatment. All the values represent three 
independent experiments with ELISA measurements for hIFN-alpha. Error bars are the 
mean±s.d. ** based on the T-test, p=0.0065 Pento vs. MTF, p=0.0019 Pento vs. MTX, 
and p=0.0055 Pento vs. EHNA. B) and C) Total RNA extracted from mouse tumors 
(CT26) and spleen after 18 h and from kidneys 4 and 36 h after the mice were i.v. injected 
with 10 µg of pentostatin or were untreated mice and packaged with protamine to 
generate protamine-RNA nanoparticles, which were incubated with hPBMCs overnight. 
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(B) hIFN-alpha and (C) hTNF-alpha were quantified in the supernatants. Pentostatin
treatment significantly enhanced the potential of endogenous RNA to induce hIFN-alpha
in all three compartments. Bars correspond to biological replicates and experimental
replicates of each biological replicate. Error bars are the mean±s.d.
D) Cytotoxicity quantification with LDH assay. CT26 cells were incubated with different
doses of EHNA, MTX, MTF and pentostatin. The viability during three days was
calculated according to the following formula: mean (A490 Treatment)-A490 blank)/mean
(A490 Untreated)-A490 blank)*100. Pentostatin showed no toxicity at any tested dose in
CT26 cells. Error bars are the mean±s.d. **** based on the T-test. p<0.0001 is extremely
significant.
Figure 3: Pentostatin activity in vivo in tumour-bearing mice depends on type I 
interferon and T cells.  
A) Survival of CT26/NY-ESO-1 tumour-bearing mice treated with pentostatin,
pentostatin+anti-IFNAR ab, anti-IFNAR ab and untreated. Pentostatin is effective for
treating CT26/NY-ESO-1-established tumours. Its activity is prevented by the anti-IFNAR
ab; n=8 in each group. Black arrows point to the day of pentostatin treatment. The
significant differences between the survival curves were calculated with the log-rank
(Mantel-Cox) test. *** p=0.0007 for pentostatin vs. pentostatin+anti-IFNARab; **
p=0.0025 for pentostatin vs. untreated, and ** p=0.0014 for pentostatin vs. anti-IFNARab.
B) Survival of CT26 tumour-bearing nude (nu\nu) and wild-type (WT) mice. T cell-deficient
nude mice showed no response to pentostatin treatment; n=5 in each group. Black arrows
point to the day of pentostatin treatment. The significant differences between the survival
curves were calculated with the log-rank (Mantel-Cox) test. ** p=0.0019.
C) Immunofluorescent staining of CT26 tumour cryo-sections from mice 36 h after
pentostatin treatment or from untreated mice. CD8+ cells visible only after pentostatin
treatment. DAPI staining is for nucleated cells, and PE-Texas Red staining marks CD8+
cells; 20x magnification.
D) Bioluminescence measurements in vivo in MB49 tumour-bearing heterozygous
reporter IFN-β+/Δβ-luc mice injected with pentostatin on day 6 or not treated. Pictures on
the right; the tumour-specific signal only present in the pentostatin-injected mice 18 hours
after injection.
Extended Figure 3: 
A) Survival of CT26/NY-ESO-1 tumour-bearing mice (n=8 in each group) and MB49 (n=7
in each group) mice treated with pentostatin and untreated mice. Pentostatin cures 67%
of CT26/ NY-ESO-1 mice and provides tumour growth stability in the MB49 tumour model.
Black arrows point to the day of pentostatin treatment. The significant differences
between survival curves were calculated with the log-rank (Mantel-Cox) test. ** p=0.0025,
left graph and p=0.0012, right graph.
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B) CT26/NY-ESO-1 tumour-bearing mice treated with pentostatin showed immune 
memory in a tumour re-challenge experiment. Pentostatin-cured animals were re-
challenged with same tumours 60 days after the first tumour was implanted and showed 
no tumour growth for over 90 days. In parallel, an untreated group was implanted with 
tumours and showed the expected progression (n=5). Black arrows point to the day of 
pentostatin treatment, and red arrows represent the day of tumour re-challenge. 
C) Percent of tetramer-specific CD8+ cells measured in the blood from mice 4 days after 
pentostatin treatment (n=8) or from untreated mice (n=5). The percentage of CD8+ cells 
specific for the NY-ESO-1 epitope increased after pentostatin-treatment.  
D) Mouse IL-6 quantification in supernatants from splenocytes incubated with different 
doses of Pentostatin, or 0.25 mg/ml Protamine-RNA (unmodified luciferase encoding 
mRNA) nanoparticles. Error bars are the mean±s.d.  
 
Figure 4: Pentostatin activity in vivo in tumour-bearing mice requires TLR3. 
A) MB49 tumour volume measurements in tumour-bearing mice (WT, TLR3 KO, TLR7 
KO and MAVS KO, left to right) with or without pentostatin treatment. Pentostatin 
controlled tumour growth in all mice except TLR3 KO mice. Error bars are the 
mean±s.e.m. Summarized responsiveness (WT (n=7), TLR3 KO (n=7), TLR7 KO (n=6) 
and MAVS KO (n=7)) in stacked bars according to whether it was a progressive disease, 
with an at least 20% increase in tumour volume, an objective response, with stable 
disease (tumour size increased less than 20% or decreased up to 30%) or a partial 
response (decrease in tumour volume of at least 30%). Objective responses for day 10 
vs. day 6 shown for pentostatin-treated WT, TLR7 KO and MAVS KO mice; the TLR3 KO 
mice showed no objective response.  
B) Inosine quantification in kidney RNA according to the editing frequency in RNA-seq 
datasets from pentostatin-treated (18 hours post-injection) and untreated mice. The 
distributions of editing frequencies in each sample at sites listed in RADAR were 
visualized as boxplots. Y-axis shows editing frequency, corresponding to a fraction of 
aligned reads with edited base as listed in RADAR. Each point in the figure is a genomic 
site listed in RADAR and having a depth of coverage of at least five reads. Editing 
frequency and thereby inosine incorporation were not affected in the total RNA of 
pentostatin-treated mice. 
C) Enriched gene ontology (GO) terms were visualized as a network of enriched GO 
terms and differentially expressed genes connected to them. Genes with lower and 
higher expression in treated samples were coloured green and red, respectively. 
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Extended Figure 4 
A) Survival curves for TLR7 KO and TLR3 KO and MB49 tumour-bearing mice treated 
with pentostatin or untreated (n=7). Pentostatin promoted longer survival times in TLR7 
KO mice, whereas TLR3 KO mice showed no responses to pentostatin treatment. The 
significant differences between the survival curves were calculated with the log-rank 
(Mantel-Cox) test. ** p=0.0015; 
B) Survival curves and tumour growth in TRIF KO MB49 tumour-bearing mice treated 
with pentostatin and untreated (n=5). TRIF KO mice did not respond to pentostatin 
treatment. Error bars are the mean±s.e.m. Black arrow points to the day of pentostatin 
treatment. 
C) Induction of endogenous retroviruses quantified by real-time PCR in total RNA 
extracted from HEK cells incubated 2 days with 0, 7.5; 15; 30 µg/ml of Pentostatin. All 
values represent duplicates and dCT value is calculated by substracting the average 
value obtained for GAPDH to the experimental value. Error bars are the mean±s.e.m. 
D) Survival curves in TLR4 ko and TLR9 ko MB49 tumor-bearing mice treated with 
Pentostatin and untreated (n=7). Both TLR4 ko and TLR9 ko responded to Pentostatin 
treatment. Error bars are the mean±s.e.m. Black arrow points to the day of pentostatin 
treatment. 
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Methods and materials  
Mice 
WT and nude mice were purchased from Envigo.  Tlr3-/-, Tlr7-/-, Tlr4-/-, Tlr9-/-, MAVS-/- and 
TRIF-/- (all on have C57BL/6 genetic background) were bred in house. IFN beta/Luc reporter 
mice were kindly provided by Dr. Stefan Lienenklaus (University of Hannover) and bred in house. 
Age-matched (6–12 weeks) female and male animals were used throughout experiments. Animal 
experiments were approved by the regulatory authorities (license 175/2015 “Study of the 
immunological anti-cancer effects of Pentostatin, an ADA inhibitor”). All mice were kept in 
accordance with regulations from the Laboratory Animal Services Center (LASC) at the 
University Hospital of Zurich. 
Tumour cell lines 
CT26/NY-ESO-1 is a murine colorectal cancer cell line expressing NY-ESO-1 and was kindly 
provided by Professor Hiroyoshi Nishikawa (Muraoka et al., 2010). MB49 bladder cancer cell line 
was kindly provided by Dr. Sonia Domingos-Pereira (University Hospital of Lausanne, 
Switzerland). All cell lines were kept in RPMI medium containing 10% fetal bovine serum 
(Thermo Fisher Scientific) and 1% 200 mM L-glutamine and implanted subcutaneously (1 million 
in 200 microliters of PBS). Cells were tested for pathogens and approved from LASC regulatory 
office. In house testing for mycoplasma was performed during the time of experiments.  
E. coli, S. cerevisiae and D. melanogaster, human and mouse RNA 
E. coli, human muscle, human pancreas, mouse embryo and HeLa RNAs were ordered from 
Ambion (Thermo Fisher Scientific). Tablets of dormant S. cerevisiae were reactivated in water 
solution containing 1% D-glucose and 0.1% yeast extract kept at 28-30 degrees with slow steering 
for 6-8 h. D. melanogaster flies were provided by Julia Falschlunger (Institute of Molecular Life 
Sciences, University of Zurich). 
RNA preparations 
Total RNA from cells or tissues was obtained using miRNeasy Mini Kit (Qiagen) according to 
manufacturer instructions. For the isolation of RNA from yeast, a combination of 
lyticase/zymolase mixtures prior to RNA isolation was employed in combination with RLT 
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(Qiagen) buffer. All RNAs were checked either on 1.2% agarose containing 1% MOPS-EDTA 
and 0.75% of 37 % formaldehyde (Sigma) or on Agilent RNA 600 Nano chips using 2100 Agilent 
bioanalyzer. Agilent bioanalyzer and software were kindly provided from Silvia Lang 
(Gastroenterology Department, University Hospital Zurich). 
Protamine RNA formulations 
Protamine (IPEX) was purchased from Meda and stored at 4 degrees. Total RNA diluted in water 
at 0.5 ug/ul was combined with Protamine diluted in water at 0.5 ug/ul. Particle size was checked 
using light scattering spectroscopy (Zeta Sizer, Malvern). Stability and further properties of 
Protamine-RNA formulations have been published (Rettig et al., 2010; Tusup and Pascolo, 2017). 
1 ug of diluted total RNA mixed with 2 ug of diluted Protamine are incubated at room temperature 
for 10 minutes before addition of 200 microliters of complete medium containing one million of 
human PBMCs and incubation 24 hours at 37°C. 
ELISA measurements 
Human IFN-alpha pan (Mabtech) and TNF alpha (Biolegend) were measured in fresh and frozen 
cell culture supernatants. Values were obtained on Biotek reader at 450 nm using Gen5 software. 
VeriPlex human cytokine 16-Plex ELISA (PBL) was employed for multiple cytokine 
measurements. Image J was used as a software for quantifying values obtained from 
chemiluminescent measurement of VeriPlex ELISA.  
Drugs 
Pentostatin (Sigma) stored as powder at -20, was diluted in PBS for a working concentration of 10 
mg/ml and used immediately. EHNA (Sigma), Metformin (Merck Serano) and Methotreaxate 
(Pfizer) were stored and diluted according to manufacturer instructions.  
Tumor models and treatment 
Mice were inoculated subcutaneously with 1x106 tumor cells. Tumor sizes were measured 
unblinded with a caliper every second day for calculating tumor volumes using the equation 
(a2×b)/2 (a, width; b, length). Animals were euthanized when exhibiting signs of impaired health 
or when tumor volume exceeded 1 cm3. Pentostatin (Sigma) was injected intravenously when 
tumors were palpable (day 6 for MB49 and day 7 for CT26). When indicated, 1mg of anti-IFNAR1 
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blocking antibody (MAR1-5A3, BioXCell) solution was injected intraperitoneally at the same day 
than Pentostatin.  
Bioluminescent in vivo imaging 
Bioluminescence in vivo imaging of tumor bearing IFN beta reporter mice was performed on IVIS 
Lumina (PerkinElmer) at specific time point post Pentostatin injection. Immediately prior to 
measurements D-Luciferin (Synchem) dissolved in PBS (15 mg/ml stock) and sterile filtered was 
injected (150 µg/g intraperitoneally per mouse). Emitted photons from live animals were 
quantified 10-20 minutes post Luciferin injections with an exposure time of 1 min. Regions of 
interest (ROI) were quantified for average radiance (photons s−1 cm−2 sr−1) (IVIS Living Image 
4.0). 
Immunofluorescence staining 
CD8+ staining was performed on 6-8-μm sections of cryo-preserved tumors. Cryosections were 
fixed for 5 min in -20 cold methanol and equilibrated for 5 min in PBS. After three washes in PBS 
containing 0.1% Tween 20 (PBST), slides were blocked for 1h at RT in 12% BSA in PBS 
containing 0.1% NP-40 (blocking buffer). CD8 antibody (eBioscience, Thermo Fischer Scientific) 
PE conjugated at 1:1000 dilution in blocking buffer were incubated overnight at 4 degrees. 
Sections were washed three times in PBST. Nuclei were stained with DAPI (Sigma) (1:2000). 
After three washes with PBST, sections were quickly washed in water, mounted in fluorescent 
mounting-medium and air-dried for 2 h at room temperature. Immunofluorescence images were 
acquired using Zen Pro Axio Zeiss microscope and software.  
Flow cytometry 
Monoclonal antibodies for extracellular staining included CD4, CD8 and CD11c (eBioscience, 
Thermo Fischer Scientific). Quantification of NY-ESO-1-specific CD8+ T cells with APC-
labelled H-2Dd tetramer loaded with the 81-88 NY-ESO-1 peptide (TCmetrix) was made using 
mouse blood five days after Pentostatin injection. Collected blood was washed in fluorescence-
activated cell sorting (FACS) buffer and tetramer staining was performed in FACS buffer 
simultaneously with CD4 and CD8 stainings.  Erythrocyte lysis with BD FACS lysing solution 
was performed after 1h of incubation with antibodies. After lysis samples were washed in PBS 
136 
and suspended in FACS buffer for measurement on FACS Canto I with FACS Diva BD software. 
For quantification and analysis of cell populations of interest FlowJo X was used. 
LDH assay 
Different cell lines were seeded (5000 cells per well) in 300 ul of complete medium in 48 well 
plate. One day later, supernatants are replaced by 200 microliters of complete medium. Different 
doses of tested drug were added in 200 ul.  After three days of growth wells were washed gently 
with MEM (no serum) and frozen in 500 microliters of PBS at -80°C. Next day, plates were placed 
at room temperature 3 hours at least, with one hour of shaking, then plates were spun for 5 minutes 
at 1500 rpm. From plates 10 microliter supernatants were transferred in 96 well plate with addition 
of 40 µL substrate for LDH from Cytotox96 kit (Promega). 10 microliters of PBS plus 40 µL of 
substrate was used for background value. Reactions were stopped with the addition of 40 µL stop 
solution and plates were measured at OD 490nm. The percentage of cells was calculated according 
to the formula: (experimental value-background)/(untreated cells-background)x100. 
Reverse transcription and quantitaive Polymerase chain reaction (qPCR) 
Total RNA extracted by miRNeasy kit (Qiagen). 1 μg of RNA was reverse transcribed using the 
High-Capacity cDNA Reverse Transcription Kits (Applied Biosystems) as recommended by the 
manufacturer. An equivalent of 16 ng of initial RNA was used per well in  qPCR (Roche) reactions 
using primers specific for house keeping genes (Glyceraldehyde-3-phosphate dehydrogenase - 
GAPDH and hypoxanthine–guanine phosphoribosyltransferase - HPRT) as well as primers 
specific for several endogenous retroviruses (from (Chiappinelli et al., 2015)). The dCT value was  
calculated by substracting the average value obtained for GAPDH to the experimental value.  
Statistical analyses and data presentation 
All results are expressed as mean±s.d. Biological replicates were used in all experiments unless 
stated otherwise. Unpaired two-tailed Student’s t-test was used for comparison of two groups. 
One-way analysis of variance (ANOVA) was performed when more than two groups were 
compared, and when determined significant (P<0.05). 
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Chapter 9
Generation of Immunostimulating 130 nm 
Protamine–RNA nanoparticles
Marina Tusup and Steve Pascolo
Abstract
Nanoparticles of defined size can be easily obtained by simply mixing Protamine, a pharmaceutical drug 
that is used to neutralize heparin after surgery, and RNA in the form of oligonucleotides or messenger 
RNA. Depending on the concentrations of the two reagents and their salt contents, homogenous nanopar-
ticles with a mean diameter of 50 to more than 1000 nm can spontaneously be generated. RNA is a danger 
signal because it is an agonist of for example TLR-3, -7, and -8; therefore, Protamine–RNA nanoparticles 
are immunostimulating. We and others have shown in vitro that nanoparticle size and interferon-alpha 
production by human peripheral blood mononuclear cells (PBMCs) are inversely correlated. Conversely, 
nanoparticle size and TNF-alpha production by PBMCs are positively correlated (Rettig et al., Blood 
115:4533–4541, 2010). Particles of less than 450 nm are most frequently used for research and clinical 
applications because they are very stable, remain polydispersed and induce interferon-alpha proteins, which 
are a natural antiviral and anticancer protein family with 12 members in humans. Herein, we describe a 
method to generate 130 nm nanoparticles as well as some of their physical and biological characteristics.
Key words RNA, Protamine, Nanoparticles, Toll like receptor, Interferon-alpha, TNF-alpha
1 Introduction
Danger signals are immunostimulatory molecules that can stimu-
late surface, intravesicular, and intra-cytosolic receptors. Danger 
signals can be used as vaccine adjuvants as well as monotherapies to 
induce/boost innate and adaptive immunity against pathogens and 
tumor cells [1]. Toll-like receptors (TLRs) are specialized in the 
recognition of danger signals [2] and are expressed in different 
immune cells and different subcellular locations. When triggered, 
TLRs induce specific intracellular activation pathways that can result 
in the expression of different types of innate immune response mol-
ecules, such as alpha interferons (all 12 human alpha interferon 
Electronic supplementary material: The online version of this chapter (doi:10.1007/978-1-4939-6481-9_9) 
contains supplementary material, which is available to authorized users.
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protein family members) and/or TNF-alpha. Unmodified single-
stranded RNA (ssRNA) is recognized by human TLR-7 (expressed, 
for example, in plasmacytoid dendritic cells, the main producers of 
interferon-alpha) and human TLR-8 (expressed, for example, in 
monocytes, which are capable of producing large amounts of TNF-
alpha) [3]. Thereby, ssRNA can trigger a broad range of immune 
cells and activation pathways [4, 5]. To protect it from RNase activ-
ity and successfully deliver it to endosomes in which TLR-7 and 
TLR-8 are located, ssRNA must be formulated for example in lipo-
plexes or polyplexes (or lipopolyplexes). Several teams including us 
have developed RNA polyplex formulations based on Protamine, a 
natural cationic peptide that is used as a drug to inhibit heparin and 
that also spontaneously associates with nucleic acids [4–9]. Thus, 
immunostimulating polyplexes can be produced for injections into 
humans, and we used these polyplexes as vaccines [10] or peptide 
vaccine adjuvants [11, 12] as experimental immunotherapy in can-
cer patients. Remarkably, the size of the Protamine–RNA poly-
plexes can be specifically and simply determined by regulating the 
salt concentration in the Protamine and RNA components before 
mixing to promote the spontaneous formation of specifically sized 
particles [13]. As the salt concentration decreases, the particle size 
decreases. In this manner, particles from 50 nm to above 1000 nm 
can be easily produced. Surprisingly, the size of the particles dictates 
their immunostimulating features. Only particles less than 450 nm 
efficiently stimulate plasmacytoid dendritic cells and thereby 
induced high levels of interferon-alpha. Larger particles activate 
monocytes but not plasmacytoid dendritic cells and thereby trigger 
the production of TNF-alpha but not alpha interferons [13]. Thus, 
Protamine–RNA particles of different sizes are ideal, versatile tools 
to activate immune cells of interest, such as in dendritic cell-based 
vaccination [14]. Meanwhile, because alpha-interferons are of great 
interest for anticancer and antivirus therapies, we have focused our 
research on Protamine–RNA particles that are less than 450 nm in 
size. These particles are further being developed as immunomodu-
latory drugs (Tusup and Pascolo, ongoing studies) and are also 
used as adjuvants for mRNA vaccines [15]. This article presents 
detailed methods for generating immunostimulating Protamine–
RNA particles approximately 130 nm in size.
2 Materials
For dilutions, resuspension, and analysis, we use ultrapure water 
(prepared by purifying deionized water to attain a sensitivity of 
18.2 M Ω cm at 25 °C, 4 ppb TO—Milli-Q® Advantage A10 ultra-
pure water).
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1. Protamine. Pharmaceutical Protamine is available at two
concentrations: 1000 (1 ml neutralizes 1000 IU of heparin) or
5000 (1 ml neutralizes 5000 IU of heparin). To generate par-
ticles of 130 nm, we use Protamine Ipex 5000 from MEDA
Pharmaceuticals (Protamine hydrochloride 5000 IU/ml, see
Note 1). The Protamine is stored at 4 °C (see Note 2).
2. Messenger RNA. Highly purified mRNA coding for firefly
Luciferase was produced by in vitro transcription and provided
by BioNTech Ag (Prof. Ugur Sahin, Mainz, Germany). The
transcript is approximately 1800 bases and contains canonic A,
C, G and U residues with a 5′ cap and 3′ poly-A tail (see Note 3).
The mRNA is stored at −20 °C (see Note 4).
1. Zetasizer (Malvern) 3000HSA Particle Analyzer equipped
with PCS software.
2. Transparent cuvettes (Disposable cuvettes, 1.5 ml, semi-micro,
Brand + CO Gmbh, Germany).
1. Heparin tubes (BD vacutainer LH 17 IU/ml, cat no. 367526).
2. Ficoll solution (Ficoll-Paque™ Plus, GE Healthcare Life
Sciences, 17-1440-02).
3. Pasteur pipets.
4. Centrifuge with controllable brake (Eppendorf™ Model 5810
Centrifuge).
5. Phosphate Buffered Saline (PBS) (without Ca and Mg, pH 7.2,
sterile, not for infusion, Kantonsapotheke Zurich, Switzerland).
6. 15 ml Falcon tubes.
7. Complete medium: RPMI medium 1640 (Sigma cat no.
R0883) containing 10 % heat-inactivated fetal bovine serum
(Gibco, Life Technologies, Thermo Fischer Scientific), 1:100
antibiotics (Penicillin-Streptomycin Thermo Fischer, cat no.
15140-122) and l-Glutamine (200 mM, Merck Milipore cat
no. K 0282).
8. 96-well U bottom plate (Falcon).
9. Humidified 37 °C CO2 incubator.
1. Pan interferon-alpha kit (MABTECH, cat no. 3425-1A-6).
2. ELISA reader (Biotek, ELx808 Absorbance Reader, software
Gen 5, 2.07 version).
2.1 Particle 
Components
2.2 Particle Analyzer
2.3 Stimulation 
of Human Blood Cells
2.4 Detection 
of Alpha Interferons
Protamine–RNA Nanoparticles
158
3 Methods
Carry out all procedures at room temperature unless otherwise 
specified.
 This step is performed under laminar flow using sterile 
equipment.
1. Prepare a 0.5 mg/ml Protamine solution (see Note 5) by dilut-
ing 10 μl of Protamine 5000 in 280 μl of water.
2. Prepare a 0.5 mg/ml RNA solution (see Note 5) by diluting
the RNA stock with the appropriate amount of water.
3. Add an equal amount of Protamine solution to the RNA solu-
tion (see Note 6), and pipet quickly up and down at least ten
times (see Note 7).
4. Leave the solution at room temperature for 10 min (see Note 8).
1. Dilute 40 μl of the Protamine–RNA formulation (containing
10 μg of RNA and 10 μg of Protamine) with 1 ml of water (see
Note 9).
2. Set the viscosity of the analyzer to 0.89 (select within the soft-
ware setting either measurement in water or a viscosity of
0.89). As shown in Fig. 1, particles made in the conditions
described above are approximately 130 nm in size with a poly-
dispersity index (PDI) of less than 0.3 (see Note 10).
3.1 Production 
of the 130 nm 
Protamine–RNA 
Nanoparticles
3.2 Particle Size 
Measurement
20 50 100 200 500
20
40
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Fig. 1 Measurement of particle size displaying “Intensity-Weighted Gaussian 
Distribution Analysis” for solid particles. Average size is 131 nm and PDI is 0.214
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This step is performed under laminar flow using sterile equipment.
1. Place 5 ml of fresh venous blood (collected from a healthy
donor in a heparin tube, see Note 11) in a 15 ml Falcon tube.
2. Add a Pasteur pipet to the tube, and make sure that the tip of
the Pasteur pipet is at the bottom of the tube.
3. Using a 5-ml pipet attached to a pipet aid, pipet 5 ml of Ficoll
inside the Pasteur pipette. This fluid will underlay the blood.
Elevate the Pasteur pipet slightly if the Ficoll does not flow eas-
ily into the bottom of the tube. When the maximum of Ficoll
has gone in the 15 ml tube (when the level of Ficoll in the
Pasteur pipet is at the level of the blood in the tube), close the
Pasteur pipet with an index finger and lift it out of the Falcon
tube. Discard the Pasteur pipet.
4. Carefully place the tube in a centrifuge with a balance tube on
the opposite side of the rotor and centrifuge the tubes at
805 × g, 20 °C for 20 min without braking (see Note 12).
5. Prepare a 15 ml Falcon tube with 10 ml PBS.
6. Carefully place the tube containing blood and Ficoll under lami-
nar flow, aspirate the upper phase (plasma) up to approximately
5 mm above the interface, and collect up to 3 ml of the interface
liquid (it will contain some cells in plasma and some Ficoll) using
a 5-ml pipet attached to a pipet aid. Perform small rotations with
the pipette tip to collect cells that may be close to the tube wall.
7. Dilute the 3 ml collected in 10 ml PBS (tube prepared in step 5).
8. Mix by inverting the tube three times and place it in a centri-
fuge (equilibrated with a balance tube on the opposite of the
rotor), and centrifuge the tubes at 453 × g, 20 °C for 10 min.
9. Discard the supernatant, loosen the pellet by tapping the bot-
tom of the Falcon tube several times, and repeat the PBS wash
(add 10 ml of PBS on the cells and centrifuge as in step 7).
Loosen the pellet and add 1 ml of complete medium.
 10. Count the cells (Peripheral Blood Mononuclear Cells
[PBMCs]), which should total approximately 5 million.
11. Adjust the cell concentration to 5 million per ml (if needed,
spin the cells again at 453 × g for 10 min and after having loos-
ened the pellet, resuspend in an adequate amount of complete
medium).
12. Place 4 μl of 130 nm Protamine–RNA particles (containing
1 μg of RNA and 1 μg of Protamine, obtained in step 4 of
Subheading 3.1) at the bottom of a well in a 96-well U bottom
plate.
13. Add 200 μl of cells (one million) on top of the 4 μl of particles.
As controls, prepare one well with 200 μl of cells alone, one
well with 200 μl of cells and 1 μg of Protamine and one well
with 200 μl of cells and 1 μg of RNA.
3.3 Evaluation 
of Interferon- Alpha- 
Inducing Capacities 
in Human Blood Cells
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14. Incubate overnight at 37 °C in a humidified CO2 incubator.
 15. Transfer cell culture supernatants to a fresh 96-well plate.
Proceed to step 15 or store at −80 °C (see Note 13).
16. Use 20 μl of cell culture supernatant (add 80 μl per well of
assay diluent: 1 % BSA in PBS) in the pan-interferon-alpha
ELISA kit strictly following the manufacturer’s instructions
(see Note 14).
17. Calculate experimental values. As shown in Fig. 2, Protamine–
RNA nanoparticles of approximately 130 nm efficiently induce
interferon-alpha expression in PBMCs in vitro (see Notes 15
and 16).
4 Notes
1. Protamine sulfate, such as Valeant Protamine, gave identical
results.
2. We have observed that freezing Protamine solutions may jeop-
ardize its functionality as far as production of  immunostimulating 
RNA polyplex is concerned. Pharmaceutical Protamine should
be stored at 4 °C as indicated on the package.
3. Any RNA (oligonucleotide, long uncapped and/or non-
polyadenylated mRNA, or capped mRNA) can be used to gen-
erate the 130 nm particles.
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Fig. 2 Quantification of alpha interferons. The graph reports the calculated values 
of alpha-interferon content in supernatants from PBMCs alone (“PBMCs”) or 
incubated with RNA (“RNA”), Protamine (“Protamine”), or Protamine–RNA 
nanoparticles approximately 130 nm in size (Prot-RNA). Each bar represents the 
average value of three data points (three culture wells) and the standard 
deviation
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4. Highly pure sterile RNA in water is very stable at room tem-
perature. However, because contaminating RNases could the-
oretically be present, we store RNA at 4 °C (day storage) or
−20 °C (long term storage) and bring it to room temperature
when doing the experiments before immediately placing it
back at 4 °C or −20 °C.
5. The more RNA and Protamine are diluted, the smaller the
resulting particles will be (Supplementary Fig. 1a). Particles of
50–250 nm in size induce interferon-alpha in human blood
cells in vitro to similar extents (Supplementary Fig. 1b).
6. Mixing equal mass amounts of Protamine and RNA will generate
nearly neutral or slightly positive particles (zeta potential). Using
a twofold mass excess of Protamine or a twofold mass excess of
RNA will generate particles with positive or negative zeta poten-
tials, respectively, as previously described [13]. Size (Supplementary 
Fig. 2a) and in vitro immunostimulation characteristics
(Supplementary Fig. 2b) of the particles are similar when using
particles with a positive, neutral, or negative surface charge within
this range (twofold excess of one of the two components).
7. We always add Protamine to RNA, not RNA to Protamine.
8. This formulation is very stable at room temperature (as long as
it is made using sterile RNA, Protamine, and water and in ster-
ile conditions, i.e., under a laminar flow) or in the fridge. We
have tested storage of this material up to 1 week and found
that the storage period did not affect particle size or immuno-
stimulatory capacity (Supplementary Fig. 3). By contrast,
freezing the particles at −20 °C destroys their immunostimula-
tory capacity. Thus, it is of utmost importance to store the
130 nm Protamine–RNA nanoparticles in liquid solutions, and
we recommend storage of undiluted particles at 4 °C.
9. We observed that the particles aggregate over time when
diluted in salt-containing solutions, such as PBS or Ringer lac-
tate, and thereby will appear larger than their original size if
analyzed in those solutions. The original particle size is pre-
served when the particles are undiluted or diluted in water or
other low-salt solution (e.g., isotonic 5 % glucose). Thus, for
particle size measurement, Protamine–RNA nanoparticles
must be preserved by dilution in water or other low-salt
solution.
10. A PDI value of 1 indicates that the sample has a very broad size
distribution and may contain large particles or aggregates that
could be slowly sedimenting. A PDI value closer to zero
denotes a monodispersed system (one unique particle size in
the sample). For biological particles, it is usually accepted that
a PDI value below 0.5 represents a relatively homogenous
formulation.
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11. Blood stored up to 24 h at 4 °C can be used. However, frozen
blood cells did not respond as well as did fresh or stored (up to
24 h) blood. We suspect that plasmacytoid dendritic cells, an
important producer of interferon-alpha, do not survive freeze–
thaw cycles well when cells are frozen in physiologic solutions
containing 10 % DMSO.
12. The centrifuge should accelerate and decelerate as slowly as
possible. Should acceleration or deceleration be too fast, the
interface between blood and Ficoll will be perturbated, and the
collection of peripheral blood mononuclear cells will be jeop-
ardized. Should this happen (for example, by mistake the brake
is not disabled during centrifugation), the blood and Ficoll can
be manually further mixed together (inverting the tube few
times) and 5 ml Ficoll can again be underlay with 5 ml of Ficoll
as in step 3 of Subheading 3.3 before centrifugation under the
appropriate conditions.
13. We observed that supernatants stored at −20 °C were not well
preserved as far as interferon-alpha is concerned.
14. Using 20 μl of cell culture supernatants usually allows experi-
mental ELISA optical densities (ODs) that are in the range of
the standard titration (from 0 to 1000 pg/ml).
15. The total amount of alpha interferon detected in supernatants
varies from donor to donor and can be in the range of 1000–
10,000 pg/ml.
16. For each condition, we performed three PBMC cultures (trip-
licates) and presented the data as the means plus standard
deviation.
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Supplementary Fig. 1 (a) Influence of reagent dilutions: Particle size. Protamine 
and RNA were diluted in water at 0.1, 1, or 2 mg/ml before being mixed together 
(mass ratio 1:1). The graphs report “Intensity-Weighted Gaussian Distribution 
Analysis” for solid particles. Average particle sizes are 85 nm for 0.1 mg/ml, 146 
nm for 1 mg/ml, and 192 nm for 2 mg/ml. Thus, particle size can be finely tuned 
by adjusting the Protamine and RNA ratio. The greater the dilution, the smaller 
the particles. (b) Influence of reagent dilutions: Induction of alpha interferons. 
The graph reports the calculated values of alpha-interferon contents in 
supernatants from PBMCs alone (“PBMCs”) or those incubated with Protamine–
RNA nanoparticles made with reagents at 0.1 mg/ml (“PR01”), 1 mg/ml (“PR1”), 
or 2 mg/ml (“PR2”). Each bar represents the average value of three data points 
(three culture wells) and the standard deviation. The three types of particles 
induce similar amounts of alpha interferons. 
Supplementary Fig. 2 (a) Influence of reagent ratio: Particle size. Protamine and 
RNA were diluted in water at 0.5 mg/ml before being mixed together at mass 
ratios of 1:2 (twofold more RNA than Protamine “PR12”), 1:1 (equivalent mass 
amounts of RNA and Protamine “PR11”), or 2:1 (twofold more Protamine than 
RNA “PR21”). The graphs report “Intensity-Weighted Gaussian Distribution 
Analysis” for solid particles. Average particle size is 174.7 nm for the 1:2 ratio, 
131.6 nm for the 1:1 ratio, and 154.7 nm for the 2:1 ratio. Thus, particle sizes are 
similar when using Protamine–RNA ratios from 1:2 to 2:1. (b) Influence of 
reagent ratio: Induction of alpha interferons. The graph reports the calculated 
values of alpha-interferon content in supernatants from PBMCs alone (“PBMCs”) 
or those incubated with Protamine–RNA nanoparticles made with reagents at a 
1:2 mass ratio (“PR12”), 1:1 mass ratio (“PR11”) or 2:1 mass ratio (“PR21”). Each 
bar represents the average value of three data points (three culture wells) and the 
standard deviation. The three types of particles induce similar amounts of alpha 
interferons. 
Supplementary Fig. 3 Stability of particles: Induction of alpha interferons. The 
graph reports the calculated values of alpha-interferon content in supernatants 
from PBMCs alone (“PBMCs”) or those incubated with Protamine–RNA 
nanoparticles made with reagents at a 1:1 mass ratio and used immediately (“PR11 
fresh”) as well as after storage at room temperature for 1 week (“PR11 7 days RT”) 
or 4 °C for 10 days, (“PR11 10 days 4 °C”) or after having been frozen and thawed 
once (“PR11 −20 °C”). Each bar represents the average value of three data points 
(three culture wells) and the standard deviation. The particles are very stable 
when kept in liquid but partly deactivated by freezing/thawing. 
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measure the relative expression of immune-related genes in 
peripheral blood mononuclear cells (PBMCs).
Results Overall, nine patients [median age 72 years; 
interquartile range (IQR), 68–78 years] were treated. No 
dose-limiting toxicities as defined in the protocol were 
observed. Three patients experienced partial response, and 
two patients had stable disease. The median time to pro-
gression was 4 months (95% CI 0.8–7.2), and the median 
overall survival was 7.6 months (95% CI 5.3–9.9). Among 
86 assayed immune genes, three were significantly differ-
entially expressed in PBMCs from responding versus non-
responding patients: interferon-gamma receptor-1, toll-like 
receptor 2, and beta-2 microglobulin.
Conclusions The addition of chloroquine to gemcitabine 
was well tolerated and showed promising effects on the clini-
cal response to the anti-cancer chemotherapy. Based on these 
initial results, the efficacy of the gemcitabine–chloroquine 
combination should be further assessed.
Keywords Chloroquine · Gemcitabine · Pancreatic 
cancer · Interferon-gamma receptor-1 · Toll-like receptor 
2 · Beta-2 microglobulin
Introduction
Pancreatic adenocarcinoma is the fourth most common cause 
of cancer-related death, and it has a poor prognosis: for all 
stages combined, the 5-year relative survival rate is 8%; for 
local disease, the 5-year survival is approximately 29% [1]. 
The median survival for locally advanced and metastatic dis-
ease, which collectively represents more than 80% of indi-
vidual cases, is approximately 10 and 6 months, respectively. 
In patients with locally advanced or metastatic pancreatic 
cancer, chemotherapy with gemcitabine alone at a weekly (3 
Abstract 
Purpose Following a previously published pre-clinical 
validation, this phase I study evaluated the safety, maximum 
tolerated dose, anti-tumour activity and immune status of 
a gemcitabine–chloroquine combination as a first- or late-
line treatment in patients with metastatic or unresectable 
pancreatic cancer.
Methods In this 3 + 3 dose escalation study, patients 
received a single weekly standard dose of intravenous gem-
citabine, followed by single weekly oral intake of 100, 200 
or 300 mg of chloroquine. Tumour response was assessed 
using the Response Evaluation Criteria in Solid Tumors 
version 1.1. Immune status was evaluated by RT-PCR to 
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of 4 weeks) dose of 1000 mg/m2 is widely used to improve 
patient’s quality of life with a modest survival benefit [2]. 
Furthermore, a median overall survival of 11.1 months 
can be achieved with FOLFIRINOX (5-fluorouracil, leu-
covorin, irinotecan, oxaliplatin), in contrast to 6.8 months 
using weekly gemcitabine treatment [3]. However, signifi-
cantly more adverse events were noted in the FOLFIRINOX 
group, highlighting the need to carefully select patients for 
this more intensive protocol. More recently, a weekly gem-
citabine-based combination with albumin-bound paclitaxel 
(nab-paclitaxel, 3 of 4 weeks) also resulted in improved 
outcomes compared to gemcitabine alone in patients with 
advanced pancreatic cancer, thus establishing the former 
regimen as an additional option in patients with advanced 
disease. The median overall survival was improved from 
6.7 months with gemcitabine alone to 8.5 months with the 
combination treatment. Relevant adverse events observed 
with this combination treatment included fatigue, peripheral 
neuropathy and diarrhoea [4].
Chloroquine has been a widely used prophylactic (300 mg 
per week) and therapeutic (300 mg daily) anti-malarial drug 
for more than 60 years [5]. More recently, chloroquine was 
shown to be an immunomodulator [6] and demonstrated 
anti-cancer activities in vitro and in pre-clinical models [7]. 
Chloroquine increases the endosomal pH and has opposing 
effects depending on the dose and schedule [7]. For exam-
ple, chloroquine helps control autoimmune diseases (lupus 
erythaematosus and rheumatoid arthritis) when administered 
at high daily doses (300 mg daily), whereas a single dose of 
300 mg of chloroquine administered 2 days before a protein 
vaccine enhances the induction of T cells [8]. In addition, 
chloroquine has several anti-tumour activities in vitro and 
in vivo, either by having a direct effect on cancer (stem) 
cells or by modifying the tumour microenvironment [7, 9]. 
Daily uptake of chloroquine combined with chemotherapy 
(carmustine) and radiotherapy was found to enhance the 
overall survival of patients with glioblastoma (post-surgical 
tumour ablation) [10, 11]. Similarly, previous work in our 
laboratory showed that in mouse tumour models, the effi-
cacy of gemcitabine is improved by the administration of 
chloroquine [12]. Importantly, the single administration of 
chloroquine must follow, not precede, the single injection 
of gemcitabine to enhance the control rate of established 
tumours in animal models. However, when tested as an anti-
cancer drug, chloroquine was usually added daily (before, 
during and after radiochemotherapies [10, 11]), without 
preliminary evaluation of the potential opposite effects of 
the anti-cancer treatments and chloroquine. Certain chemo-
therapeutic drugs, such as gemcitabine, belong to a group of 
immunologic cell death inducers and contribute to the induc-
tion of anti-cancer immunity by dying tumour cells [13]. 
This induced immune response helps control the disease. It 
was previously postulated by our laboratory that chloroquine 
administered after gemcitabine further induces the death of 
tumour cells (including tumour stem cells) without jeop-
ardizing anti-cancer immunity [12]. A phase I study was, 
therefore, implemented with the objective of evaluating the 
safety, tolerability and preliminary efficacy of increasing 
doses of chloroquine given 1 day after weekly gemcitabine 
treatment in patients with locally advanced or metastatic 
pancreatic cancer. An additional objective was to analyse 
peripheral blood to identify immune markers that would cor-
relate with treatment response.
Materials and methods
Patient population
Patients 18 years or older with a WHO performance status 
of 0–2 and histologically or cytologically confirmed non-
resectable locally advanced or metastatic adenocarcinoma 
of the pancreas were eligible. Adequate liver and kidney 
function tests [bilirubin < 2× upper limit of normal (ULN), 
alanine aminotransferase (ALT) < 5× ULN, alkaline phos-
phatase < 5× ULN, estimated creatinine clearance > 40 ml/
min using the Cockcroft formula], and adequate haemato-
logical values (haemoglobin > 80 g/l, leucocytes > 3.0 G/l, 
neutrophils > 1.0 G/l, platelets > 100 G/l) were mandatory 
prior to inclusion in the study. Previous treatment with 
chemotherapy, including gemcitabine, and/or radiotherapy 
was not an exclusion criterion.
Study design
ONK-USZ-004 is a single-arm monocentric phase I study 
sponsored by the University Hospital of Zürich. The study 
protocol and amendments were approved by the local Ethics 
Committee and Swissmedic (ClinicalTrials.gov identifier: 
NCT01777477). Each patient provided informed consent. 
Although the protocol was initially written for exclusive 
recruitment of treatment-naïve patients, an amendment was 
filed in April 2014 to permit the recruitment of previously 
treated patients. Dose escalation was conducted using a tra-
ditional 3 + 3 algorithm, with cohorts of three patients who 
were sequentially enrolled at chloroquine single doses of 
100 mg (the lowest dose used for prophylaxis of malaria: 
1 tablet), 200 and 300 mg (the highest recommended daily 
dose) total per week (on days 2, 9, and 16 of a 4-week cycle 
repeated on day 30) orally 1 day after gemcitabine admin-
istration (1000 mg/m2 i.v. on days 1, 8 and 15 of a 4-week 
cycle; repeated on day 29). Treatment was performed until 
progression or unacceptable toxicity was observed or until 
the patient requested treatment termination. Dose-limiting 
toxicity (DLT) was defined as an adverse event (AE) or 
laboratory abnormality that fulfilled the following criteria 
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during the first cycle of systemic treatment: grade 4 neutro-
penia lasting at least 7 days or febrile neutropenia; grade 
4 thrombocytopenia; grade 3/4 gastrointestinal symptoms 
(diarrhoea, vomiting or mucositis) that were not reduced to 
grade 1 within 7 days of appropriate supportive care; grade 
3/4 skin toxicity (e.g. rash or hand-foot-syndrome); grade 
3/4 ocular toxicity (e.g. blurred vision or retinopathy); grade 
3/4 auditory toxicity (e.g. hearing loss or tinnitus); grade 
3/4 neurologic toxicity; grade 3/4 pulmonary toxicity (e.g. 
dyspnoea, oedema or alveolitis) that did not resolve to grade 
1 within 3 days after treatment cessation; grade 3/4 elevation 
of liver transaminases and bilirubin, despite discontinuation 
of treatment and exclusion of stent failure or hepatic tumour 
progression; and any grade 3/4 toxicity that was considered 
dose limiting by the principal investigator. Adverse events 
that were determined by the investigator to be unrelated or 
remotely related to the experimental drug (chloroquine) were 
not considered in the decision of whether to escalate the 
dose in the next cohort. The maximum tolerated dose (MTD) 
of chloroquine in combination with the fixed dose of gem-
citabine was defined as one dose level below the dose level 
that caused DLTs in at least two patients. No further dose 
escalation of chloroquine above 300 mg per week was pur-
sued because higher doses may cause immunosuppression 
[14, 15] and increased incidence of retinopathy.
Study endpoints
The MTD of orally administered chloroquine combined with 
intravenous gemcitabine was the primary endpoint. The sec-
ondary endpoints were response rate according to RECIST 
v1.1, best response under trial treatment (assessed every 2 
months), progression-free survival and overall survival.
Since gemcitabine and chloroquine are immune-related 
drugs, immune assessments of the patients were also 
performed.
Assessments
Adverse events were graded according to the National Can-
cer Institute Common Terminology Criteria for Adverse 
Events (NCI-CTCAE) v4.0 http://evs.nci.nih.gov/ftp1/
CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.
pdf). Tumour response was assessed by the investigator 
every 2 months during therapy and every 3 months thereafter 
by computed tomography (CT) scans of the chest, abdomen, 
or pelvis.
Immunomonitoring
For each patient, 6 lithium heparin tubes (approximately 
50 ml in total) and 1 serum blood sample (approximately 
10 ml) were collected prior to treatment initiation and at 
every other cycle during therapy, including once at the 
first follow-up visit. Peripheral blood mononuclear cells 
(PBMCs) were recovered from heparin tubes by centrifuga-
tion in a Ficoll gradient and then were frozen in foetal calf 
serum containing 10% DMSO (up to 10 million cells per 
aliquot). For analysis, one aliquot was thawed, and RNA 
was extracted using the Qiagen miRNA Kit according to 
the manufacturer’s instructions. The RNA was then reverse 
transcribed and used in the Qiagen RT2 profiler according 
to the manufacturer’s instructions.
Results
Patients
Between October 2012 and February 2015, nine patients 
(four female and five male patients) were enrolled in the 
study (Table 1). The median age of the patients was 72 years 
[interquartile range (IQR), 68–78 years]. All patients had 
symptomatic pancreatic cancer at study entry (e.g. pain, 
fatigue, anorexia, and weight loss). One patient underwent 
resection of the primary tumour at diagnosis. This patient 
had an additional small neuroendocrine tumour of the pan-
creatic tail (13 mm in diameter, G1, MIB < 2%), which had 
been completely excised at primary resection. After discus-
sion with the study team, the patient was considered eligi-
ble despite the underlying additional low-grade malignancy. 
Two patients received anti-cancer treatment before study 
entry: one patient was treated with radiotherapy in combina-
tion with capecitabine for locally advanced disease, and the 
other patient received gemcitabine monotherapy for meta-
static disease. All patients received at least two subsequent 
weekly infusions of gemcitabine followed by chloroquine 
1 day later and were thus evaluable. Two patients had locally 
advanced inoperable pancreatic cancer, and all other patients 
had metastatic disease.
Dose modifications and safety
A total of 39 cycles were administered. Gemcitabine was 
administered at 110 (94%) of the planned 117 therapy visits, 
with subsequent intake of chloroquine the day after in 109 
(93%) of these visits: the planned infusion of gemcitabine 
on day 15 and the subsequent chloroquine intake on day 
16 of the final treatment cycle were omitted in six patients. 
Additional administrations of gemcitabine and chloroquine 
on days 15 and 16, respectively, of the second to last cycle 
were also omitted in one patient. Thrombocytopenia induced 
by gemcitabine led to a dose reduction of the chemothera-
peutic drug on day 8 or 15 in 13 of the total of 110 (12%) 
gemcitabine infusions without reduction of the subsequent 
chloroquine dose.
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Most adverse events observed were expected accord-
ing to the underlying disease and the administration of 
gemcitabine. Five episodes of temporary grade 1/2 vision 
impairment (blurred vision) observed in two patients were 
considered possibly related to chloroquine and did not 
result in treatment changes. All adverse events ≥ grade 3 
are listed in Table 2. The complete list of adverse events 
is available as Supplementary Table 1.
No DLTs as defined in the protocol were observed, and 
the number of patients did not need to be increased in any 
cohort. Significant overlapping toxicities of the additional 
intake of chloroquine were not observed up to the highest 
dose evaluated of 300 mg once per week.
Clinical outcomes
The objective tumour responses according to RECIST cri-
teria are shown in Table 3. Overall, three patients (33%) 
experienced partial responses, and two patients (22%) had 
stable disease. One patient decided to stop therapy after 
two cycles despite disease stabilization and subsequently 
received a dose-reduced FOLFIRINOX regimen. Therefore, 
the analysis of time to progression was performed as inten-
tion to treat and as per protocol after censoring this patient 
at the time of new treatment initiation.
Disease stabilization was reached as early as 1.9 
months after treatment start and lasted up to 7.9 months 
Table 1  Patient characteristics
LN lymph nodes, WHO PS World Health Organization Performance Score Status
Chloro-
quine single 
dose
# Age Sex WHO PS Tumour location Tumour extent Metastatic sites at 
baseline
Previous treatment Relevant pre-exist-
ing conditions
100 mg 1 73 Female 1 Tail Metastatic LN, liver – Venous sinus
thrombosis;
poliomyelitis; 
apoplexy; hyper-
tension
2 72 Female 2 Head Metastatic LN, liver, lung – Fatigue; recurrent
erysipelas; meta-
bolic syndrome
3 78 Male 1 Tail Metastatic LN, peritoneum, 
lung, bone
– Deep vein throm-
bosis with pulmo-
nary embolism; 
fatigue
200 mg 4 63 Male 1 Head Locally advanced None Radiotherapy plus 
Capecitabine
Pancreatic fistula 
with pleural effu-
sion; duodenal 
stenosis; diabetes 
mellitus
5 70 Female 0 Head/body Locally advanced None – Neuropathy; renal
insufficiency;
hypertension
6 82 Male 1 Body/tail Metastatic LN, liver, perito-
neum
Resection of the 
primary tumour
Pulmonary hyper-
tension; deep 
vein thrombosis; 
ascites
300 mg 7 63 Male 2 Head Metastatic Lung, peritoneum – Portal vein 
thrombosis with 
portal hyperten-
sion; occlusion 
of mesenteric 
and splenic vein; 
congenital heart 
valve disease
8 68 Female 0 Tail Metastatic LN, liver, perito-
neum
–
9 82 Male 0 Head Metastatic LN, liver Gemcitabine Fatigue; hyperten-
sion
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in one patient. Response was achieved after 1.8 months 
in one and after 3.9 months in two patients. Response 
duration lasted between 2.2 and 6.9 months. The median 
time from treatment start to tumour progression was 4 
months (95% CI 0.8–7.2) in the intention to treat analy-
sis and 4 months (95% CI 0.9–7.1) as per protocol. The 
Table 2  Total number of 
observed adverse events ≥ grade 
3, regardless of relationship 
to treatment, reported 
during treatment (39 cycles 
administered overall) or during 
follow-up of the nine patients
Only pre-existing conditions that worsened during or after treatment are reported. The highest grade 
observed of each AE is reported
Adverse event Dose level 1 (100 mg) Dose level 2 (200 mg) Dose level 3 
(300 mg)
Grade 3 Grade 4 Grade 3 Grade 4 Grade 3 Grade 4
Haematologic events
 Anaemia 2 1
 Leukocytopenia 2 1 2
 Neutropenia 4 1 2
 Lymphocytopenia 1 2 2
 Thrombocytopenia 2 1 1
Non-haematologic events
 Diarrhoea 1 1
 Nausea/vomiting 2
 Fatigue/weakness 1 1
 Anorexia/weight loss 1 2
 Pain 1 1 1
 Bile duct/duodenal/urinary 
tract compression
1 2 1
 Infection, any 1 3 1
 Peritoneal effusion 1 1
 Secondary malignancy 1
 ASAT/ALAT elevation 1 2
 AP/GGT elevation 1 1
 Hypoalbuminaemia 2
 Hyponatraemia 1
 Hypokalaemia 2 1 1
Table 3  Objective response rates
The percent increase or decrease of the total tumour volume compared to baseline is shown in brackets. In addition, the increase of the tumour 
volume compared to the nadir is shown underlined in patient #2, indicating progressive disease
PR partial response, SD stable disease, PD progressive disease
Chloroquine dose Patient # Month 2 Month 4 Month 6 Month 8 Month 9 Cycles 
adminis-
tered
100 mg 1 SD (− 27%) PR (− 39%) PR (− 35%) 6
2 PR (− 39%) PD (− 11%; +46%) 4
3 SD (− 16%) 2
200 mg 4 SD (− 20%) PR (− 39%) PR (− 45%) PR (− 45%) 6
5 SD (+ 12%) SD (− 11%) SD (− 6%) SD (− 11%) SD (+ 2%) 11
6 PD (− 24% but new lesions) 2
300 mg 7 PD (− 3% but new lesions) 5
8 PD (+ 9 plus new lesions) 2
9 PD (clinical assessment) 1
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median overall survival was 7.6 months (95% CI 5.3–9.9) 
(Fig. 1).
Immune status
Gemcitabine is an immunologic cell death inducer, and 
thus the PBMCs of patients were analysed at baseline to 
identify correlations between immune status and clinical 
outcome after gemcitabine/chloroquine treatments. To 
obtain a broad picture of the immune status, the expression 
levels of 81 immune-related genes (innate and adaptive 
immunity) in PBMCs were measured by real-time PCR 
with the Qiagen RT2 system. The analyses were compared 
among three patients with an objective clinical response 
(partial response according to RECIST was observed in 
patients #1, #2 and #4) and patients with progressive dis-
ease (only patients #6, #7 and #9 were used because the 
quality of RNA extracted from the PBMCs of patient #8 
was not adequate to perform the RT2 assay). After nor-
malization to the beta actin expression levels, three of the 
81 tested genes were significantly differentially expressed 
between these two patient groups: interferon-gamma 
receptor-1 (IFNGR1) and toll-like receptor-2 (TLR2) 
were decreased in responding patients compared with non-
responding patients, whereas beta-2 microglobulin (B2M) 
was increased in responding patients compared with non-
responding patients (Fig. 2). The data for all genes are 
reported in Supplementary Table 2.
Discussion
Chloroquine, a drug that diffuses freely and rapidly across 
cell membranes and enhances endosomal pH, has a plethora 
of biological effects that are dose/schedule dependent and 
may be useful against cancer [7], including the induction of 
apoptosis, vacuolization, inhibition of autophagy, inhibition 
of the multiple resistance pump (MRP), buffering of tumour 
milieu (for improved biodistribution of charged chemothera-
peutic drugs), interaction with nucleotides, toxicity in cancer 
stem cells, normalization of the vasculature, and modula-
tion of the immune response. In mice, the administration 
of chloroquine after intraperitoneal infusion of gemcitabine 
enhances the control of tumour growth, although the exact 
underlying mechanisms have not been elucidated [12]. 
Gemcitabine is an immunological death inducer [13], and 
its anti-cancer activity is partially attributed to the stimula-
tion of innate immunity by dead cells and the induction of 
an anti-cancer adaptive immune response. Thus, the efficacy 
of gemcitabine requires a functional immune system and 
may be limited when used in combination with an immu-
nosuppressive treatment, such as 300 mg daily chloroquine. 
The present phase 1 dose escalation trial was conducted 
to evaluate the safety of chloroquine when combined with 
gemcitabine and to assess preliminary data on the efficacy 
of this chemotherapeutic combination in a selected patient 
population with pancreatic cancer. Nine patients diagnosed 
with locally advanced or metastatic pancreatic cancer were 
recruited at three chloroquine doses following the classical 
Fig. 1  Kaplan–Meier analysis 
of the overall survival of the 
patients. The median overall 
survival was 7.6 months (95% 
CI 5.3–9.9)
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3 + 3 enrolment rule (Table 1). In total, more than 100 infu-
sions of gemcitabine plus 100/200/300 mg chloroquine were 
administered, according to the respective cohort.
Excess toxicity with increasing doses of chloroquine 
added to gemcitabine was not observed among the patients 
in this study. The documented adverse events (Table 2) were 
predominantly related to the health status of the patients or 
were anticipated during gemcitabine treatment. Omission of 
gemcitabine infusion at day 15 is frequent in daily practice 
outside clinical trials. Such omissions are usually the result 
of higher grade thrombocytopenias or granulocytopenias, 
which are typical adverse events of gemcitabine observed 
in up to 25% of patients, even when administered as mono-
therapy. Accordingly, the need for treatment omission was 
not unusual within this trial. Thus, the highest evaluated 
chloroquine dose of 300 mg per week combined with stand-
ard dosed gemcitabine was feasible. No DLT and no grade 
4 toxicities were observed in this cohort.
Three of nine patients showed a partial response, and two 
patients had stable disease according to the RECIST criteria 
for an overall response rate of 33% and a tumour control 
rate of 55%. This finding compares favourably to the previ-
ously reported and anticipated response rates of up to 10% 
with gemcitabine alone in patients with advanced pancreatic 
cancer [2–4]. Responses were observed in the groups receiv-
ing lower doses of chloroquine (100 or 200 mg), suggest-
ing that, as indicated in our pre-clinical studies [12], lower 
doses of chloroquine may be more efficacious in this treat-
ment setting. However, as only nine rather elderly patients 
were treated, the outcome analysis may only be considered 
exploratory.
Evaluation of the global immune status of the patients 
based on expression profiling of 80 immune-related genes 
in PBMCs obtained immediately before the start of therapy 
revealed that three genes may predict the response to ther-
apy: relatively low expression of IFNGR1 and TLR2 or rela-
tively high expression of B2M. Indeed, it has been reported 
that the gamma-interferon axis may be tumour promoting 
by inducing immunosuppressive effectors (e.g. indoleamine-
2,3-dioxygenase or PDL1 [16]). The interim analysis of a 
randomized phase III trial showed statistically shorter over-
all survival in cancer patients who received IFN-γ 1b plus 
paclitaxel/carboplatin compared to patients who received 
paclitaxel/carboplatin alone [17]. This decrease in overall 
survival and increase in treatment-limiting AEs led to the 
termination of this trial at the second interim analysis. Thus, 
interferon-gamma is a double-edged sword, and a relatively 
decreased susceptibility to interferon-gamma through lower 
IFNGR1 expression may increase the anti-cancer immunity 
required for the full efficacy of gemcitabine. A similar asso-
ciation between high expression and unresponsiveness to 
therapy has been reported for TLR2, the second gene identi-
fied in this study as overexpressed in non-responding versus 
responding patients. Specifically, Yang et al. reported that 
the persistent activation of TLR2 by heat-shock protein 60 
by tumour cells led to the release of immunosuppressive 
cytokines and chemokines [18]. Accordingly, TLR2 defi-
ciency protected mice from the progression of B16 mela-
noma, and combining an anti-TLR2 antibody with gemcit-
abine improved the survival of wild-type tumour-bearing 
mice. Responding patients showed a significantly higher 
expression of B2M. Because this protein is involved in anti-
gen presentation to cytotoxic T cells, its expression is needed 
to educate lymphocytes and promote T cell-mediated kill-
ing of their target cells. Thus, it could be postulated that 
high expression of B2M predisposes patients to an improved 
Fig. 2  Differential expression of immune genes between respond-
ers and non-responders. PBMCs obtained from the patients immedi-
ately prior to the first infusion of gemcitabine were frozen in liquid 
nitrogen. Total RNA from thawed cells was used for real-time PCR 
with the Qiagen RT2 Innate and Adaptive Immunity Kit. Responding 
patients (defined as a partial response according to the RECIST crite-
ria) were #1, #2 and #4. Non-responding patients (defined as having 
progressive disease according to RECIST) were #6, #7 and #9. The 
relative expression levels were calculated using the following for-
mula:  2−(CTgene_of_interest−CT beta_actin). Long horizontal lines and short 
horizontal lines indicate the means and standard errors of the mean, 
respectively. The p value between responders and non-responders was 
calculated using a two-tailed unpaired t test
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cytotoxic T cell response. The confirmation of a favourable 
baseline signature based on the expression of IFNGR1, 
TLR2 and B2M would require the analysis of PBMCs from 
more patients in a subsequent trial. These immune param-
eters were not studied during treatment because the drugs 
given to the patients, particularly gemcitabine and chloro-
quine, modify the immune system.
In conclusion, the results of this study demonstrate that 
the gemcitabine–chloroquine regimen is well tolerated, 
especially in elderly patients with advanced pancreatic can-
cer, and may induce promising clinical responses. Immune 
parameters, such as a low expression of IFNGR1 and TLR2 
and high expression of B2M, may predispose patients to a 
better response to this combination treatment. Furthermore, 
adding chloroquine to the administration of chemotherapeu-
tic drug(s), mostly those inducing immunological cell death, 
may be a safe way to enhance clinical responses. The optimal 
timing and dosing of chloroquine must be defined through 
pre-clinical studies; however, the appropriate administration 
of chloroquine (time and dose) as presented here may be a 
safe adjuvant to approved anti-cancer treatments. Based on 
these data, the efficacy of chloroquine added to gemcitabine 
monotherapy or combination regimens should be evaluated.
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7. Conclusion and outlook 
Presence of diverse posttranscriptional RNA modifications in natural RNA provides an additional 
level of complexity in RNA biology. RNA functionality was mainly attributed to its sequence 
information. However, advances in identification and localization of nucleotide modifications 
started to disclose new functional roles (Dominissini et al., 2012; Safra et al., 2017; Schwartz et 
al., 2014a). In particular, studies using lipofectin-formulated modified synthetic RNA or 
subpopulations of RNA showed presence of these modifications suppresses recognition by specific 
receptor of the innate immunity and underlined their relevance in self- versus non-self RNA 
recognition (Kariko et al., 2005).  
Research on m6A and m1A provided a novel role of modifications indicating that these RNA 
markings are rather dynamic than static (Dominissini et al., 2016; Jia et al., 2012). Studies of the 
enzymatic machineries introducing, reading and removing m6A modifications opened a field of 
research for regulatory networks guiding these reactions. Moreover, single nucleotide mapping of 
m6A, m1A, 2′-O-methylation and Ψ showed that these modifications are abundant in mRNA and 
non-coding fractions other than rRNA and tRNA: lncRNA, miRNA, snRNA and snoRNA (Carlile 
et al., 2015; Dominissini et al., 2012; Dominissini et al., 2016; Krogh et al., 2017; Li et al., 2016b; 
Meyer et al., 2012; Schwartz et al., 2014a). Localizing and mapping these modifications in the 
complete population of mRNA found in a cell constitutes the epitranscriptome (Grozhik and 
Jaffrey, 2017). It has been shown that m6A differentially affects translation, alternative splicing, 
polyadenylation, and nuclear export of mature mRNA depending on its position the molecule 
(Fustin et al., 2013; Ke et al., 2015; Liu et al., 2015; Liu et al., 2017; Meyer et al., 2015; Zhou et 
al., 2015). Possessing all these roles suggested m6A and possibly other modifications act as 
molecular switches linking environmental changes and prompted cellular responses. 
Summarizing the known roles of the m6A, inosine, 2′-O-methylation and Ψ epitranscriptome in 
cancer we highlight the possibility to take into consideration epitranscriptomics in future diagnosis 
and treatment of cancer. In addition, we show that a chemotherapeutic drug known to block 
methylation of nucleic acids is changing the immunostimulating profile triggered by RNA.  
 capable of changing RNA modifications. Pentostatin was identified over thirty years ago as a 
chemotherapy efficacious for the treatment of specific leukemias and lymphomas (Braiteh et al., 
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2006; Dillman et al., 1988; Dohner et al., 1993; Grever et al., 1983; Spiers et al., 1984). 
Surprisingly, it is not toxic on cancer cells in vitro (Wilson et al., 1998).  
Studying innate immune responses triggered by total RNA from organisms of different 
evolutionary complexity we found that Protamine-RNA nanoparticles are able to unravel the 
immunostimulatory potential of mammalian RNA. Namely, we demonstrated that total RNA from 
lower but also higher organisms when formulated in Protamine induce TNF-α production in 
hPBMCs. This contradicted previous findings where only RNA from lower organism was found 
to be immunostimulating. This discrepancy is possibly due to differences in formulations. 
Protamine-RNA nanoparticles may deliver RNA preferentially to the endosomes while liposomal 
formulations may deliver RNA preferentially to the cytosol resulting in different spatial 
distribution and sensing by segregated immune receptors. Since RNA-recognizing TLRs are in the 
endosomes, the induction of TNF-α that we observe with Protamine-RNA was most probably 
missed in studies using lipofectin as transfecting agent.  
Through further characterizing the immunostimulation profiles induced by natural RNA we could 
show that even heavily modified mammalian RNA induces not only TNF-α but several other 
cytokines in hPBMCs. However, IFN-α was induced exclusively by total RNA isolated from lower 
organisms. Knowing that RNA from higher organisms bears more modifications compared to 
RNA from lower organisms, we hypothesized that the presence of specific RNA modifications is 
responsible for blocking IFN-α induction by total mammalian RNA. Our own experiments and the 
literature pointed to a possible role of adenosine to inosine editing and methylations in masking 
RNA from immune sensors. Therefore, we tested drugs that inhibit adenosine deaminases 
responsible for maintenance of balanced methylation index and inosine level in cells (Glazer and 
Hartman, 1980; Johnston and Kredich, 1979; Kredich, 1980). From all drugs known to directly or 
indirectly block adenosine deaminases only Pentostatin, the most potent inhibitor, showed to 
enhance triggering of type I interferon by mammalian RNA in vitro and in vivo. In the early 
eighties it was already shown that Pentostatin affects 2′-O-methylation in RNA (Hershfield et al., 
1983). 2′-O-methylation was evidenced to block recognition of RNA by TLR3 and TLR7 in human 
cells (De Clercq et al., 1972; Jung et al., 2015). Of note, recombinant alpha interferon was used as 
a treatment against hairy cell leukemia before introduction of Pentostatin (Golomb et al., 1986). 
We were able to associate this previous knowledge with our findings and show that Pentostatin 
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although not toxic on cancer cells in vitro is efficacious in the treatment of tumor bearing mice via 
dsRNA sensing by TLR3 and resulting type I interferon induction. All these findings re-purpose 
Pentostatin as an immunomodulating drug having potential in cancer treatment alone or in 
combination with other current chemotherapies or immunotherapies (anti-PD1 or anti-CTLA4) as 
well as new vaccines.  
Among vaccine formats, recent clinical studies using ivt mRNA for cancer treatment showed very 
promising results (Sahin et al., 2017a). Both ivt mRNA coding shared tumor antigen or individual 
mutations can be used to prime/restimulate anti-cancer specific immunity (Kreiter et al., 2015; 
Rittig et al., 2011; Sahin et al., 2017a). Functionality of ivt mRNA has been very much increased 
through utilization of stabilization sequences (5′ and 3′ UTRs) (Carralot et al., 2004; Holtkamp et 
al., 2006; Kariko et al., 1999), optimal 5′ cap (Kuhn et al., 2011), optimized open reading frame 
(codon usage) (Gustafsson et al., 2004; Malarkannan et al., 1999) and extended poly A tail 
(Holtkamp et al., 2006). Still, further optimization of ivt mRNA functionality can be envisioned 
based on the utilization of modified nucleotides or incorporation of helper sequences. Concerning 
the first aspect, understanding the role of RNA modifications (see above) can be used to generate 
better ivt mRNA. Investigating the second aspect, we could show that employing an aptamer that 
attracts the eIF4G protein at the 5′ end of the ivt mRNA can enhance translation. 
Integrating epitanscriptomics, improved ivt mRNA-based formulations and individual parameters 
(identification of mutations, immune fitness) we aim at defining personalized 
immunochemotherapy treatments that will efficaciously and safely cure or prevent cancers. 
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